Substituted quinazolinone derivatives and their use as positive allosteric modulators of MGLUR4

By using quinazolinone derivative compounds as mGluR4 positive allosteric regulators, the side effects and motor dysfunction of dopamine agonists in Parkinson's disease treatment are solved, and effective reduction of Parkinson's symptoms and neuroprotection are achieved.

CN112566906BInactive Publication Date: 2024-11-12DOMAIN THERAPEUTICS SA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201980049845.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2018-07-26
Filing Date
2019-07-26
Publication Date
2024-11-12
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing treatments for Parkinson's disease have long-term side effects and are not effective in delaying disease progression, especially the dyskinesia and insufficient neuroprotective activity caused by dopamine agonists.

Method used

A novel quinazolinone derivative compound has been developed as a positive allosteric regulator of the metabolic glutamate receptor mGluR4, which regulates glutamate signaling by binding to mGluR4, for the treatment of Parkinson's disease and related symptom.

Benefits of technology

The compound showed a low EC50 value mGluR4 positive allosteric regulatory activity, which can effectively alleviate the symptoms of dyskinesia in Parkinson's disease and provide neuroprotective effects, potentially used in the treatment of a variety of neurological diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN112566906B_ABST
    Figure CN112566906B_ABST
Patent Text Reader

Abstract

The present invention relates to novel quinazolinone derivatives of formula (I) and pharmaceutical compositions containing these compounds. The compounds of formula (I) provided herein are useful as positive allosteric modulators of metabotropic glutamate receptor subtype 4 (mGluR4), and thus can be used as therapeutic agents, particularly in the treatment or prevention of disorders associated with altered glutamatergic signaling and / or function and / or disorders that can be affected by alterations in glutamate levels or signaling. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present invention relates to novel quinazolinone derivatives of formula (I) and pharmaceutical compositions containing these compounds. The compounds of formula (I) provided herein can be used as positive allosteric modulators of metabotropic glutamate receptor subtype 4 (mGluR4) and, therefore, can be used as therapeutic agents, particularly in the treatment or prevention of conditions associated with altered glutamatergic signaling and / or function or conditions that can be affected by changes in glutamate levels or signaling.

[0002] Glutamate is the major amino acid transmitter in the mammalian central nervous system (CNS). Glutamate plays an important role in many physiological functions such as learning and memory, as well as sensory perception, the development of synaptic plasticity, motor control, breathing, and cardiovascular function regulation. In addition, glutamate is at the center of a variety of different neurological and psychiatric diseases in which there is an imbalance in glutamatergic neurotransmission.

[0003] Glutamate mediates synaptic neurotransmission through activation of ionotropic glutamate receptor channels (iGluRs), namely NMDA, AMPA, and kainate receptors, which are responsible for fast excitatory transmission (Nakanishi et al., (1998) Brain Res. Rev., 26:230-235).

[0004] In addition, glutamate activates metabotropic glutamate receptors (mGluRs), which have more regulatory effects and contribute to the fine-tuning of synaptic efficacy. mGluRs are G protein-coupled receptors (GPCRs) with seven transmembrane domains. Together with calcium sensing, GABAb and pheromone receptors, they belong to GPCR family 3. The mGluR family consists of 8 members. According to sequence homology, pharmacological properties and the properties of the activated intracellular signaling cascade, they are classified into 3 groups (Group I includes mGluR1 and mGluR5; Group II includes mGluR2 and mGluR3; Group III includes mGluR4, mGluR6, mGluR7 and mGluR8) (Schoepp et al., (1999) Neuropharmacology, 38:1431-1476).

[0005] Glutamate activates mGluRs by binding to the large extracellular amino-terminal domain of the receptor, referred to herein as the orthosteric binding site. This activation induces a conformational change in the receptor that leads to activation of G-proteins and intracellular signaling pathways.

[0006] In the central nervous system, mGluR4 receptors are most densely expressed in the cerebellar cortex, basal ganglia, sensory relay nuclei of the thalamus, and hippocampus (Bradley et al., (1999) Journal of Comparative Neurology, 407:33-46; Corti et al., (2002) Neuroscience, 110:403-420). mGluR4 subtype is negatively coupled to adenylate cyclase via activation of Gi / o proteins and is mainly expressed on presynaptic terminals, functions as an autoreceptor or heteroreceptor, and activation of mGluR4 leads to reduced transmitter release from presynaptic terminals (Corti et al., (2002) Neuroscience, 110:403-420; Millan et al., (2002) Journal of Biological Chemistry, 277:47796-47803; Valenti et al., (2003) Journal of Neuroscience, 23:7218-7226). In certain brain tissues, such as the cerebellar cortex of rodents, mGluR4 receptors can also couple to Gq proteins and PLC effector systems to reduce glutamate synaptic transmission again (Chardonnet S et al. (2017) Neuropharmacology, 121:247-260).

[0007] A variable pocket was recently discovered that is responsible for selectivity of mGluR subtypes within group III and is adjacent to the glutamate binding site (Goudet C et al. (2012) FASEB J, 26(4):1682-93; Selvam C et al. (2018) J Med Chem, 61(5):1969-89). Previously, most orthosteric agonists of mGluR4 were not selective and could therefore activate other group III mGluRs (Schoepp D et al. (1999) Neuropharmacology, 38:1431-1476). The Group III orthosteric agonist L-AP4 (L-2-amino-4-phosphonobutyrate) can reduce motor deficits in animal models of Parkinson's disease (Valenti O et al. (2003) J. Neurosci., 23:7218-7226) and reduce excitotoxicity (Bruno V et al. (2000) J. Neurosci., 20; 6413-6420), and these effects are apparently mediated through mGluR4 (Marino MJ et al. (2005) Curr. Topics Med. Chem., 5:885-895). In addition to L-AP4, another selective Group III mGluR agonist, ACPT-1, has been shown to cause a dose- and structure-dependent reduction in haloperidol-induced catalepsy and attenuate haloperidol-inducible proenkephalin mRNA expression in the striatum (Konieczny J et al. (2007) Neuroscience, 145: 611-620). Furthermore, Lopez et al. (2007, J. Neuroscience, 27: 6701-6711) have demonstrated that bilateral infusion of ACPT-1 or L-AP4 into the globus pallidus completely reversed the severe akinesia produced by 6-hydroxydopamine lesions of nigrostriatal dopamine neurons in a reaction-time task without affecting control performance. Furthermore, the reversal of haloperidol-induced catalepsy caused by ACPT-1 in the globus pallidus was prevented by simultaneous administration of the selective Group III receptor antagonist (R5)-α-cyclopropyl-4-phosphonophenylglycine.These results suggest that among mGluR subtypes, group III mGluRs, especially mGluR4, are very interesting new drug targets for the treatment of Parkinson's disease (for review, see Conn PJ et al. (2005) Nature Review Neuroscience, 6:787-798, and more recently see Charvin D, (2018) Neuropharmacology, 135:308-315).

[0008] The common endpoint of Parkinson's disease (PD) pathology is the progressive degeneration of dopaminergic neurons located in the substantia nigra pars compacta (SNpc), which project to and release dopamine into the striatum. PD symptoms typically appear when more than 60% of SNpc neurons have disappeared. This leads to profound movement disturbances, including resting tremors, stiffness and rigidity, gait and balance control dysfunction, and dementia, which significantly worsen the quality of life of patients and their families.

[0009] Current treatments are intended to replace missing dopamine or mimic its effects by providing the patient with the dopamine precursor L-DOPA, inhibitors of dopamine catabolism enzymes (MAO inhibitors) or direct dopamine receptor agonists for a long time. Although these treatments have been shown to be more effective in controlling the main symptoms of PD, their long-term use is associated with serious side effects. Conventional treatments for Parkinson's disease typically include the use of a combination of levodopa and carbidopa (SINEMET (TM)) or a combination of levodopa and benserazide (MADOPAR (TM)). Dopamine agonists such as bromocriptine (PARLODEL(TM), lisuride and pergolide (CELANCE(TM)) act directly on dopamine receptors and are also used to treat Parkinson's disease. These molecules have the same side effects as levodopa. For example, after several years of treatment, the efficacy of L-DOPA tends to decrease in both intensity and stability, resulting in uneven on / off periods requiring increasing doses. In addition, long-term administration of high doses of L-DOPA is associated with the development of involuntary movements (dyskinesias). Despite various attempts to control this disorder, levodopa-induced dyskinesias affect nearly all levodopa-treated PD patients at some point in their disease course (Rascol O et al., (2015), Mov Disord, 30(11):1451-1460). Therefore, since 86% of PD patients are currently treated with levodopa, there is an urgent clinical need to improve levodopa-induced dyskinesias (Hechtner MC et al., (2014) Park Relat Disord, 20:969-74). Excessive dopamine supply in the brain has also been linked to psychiatric disorders, including depression, psychotic symptoms, obsessive-compulsive behavior, and sleep disturbances. Finally, none of the compounds currently listed in the pharmacopoeia for PD demonstrate neuroprotective activity that can delay disease progression. Therefore, to address these significant unmet medical needs, efforts are needed to develop new treatments for PD that target the neurochemical systems downstream of dopamine itself.

[0010] In healthy subjects, dopamine's motor control follows a complex pattern of interactions between neurochemical systems and brain structures, for which models have been described over the past few decades (Wichmann T and Delong MR, (2003) Adv Neurol 91:9-18). This model is now developing towards a more refined understanding of basal ganglia function (for a summary, see Kravitz AV et al., (2010) Nature, 466:622-26; Cui G et al., (2013) Nature, 494:238-42; Cazorla M et al., (2015) Mov Disord, 30:895-903). The basal ganglia, primarily composed of the substantia nigra (SN) and the striatum and thalamus complex, form the cornerstone of these interactions. The internal capsule of the globus pallidus (GPi) and the SN pars reticulum (SNpr) act as relays between cortical areas (which directly control movement) and the basal ganglia themselves. GPi and SNpr receive inhibitory direct connections (direct pathway) and excitatory indirect inputs (indirect pathway) from the basal ganglia. Both pathways are regulated by dopamine with opposite valence, so that the direct pathway is stimulated while the indirect pathway is inhibited by dopamine. Therefore, in the diseased brain, the lack of dopamine causes an imbalance in the output activity of both the direct and indirect pathways. In particular, the indirect pathway is overactivated, which is reflected by the release of increased GABA into the external segment of the globus pallidus (GPe). Therefore, glutamate release increases in the SN pars compacta (SNpc), GPi and SNpr. These changes in the balance of neurotransmission in the direct and indirect pathways are considered to have led to the deposition (precipitation) of motor control abnormalities and neurodegeneration of dopaminergic neurons. The detailed analysis of these pathways provides insights into the following possibilities: targeting the dopamine downstream neurochemical pathway to restore its function in the PD brain without directly interfering with it. In particular, it has been confirmed that metabotropic glutamate receptors (mGluRs) regulate neurotransmitter release at the presynaptic level. Specifically, mGluR4 inhibition, which is expressed primarily in discrete regions of the brain, has been demonstrated to inhibit glutamate and GABA neurotransmission at subthalamic nucleus (STN)–SNpc (Valenti O et al. (2005) J Pharmacol Exp Ther 313:1296-1304) and striatum–GPe (Valenti O et al. (2003) J Neurosci 23:7218-7226; Cuomo D et al. (2009) J Neurochem, 109:1096-1105)) synapses, respectively.mGluR4 is more abundant in striatal-pallidum synapses than in striatal-substantia nigra synapses, and its localization suggests that it acts as a presynaptic heteroreceptor on GABAergic neurons (Bradley SR et al. (1999) Journal of Comparative Neurology, 407: 33-46), thereby suggesting that selective activation or positive regulation of mGluR4 can reduce GABA release in this synapse, thereby reducing the output of the indirect pathway and alleviating or eliminating the symptoms of Parkinson's disease. In addition, mGluR4 is also expressed presynaptically at corticostriatal glutamatergic terminals targeting indirect pathway neurons (Bradley SR et al. (1999) J Comp Neurol, 407: 33-46). Activation of mGluR4 at this site is expected to preferentially inhibit stimulation of the already hyperactive indirect pathway while preserving excitation of the direct pathway, thereby normalizing basal ganglia output (Bennouar KE et al. (2013) Neuropharmacology, 66:158-69; Gubellini P et al. (2014) Neuropharmacology, 85:166-77; Iskhakova L et al. (2016) Brain Struct Funct, 221(9):4589-99).

[0011] In addition, behavioral analysis confirmed the beneficial effects of mGluR4 stimulation in chronic and acute PD motor symptom rat models. For example, the freezing behavior and reserpine-induced immobility observed after haloperidol administration were reversed by positive allosteric modulators (PAMs) such as VU0155041 (Niswender CM et al. (2008) Mol Pharmacol 74:1345-1358; Niswender CM et al. (2016) ACS Chem Neurosci, 7: 1201-11; Le Poul E et al. (2012) J Pharmacol Exp Therapeut, 343:167-77; Charvin D et al. (2017) J Med Chem, 60 (20): 8515-37). These basic models mimic the key features of human disease, i.e., stiffness and akinesia, respectively. More advanced models of PD motor symptoms (e.g. unilateral or bilateral 6-OHDA in rats or MitoPark mouse transgenic models) have also been used to demonstrate the efficacy of PAMs in activating group III mGluRs, particularly mGluR4 (Dube A et al. (2014) J Neurol Sci, 510(14):452-53; Niswender CM et al. (2016) ACS Chem Neurosci, 7:1201-11; Le Poul E et al. (2012) J Pharmacol Exp Therapeut, 343:167-77; Charvin D et al. (2017) J Med Chem, 60(20):8515-37).

[0012] Ultimately, the increased release of glutamate is thought to be at least partially involved in the degeneration of the remaining dopaminergic neurons, thereby worsening the condition and reducing the effectiveness of treatment. Therefore, the mGluR4 positive allosteric modulator (PAM) PHCCC, which reduces glutamate release, also protects neurons from further degeneration in rats treated with the neurotoxin 6-hydroxydopamine (6-OHDA), which selectively destroys dopaminergic neurons (Vernon AC, (2009) J Neurosci 29:12842-12844; Betts MJ et al. (2012) Br J Pharmacol, 166:2317-30). Similar results were obtained using PHCCC in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (Battaglia G et al. (2006) J Neurosci, 26: 7222-29) or in NMDA-lesioned mice using the group III mGluR agonist (+)-4-phosphonophenylglycine PPG (Bruno V et al. (2000) J Neurosci, 20: 6413-20).

[0013] More recently, as demonstrated in the MPTP monkey model, mGluR4 PAM compounds from invention WO 2017 / 032874 have been found to be highly effective in preventing and / or treating levodopa-induced dyskinesia (LID). These results confirm the therapeutic potential of Group III mGluR activators to reduce the incidence of dyskinesia, an effect that was previously disclosed several years ago using other mGluR4 PAM compounds, i.e. LuAF21934, in the 6-OHDA rat model of LID (Bennouar KE et al. (2013) Neuropharmacology, 66: 158-69).

[0014] Together, these results suggest that stimulation of mGluR4, and more generally Group III mGluRs, has enormous potential to alleviate PD symptoms in patients, including L-dopa-induced dyskinesias, and to provide neuroprotection to remaining neurons.

[0015] A novel approach to developing selective compounds acting at mGluRs is to identify molecules that act via an allosteric mechanism, modulating the receptor by binding to a site other than the highly conserved orthosteric binding site.

[0016] Positive allosteric modulators of mGluRs have recently emerged as new pharmacological entities that provide this attractive alternative. Such molecules have been found to target mGluR1, mGluR2, mGluR4, mGluR5, mGluR7, and mGluR8 (Knoflach F et al. (2001) Proc. Natl. Acad. Sci. USA, 98: 13402-13407; Johnson MP et al. (2002) Neuropharmacology, 43: 799-808; O'Brien JA et al. (2003) Mol. Pharmacol., 64: 731-740; Johnson MP et al. (2003) J. Med. Chem., 46: 3189-3192; Marino MJ et al. (2003) Proc. Natl. Acad. Sci. USA, 100: 13668-13673; Mitsukawa et al. (2003) Proc. Natl. Acad. Sci. USA, 100: 13668-13673; K et al. (2005) Proc. Natl. Acad. Sci. USA, 102(51):18712-18717; Wilson J et al. (2005) Neuropharmacology, 49:278; Mutel V, (2002) Expert Opin. Ther. Patents, 12:1-8; Kew JN, (2004) Pharmacol. Ther., 104(3):233-244; Johnson M. et al. (2004) Biochem. Soc. Trans., 32:881-887; Ritzen A, Mathiesen, JM and Thomsen C, (2005) Basic Clin. Pharmacol. Toxicol., 97:202-213; Schann S et al. (2010) J Med Chem, 53(24):8775-79).

[0017] Looking more closely at Group III mGluRs, most examples of allosteric ligands described to date are for mGluR subtype 4 (mGluR4). PHCCC, MPEP, and SIB1893 (Maj M et al. (2003) Neuropharmacology, 45(7), 895-903; Mathiesen JM et al. (2003) Br. J, Pharmacol. 138(6), 1026-30) were the first examples described in 2003. More recently, different universities and private companies have reported in the literature (Niswender CM et al. (2008) Mol. Pharmacol. 74(5), 1345-58; Niswender CM et al. (2008) Bioorg. Med. Chem. Lett 18(20), 5626-30; Williams R et al. (2009) Bioorg. Med. Chem. Lett. 19(3), 962-6; Engers DW et al. (2009) J. Med. Chem., 52(14): 4115-18; Le Poul E et al. (2012) J Pharmacol Exp Therapeut, 343: 167-77; Bennouar KE et al. (2013) Neuropharmacology, 66: 158-69; Dube A et al. (2014) J Neurol Sci, More potent positive allosteric modulators were reported in two patent publications describing amido and heteroaromatic compounds (WO 2009 / 010454 and WO 2009 / 010455), and in Charvin D et al. ((2017) J Med Chem, 60:8515-37).

[0018] Regarding other Group III mGluR subtypes, so far, almost no allosteric ligands have been found. AMN082 is an mGluR7-specific allosteric agonist that binds in the seven transmembrane domains of the receptor, while XAP044 is an antagonist that binds in the large amino-terminal extracellular domain, but its geometric position is different from glutamate itself (Mitsukawa K et al. (2005) PNAS, 102 (51): 18712-17; Gee CE et al. (2014) J Biol Chem, 289 (16): 10975-87). Pragma Therapeutics is currently developing a chemical series of other undisclosed mGluR7 negative allosteric modulators (NAMs) for hearing and stress disorders. AZ12216052 is a mGluR8 PAM discovered by Astra Zeneca that has been shown to reduce anxiety levels in multiple rodent models (Duvoisin et al. (2010) Behav Brain Res, 212(2):168-73).

[0019] PHCCC (N-phenyl-7-(hydroxyimino)cyclopenta[6]chromene-1a-carboxamide) is a positive allosteric modulator of mGluR4 and inactive at other mGluRs (Maj et al. (2003) Neuropharmacology, 45:895-906). It has been shown to be effective in animal models of Parkinson's disease, which represents Parkinson's disease and other movement disorders and disorders (Marino et al. (2003) Proc. Nat. Acad. Sci. USA, 100:13668-13673) and neurodegeneration in Parkinson's disease (Marino et al. (2005) Curr. Topics Med. Chem., 5:885-895; Valenti et al. (2005) J. Pharmacol. Exp. Ther., 313:1296-1304). Vernon et al. (2005) Eur. J. Neurosci., 22: 1799-1806, Battaglia et al. (2006) J. Neurosci., 26: 7222-7229)) are potential new treatments. Since these seminal publications, other mGluR4 positive modulators, and more generally Group III mGluR positive modulators, have shown encouraging results in animal models of Parkinson's disease and neurodegeneration (Conn J et al. (2005) Nat Rev. Neuroscience, 6(10), 787-98; Vernon AC et al. (2007) J. Pharmacol. Exp. Then, 320(1), 397-409; Lopez S et al. (2008) Neuropharmacology, 55(4), 483-90; Vernon AC et al. (2008) Neuroreport, 19(4), 475-8; Niswender CM et al. (2008) Mol. Pharmacol. 74(5), 1345-58). Other subtypes of group III mGlu receptors (i.e., mGluR7 and mGluR8) have also been shown to have potential neuroprotective effects (Wang WY et al. (2012) Neuroscience, 205: 167-77) and anti-Parkinson's disease activities (for review, see Amalric M et al. (2013) Neuropharm, 66: 53-64; Amalric M, (2015) Curr Opin Pharmacol, 20: 29-34; Gubellini P et al. (2017) The Receptors, Humana Press, 33-57; Litim N et al. (2017) Neuropharm, 115: 166-179).Indeed, it has been demonstrated that the mGluR7-specific allosteric agonist AMN082 reverses haloperidol-induced catalepsy and akinesia in reserpine-treated rats (Greco B et al. (2010) J Pharmacol Exp Ther, 332(3): 1064-71; Broadstock M et al. (2012) British J of Pharmacol, 165(4b): 1034-45; Konieczny J and Lenda T, (2013) Pharmacol Rep, 65(5): 1194-203). The involvement of the mGluR8 subtype was also tested using the specific agonist (S)-3,4-dicarboxyphenylglycine (DCPG), which was shown to reverse prolonged (three doses of reserpine or haloperidol administered at intervals over 18-20 h before the assay), but not acute (single dose of reserpine or haloperidol administered 2 h before the assay) catalepsy and akinesia, suggesting that activation of this subtype may be particularly relevant for the restoration of promotor effects in the presence of prolonged dopamine depletion (Johnson KA et al. (2013) Neuropharmacol, 66: 187-95).

[0020] PHCCC showed a neuroprotective effect against beta-amyloid and NMDA toxicity in mixed cultures of mouse cortical neurons, thus demonstrating the ability of mGluR4 positive regulators to prevent neurodegeneration in Alzheimer's disease or neurodegeneration caused by ischemic or traumatic injury (Maj et al. (2003) Neuropharmacology, 45:895-906). Other studies have verified the potential use of Group III mGluR regulators for treating Alzheimer's disease. Significant data in this direction come from in vivo data using mGluR7 knockout mice, which demonstrated that Group III mGluR7 promotes short-term memory (Holscher C et al. (2004) Behav Brain Res, 154 (2): 473-81).

[0021] The neuroprotective potential of the group III mGlu receptor agonist ACPT-1 was recently demonstrated in animal models of ischemic stroke using both in vitro and in vivo studies, revealing that group III mGluR activation not only has a neuroprotective effect on ischemic neuronal injury but also can reduce post-ischemic functional deficits (Domin H et al. (2016) Neuropharmacology, 102:276-94).

[0022] mGluR4 positive allosteric modulators such as PHCCC or ADX88178 have also been shown to be active in animal models of anxiety (Stachowicz et al. (2004) Eur. J. Pharmacol., 498: 153-156; Kalinichev M et al. (2014) J Pharmacol Exp Ther, 350(3): 495-505) and depression (Palucha A et al. (2004) Neuropharmacology 46(2), 151-9). Previously, the group III mGluR agonist ACPT-1 has been shown to produce a dose-dependent anti-conflict effect in rats after intrahippocampal administration and an antidepressant-like effect in rats after intracerebroventricular administration (Tatarczynska et al. (2002) Pol. J. Pharmacol., 54(6): 707-710). When a combination of PHCCC and ACPT-1 compounds was used, the antidepressant effect was enhanced (Klak K et al. (2006) Amino Acids 32(2), 169-72). More recently, ACPT-1 was also shown to have anxiolytic-like effects in stress-induced hyperthermia, the elevated-plus maze in mice, and the Vogel conflict test in rats when injected intraperitoneally (Stachowicz et al. (2009) Neuropharmacology, 57(3): 227-234). Activation of Group III mGluR8 also reduces anxiety-like behavior in rodent models, as demonstrated by treatment of animals with the mGluR8-specific agonist DCPG or the PAM AZ12216052 (Duvoisin et al. (2010) Behav Brain Res, 212(2):168-73; for review, see Raber J and Duvoisin RM, (2015) Expert Opin Investig Drugs, 24(4):519-28).

[0023] Group III mGluR modulators have shown positive results in various animal models of schizophrenia (Paiucha-Poniewiera A et al. (2008) Neuropharmacology, 55(4), 517-24). Similarly, ADX88178, a brain-penetrating positive allosteric modulator of mGlu4 receptors, has shown activity in rodent models of obsessive-compulsive disorder (OCD), fear, and psychosis (Kalinichev M et al. (2014) J Pharmacol Exp Ther, 350(3): 495-505).

[0024] Furthermore, in rodent models of autism spectrum disorder, positive modulators of mGluR4 have been shown to alleviate autistic-like syndromes (Becker JA et al. (2014) Neuropsychopharmacology, 39(9): 2049-2060), while activators of mGluR7, another subtype of group III mGlu receptors, are being studied at Vanderbilt University for the treatment of Rett syndrome (Gogliotti RG et al. (2017) Sci Transl Med, 9(403)).

[0025] The correlation between epilepsy and mGluR4 transcript levels and / or genetic variations has recently been published (Parihar R et al. (2014) J Genet, 93(1): 193-197; Dammann F et al. (2018) Epilepsy Res, 139: 157-163), suggesting that mGluR4 modulators may be used for the treatment of epilepsy.

[0026] [β]-chemokine RANTES is crucial for neuronal inflammation and is involved in the pathophysiology of multiple sclerosis. Activation of group III mGluRs with L-AP4 reduces the synthesis and release of RANTES in wild-type cultured astrocytes, while the ability of L-AP4 to inhibit RANTES is significantly reduced in astrocyte cultures of mGluR4 knockout mice (Besong et al. (2002) Journal of Neuroscience, 22: 5403-5411). Expression of mGluR4 on dendritic cells can affect the TH17 / Treg balance (Hansen AM and Caspi RR, (2010) Nat Med, 16(8): 856-8; Zhao G et al. (2017) Int Immunopharmacol, 46: 80-86). Activation of mGluR4 by the endogenous agonist cinnabarinic acid or the highly selective and potent PAM ADX88178 has a protective effect in a mouse model of multiple sclerosis, also known as experimental autoimmune encephalomyelitis (EAE) (Fazio F et al. (2014) Neuropharmacology, 81: 237-43; Volpi C et al. (2016) Neuropharmacology, 102: 59-71). The underlying mechanism was recently revealed: activation of mGluR4 by ADX88178 alleviates LPS-induced inflammation in primary microglia, leading to reduced expression of proinflammatory markers TNFα, MHCII, and iNOS (Ponnazhagan R et al. (2016) J Neuroimmune Pharmacol, 11(2): 231-7). Together, these data suggest that positive allosteric modulators of mGluR4 may be effective treatments for neuroinflammatory diseases of the central nervous system, including multiple sclerosis and related disorders (for review, see Levite M, (2017) J Neural Transm, 124(7):775-98).

[0027] Two different variants of the mGluR4 receptor are expressed in taste tissues and can function as receptors for umami taste perception (Monastyrskaia et al. (1999) Br. J Pharmacol., 128: 1027-1034; Toyono et al. (2002) Arch. Histol. Cytol., 65: 91-96; Eschle BK., (2008) Neuroscience, 155(2), 522-9). Therefore, positive allosteric modulators of mGluR4 can be used as taste agents, flavoring agents, flavor enhancing agents or food additives.

[0028] There is anatomical evidence to show that most of the vagal afferents that control gastric muscles express group III mGluR (mGluR4, mGluR6, mGluR7 and mGluR8) and actively transport receptors to their peripheral terminals (Page et al. (2005) Gastroenterology, 128:402-10). Recently, it has been confirmed that the activation of peripheral group III mGluRs inhibits the mechanical sensitivity of vagal afferents in vitro, which is converted into the triggering of transient lower esophageal sphincter relaxation and gastroesophageal reflux reduced in vivo (Young et al. (2008) Neuropharmacol, 54:965-975). The labeling of mGluR4 and mGluR8 is abundant in the gastric vagal afferents of the nodose ganglion, on its termination site in the nucleus tractus solitarius and in gastric vagal motor neurons. These data show that the positive allosteric modulators of group III mGluRs may be an effective treatment for gastroesophageal reflux disease (GERD) and lower esophageal disease and gastrointestinal disorders.

[0029] Activation of mGluR4 receptors expressed in α-cells and F-cells in the islets of Langerhans inhibits the secretion of glucagon. Molecules that activate or enhance the agonist activity of these receptors can be an effective treatment for hyperglycemia, i.e., one of the symptoms of type 2 diabetes (Uehara et al. (2004) Diabetes, 53:998-1006).

[0030] In addition, mGluR4 signaling is also a mechanism involved in the regulation of chronic pain (Goudet C et al. (2008) Pain, 137(1), 112-24; Zhang HM et al. (2009) Neuroscience, 158(2), 875-84; Zussy C et al. (2018) Mol Psychiatry, 23(3): 509-520; for review, see Palazzo E et al. (2017) J Neurochem, 141(4): 507-519).

[0031] Finally, mGluR4 was shown to be expressed in prostate cancer cell lines (Pessimissis N et al. (2009) Anticancer Res. 29(1), 371-377), colorectal cancer (Chang HJ et al. (2005) CIL Cancer Res. 11(9), 3288-95) or more recently in osteosarcoma (Yang et al. (2014), J Cancer Res Clin Oncol, 140(3): 419-426; Wang et al. (2016), Mol Cli Oncol, 4(1): 65-69), and its activation by PHCCC was shown to inhibit the growth of medulloblastoma (Iacoveili L et al. (2006) J. Neurosci. 26(32) 8388-97). Similarly, recent data in neuroblastoma and glioma cell lines have demonstrated that mGluR8 overexpression induces decreased cell proliferation, increased apoptosis, and increased vulnerability to certain cytotoxic agents (Jantas D et al. (2018) Cancer Lett, 3835(18):30400-2). Therefore, Group III mGluR modulators may also be used to treat cancer.

[0032] The prior art documents related to structurally related compounds are as follows:

[0033] WO 01 / 083456 relates to fused heteroaryl derivatives.

[0034] WO 02 / 028841 relates to reagents for labelling biomolecules having aldehyde or keto functional groups.

[0035] WO 03 / 048152 relates to regulators of inflammation.

[0036] WO 2004 / 024162 discloses 2-amino-4-quinazolinones as LXR nuclear receptor binding compounds.

[0037] WO 2004 / 041755 describes quinazolinone compounds as calcilytics.

[0038] WO 2004 / 065392 discloses certain substituted quinoline and quinazoline compounds as ALK5 kinase inhibitors.

[0039] WO 2004 / 078733 relates to fused pyrimidine compounds and pyridine compounds and their use as ALK-5 receptor ligands.

[0040] WO 2004 / 078733 relates to quinazolinone compounds useful as ion channel modulators.

[0041] WO 2005 / 035526 relates to bicyclic compounds and their therapeutic uses.

[0042] WO 2006 / 051290 relates to pharmaceutical compositions.

[0043] WO 2006 / 071095 discloses quinazoline derivatives for the treatment and prevention of obesity.

[0044] WO 2008 / 020302 describes compounds based on heteroaromatic quinolines.

[0045] WO 2009 / 064388 relates to inhibitors of human methionine aminopeptidase 1 and methods of treating disorders.

[0046] WO 2009 / 111943 relates to compounds as estrogen-related receptor modulators and their use.

[0047] WO 2010 / 018458 relates to phenol derivatives and methods of using the same.

[0048] WO 2010 / 056758 discloses quinazoline derivatives as kinase inhibitors.

[0049] WO 2010 / 106436 describes certain anti-inflammatory drugs.

[0050] WO 2010 / 136475 relates to substituted quinazolines as fungicides.

[0051] WO 2011 / 011522 relates to potent small molecule autophagy inhibitors and methods of use thereof.

[0052] WO 2011 / 045258 relates to fused azine derivatives for the treatment of diseases associated with acetylcholine receptors.

[0053] WO 2011 / 082337 discloses therapeutic compounds and related methods of use.

[0054] WO 2011 / 104183 relates to microbicidal, in particular fungicidal, 2-(pyridin-2-yl)pyrimidine compounds for use in agriculture or horticulture.

[0055] WO 2012 / 028578 discloses substituted fused pyrimidone and dihydropyrimidone compounds for increasing the tolerance of plants to abiotic stress, and for enhancing plant growth and / or increasing plant yield.

[0056] WO 2013 / 003586 describes certain quinazoline derivatives as inhibitors of striatal enriched tyrosine phosphatase (STEP).

[0057] WO 2015 / 015318 relates to certain quinazolinone compounds as bromodomain inhibitors.

[0058] WO 2016 / 199943 relates to heterocyclic compounds as inhibitors of BET family proteins.

[0059] CN 103319408 describes compounds for the prevention and treatment of cardiovascular diseases.

[0060] Other prior art documents, including those related to mGluR4 PAM compounds, are as follows:

[0061] EP 2953532; WO 2011 / 050305; WO 2011 / 029104; WO 2011 / 100607; WO 2011 / 051478; WO 2012 / 009001; WO 2013 / 107862; WO 2014 / 117920; WO 2014 / 121883; WO 2014 / 121885; WO 2015 / 044075; WO 2015 / 104271; WO 2016 / 146600; WO 2016 / 030444; WO 2017 / 009275; US 2018 / 057490; US 2018 / 057491;US 2018 / 021312; US 2018 / 022744; US 2018 / 022745; and US 2018 / 022746.

[0062] The citation of any document in this application is not an admission that the document is relevant prior art to the present application.

[0063] The present invention provides novel compounds that exhibit highly potent positive allosteric modulator activity at mGluR4, making them particularly suitable as therapeutic agents. The present invention also provides compounds that are positive allosteric modulators of mGluR4 and exhibit advantageous pharmacokinetic properties.

[0064] The present invention therefore addresses the problem of providing new and / or improved therapeutic agents for medical intervention in conditions associated with altered glutamatergic signalling and / or function and / or conditions that can be affected by alterations in glutamate levels or signalling.

[0065] The present invention therefore provides compounds of formula (I) as described and defined below

[0066]

[0067] or a pharmaceutically acceptable salt thereof.

[0068] The compounds of the present invention have been found to be potent positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4) and are therefore advantageously useful as therapeutic agents, particularly in the treatment or prevention of disorders associated with altered glutamatergic signaling and / or function, or disorders that can be affected by alterations in glutamate levels or signaling.

[0069] In the context of the present invention, it was surprisingly found that for compounds to exhibit mGluR4 positive allosteric modulator (PAM) activity, the lactam nitrogen ring atom contained in the quinazolinone ring of the compound of formula (I) needs to be unsubstituted, as also shown in formula (I). This is demonstrated by comparing the mGluR4 PAM activity of the compounds depicted in the following figure:

[0070]

[0071] Compound 3 of the present invention, wherein the lactam nitrogen ring atom of the quinazolinone ring is unsubstituted, is a positive allosteric modulator (PAM) of mGluR4 with an EC50 of less than 1 μM.

[0072] In contrast, reference compound 38, an N-substituted analog of compound 3 bearing a methyl substituent on the lactam nitrogen ring atom of the quinazolinone ring, had no PAM activity at mGluR4 up to 100 μM.

[0073] It has also been surprisingly found that in order to exhibit mGluR4 PAM activity, the aromatic ring group R 1It is required to be attached to the rest of the compound [i.e., the quinazolinone ring contained in formula (I)] via a ring carbon atom and to contain a nitrogen ring atom in the ortho position, i.e., adjacent to the ring carbon atom attached to the rest of the compound of formula (I) [i.e., the quinazolinone ring contained in formula (I)]. This is demonstrated by comparing the mGluR4 PAM activity of the compounds depicted in the following figure:

[0074]

[0075] Compounds 15, 9 and 5 of the present invention are positive allosteric modulators (PAMs) of mGluR4 with EC50 below 1 μM, which contain an aromatic ring group R 1 , the aromatic ring is in the aromatic ring (R 1 ) has a nitrogen ring atom adjacent to a carbon ring atom that is attached to the rest of the compound (i.e., to the quinazolinone ring contained in the corresponding compound).

[0076] In contrast, reference compounds 20, 21, and 6 had no PAM activity at mGluR4 up to 100 μM, which contain an aromatic ring group R 1 , the aromatic ring does not have a nitrogen ring atom at a specific position adjacent to a carbon ring atom connecting the aromatic ring to the rest of the corresponding compound.

[0077] The groups / variables in the compounds of formula (I) or pharmaceutically acceptable salts thereof provided by the present invention have the following meanings:

[0078]

[0079] R 1 Any one selected from the following groups:

[0080]

[0081]

[0082] wherein each of the groups depicted above is optionally replaced by one or more groups R 11 replace.

[0083] R 11 Each independently selected from C 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, -(C 0-3 Alkylene)-OH, -(C 0-3 Alkylene)-O(C 1-5 Alkyl), -(C 0-3 Alkylene)-SH, -(C 0-3Alkylene)-S(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH2, -(C 0-3 Alkylene)-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-halogen, -(C 0-3 alkylene)-(C 1-5 Haloalkyl), -(C 0-3 Alkylene)-O-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-CN,-(C 0-3 Alkylene)-CHO, -(C 0-3 alkylene)-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-COOH, -(C 0-3 Alkylene)-CO-O-(C 1-5 Alkyl), -(C 0-3 Alkylene)-O-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-CO-NH2, -(C 0-3 Alkylene)-CO-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-CO-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 alkyl)-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO2-NH2, -(C 0-3 Alkylene)-SO2-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO2-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH-SO2-(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 alkyl)-SO2-(C 1-5 Alkyl), -(C 0-3 Alkylene)-aryl, -(C0-3 Alkylene)-heteroaryl, -(C 0-3 alkylene)-cycloalkyl and -(C 0-3 alkylene)-heterocycloalkyl, wherein said-(C 0-3 Alkylene)-aryl in the aryl part, the -(C 0-3 The heteroaryl portion of the -(C 0-3 The cycloalkyl portion of the -(C 0-3 The heterocycloalkyl moieties of the alkylene)-heterocycloalkyl groups are each optionally substituted by one or more groups R 12 replace.

[0084] R 12 Each independently selected from C 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, -OH, -O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -NH2, -NH(C 1-5 Alkyl), -N(C 1-5 Alkyl)(C 1-5 alkyl), halogen, C 1-5 Haloalkyl, -O-(C 1-5 haloalkyl), -CN, -CHO, -CO-(C 1-5 alkyl), -COOH, -CO-O-(C 1-5 alkyl), -O-CO-(C 1-5 alkyl), -CO-NH2, -CO-NH(C 1-5 Alkyl), -CO-N(C 1-5 Alkyl)(C 1-5 alkyl), -NH-CO-(C 1-5 Alkyl), -N(C 1-5 alkyl)-CO-(C 1-5 alkyl), -SO2-NH2, -SO2-NH(C 1-5 Alkyl), -SO2-N(C 1-5 Alkyl)(C 1-5 Alkyl), -NH-SO2-(C 1-5 Alkyl), -N(C 1-5 alkyl)-SO2-(C 1-5 alkyl), cycloalkyl and heterocycloalkyl.

[0085] The ring atoms X1, X2, X3 and X4 in formula (I) have the following meanings: X1 is C(R X1 ) or N; X2 is C(-LR X2) or N; X3 is C(R X3 ) or N; and X4 is C(R X4 ) or N; wherein at least one of the ring atoms X1, X2, X3 and X4 is not N.

[0086] R X1 Selected from hydrogen, C 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, -(C 0-3 Alkylene)-OH, -(C 0-3 Alkylene)-O(C 1-5 Alkyl), -(C 0-3 Alkylene)-SH, -(C 0-3 Alkylene)-S(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH2, -(C 0-3 Alkylene)-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-halogen, -(C 0-3 alkylene)-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-O-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-CN,-(C 0-3 Alkylene)-CHO, -(C 0-3 alkylene)-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-COOH, -(C 0-3 Alkylene)-CO-O-(C 1-5 Alkyl), -(C 0-3 Alkylene)-O-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-CO-NH2, -(C 0-3 Alkylene)-CO-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-CO-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 alkyl)-CO-(C 1-5 Alkyl), -(C0-3 Alkylene)-SO2-NH2, -(C 0-3 Alkylene)-SO2-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO2-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH-SO2-(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 alkyl)-SO2-(C 1-5 Alkyl), -(C 0-3 Alkylene)-aryl, -(C 0-3 Alkylene)-heteroaryl, -(C 0-3 alkylene)-cycloalkyl and -(C 0-3 alkylene)-heterocycloalkyl, wherein the -(C 0-3 Alkylene)-aryl in the aryl part, the -(C 0-3 The heteroaryl portion of the -(C 0-3 The cycloalkyl portion of the -(C 0-3 The heterocycloalkyl moieties of the alkylene)-heterocycloalkyl groups are each optionally substituted by one or more groups R X11 replace.

[0087] R X11 Each independently selected from C 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, -OH, -O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -NH2, -NH(C 1-5 Alkyl), -N(C 1-5 Alkyl)(C 1-5 alkyl), halogen, C 1-5 Haloalkyl, -O-(C 1-5 haloalkyl), -CN, -CHO, -CO-(C 1-5 alkyl), -COOH, -CO-O-(C 1-5 alkyl), -O-CO-(C 1-5 alkyl), -CO-NH2, -CO-NH(C 1-5 Alkyl), -CO-N(C 1-5 Alkyl)(C 1-5 alkyl), -NH-CO-(C 1-5 Alkyl), -N(C 1-5 alkyl)-CO-(C1-5 alkyl), -SO2-NH2, -SO2-NH(C 1-5 Alkyl), -SO2-N(C 1-5 Alkyl)(C 1-5 Alkyl), -NH-SO2-(C 1-5 Alkyl), -N(C 1-5 alkyl)-SO2-(C 1-5 alkyl), cycloalkyl and heterocycloalkyl.

[0088] L is selected from covalent bond, C 1-10 Alkylene, C 2-10 Alkenylene and C 2-10 Alkynylidene, wherein the C 1-10 Alkylene, the C 2-10 Alkenylene or the C 2-10 One or more -CH2- units contained in the alkynylene group are each optionally replaced by a group independently selected from the group consisting of: -O-, -CO-, -C(=O)O-, -OC(=O)-, -NH-, -N(C 1-5 Alkyl)-、-NH-CO-、-N(C 1-5 Alkyl)-CO-, -CO-NH-, -CO-N(C 1-5 Alkyl)-、-S-、-SO-、-SO2-、-SO2-NH-、-SO2-N(C 1-5 Alkyl)-、-NH-SO2-、-N(C 1-5 alkyl)-SO2-, carbocyclylene and heterocyclylene, wherein the carbocyclylene and the heterocyclylene are each optionally substituted by one or more groups independently selected from the following: C 1-4 Alkyl, -OH, -O(C 1-4 alkyl), -SH, -S(C 1-5 alkyl), -NH2, -NH(C 1-4 Alkyl), -N(C 1-4 Alkyl)(C 1-4 alkyl), halogen, C 1-5 Haloalkyl, -O-(C 1-5 haloalkyl) and -CN, and further wherein said C 1-10 Alkylene, the C 2-10 Alkenylene and the C 2-10 Each alkynylene group is optionally substituted with one or more groups independently selected from the group consisting of halogen, C 1-5 Haloalkyl, -O-(C 1-5 haloalkyl), -CN, -OH, -O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -NH2, -NH(C1-5 alkyl) and -N(C 1-5 Alkyl)(C 1-5 alkyl).

[0089] R X2 Selected from C 2-10 Alkyl, carbocyclic, heterocyclic and -L 1 -R X21 , wherein the C 2-10 The alkyl group, the carbocyclyl group and the heterocyclyl group are each optionally substituted by one or more groups R X22 replace.

[0090] L 1 Selected from covalent bonds, C 1-10 Alkylene, C 2-10 Alkenylene and C 2-10 Alkynylidene, wherein the C 1-10 Alkylene, the C 2-10 Alkenylene or the C 2-10 One or more -CH2- units contained in the alkynylene group are each optionally replaced by a group independently selected from the group consisting of: -O-, -CO-, -C(=O)O-, -OC(=O)-, -NH-, -N(C 1-5 Alkyl)-、-NH-CO-、-N(C 1-5 Alkyl)-CO-, -CO-NH-, -CO-N(C 1-5 Alkyl)-、-S-、-SO-、-SO2-、-SO2-NH-、-SO2-N(C 1-5 alkyl)-, -NH-SO2- and -N(C 1-5 alkyl)-SO2-, and further wherein said C 1-10 Alkylene, the C 2-10 Alkenylene and the C 2-10 Each alkynylene group is optionally substituted with one or more groups independently selected from the group consisting of halogen, C 1-5 Haloalkyl, -O-(C 1-5 haloalkyl), -CN, -OH, -O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -NH2, -NH(C 1-5 alkyl) and -N(C 1-5 Alkyl)(C 1-5 alkyl).

[0091] R X21 Selected from C 2-5 Alkyl, carbocyclyl and heterocyclyl, wherein the carbocyclyl and heterocyclyl are each optionally substituted by one or more groups R X22 replace.

[0092] R X22 Each independently selected from C 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, -(C 0-3 Alkylene)-OH, -(C 0-3 Alkylene)-O(C 1-5 Alkyl), -(C 0-3 Alkylene)-SH, -(C 0-3 Alkylene)-S(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH2, -(C 0-3 Alkylene)-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-halogen, -(C 0-3 alkylene)-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-O-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-CN,-(C 0-3 Alkylene)-CHO, -(C 0-3 alkylene)-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-COOH, -(C 0-3 Alkylene)-CO-O-(C 1-5 Alkyl), -(C 0-3 Alkylene)-O-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-CO-NH2, -(C 0-3 Alkylene)-CO-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-CO-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 alkyl)-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO2-NH2, -(C 0-3 Alkylene)-SO2-NH(C 1-5 Alkyl), -(C0-3 Alkylene)-SO2-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH-SO2-(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 alkyl)-SO2-(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO2-(C 1-5 Alkyl), -(C 0-3 Alkylene)-aryl, -(C 0-3 Alkylene)-heteroaryl, -(C 0-3 alkylene)-cycloalkyl and -(C 0-3 alkylene)-heterocycloalkyl, wherein the -(C 0-3 Alkylene)-aryl in the aryl part, the -(C 0-3 The heteroaryl portion of the -(C 0-3 The cycloalkyl portion of the -(C 0-3 The heterocycloalkyl moieties of the alkylene)-heterocycloalkyl groups are each optionally substituted by one or more groups R X23 replace.

[0093] R X23 Each independently selected from C 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, -OH, -O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -NH2, -NH(C 1-5 Alkyl), -N(C 1-5 Alkyl)(C 1-5 alkyl), halogen, C 1-5 Haloalkyl, -O-(C 1-5 haloalkyl), -CN, -CHO, -CO-(C 1-5 alkyl), -COOH, -CO-O-(C 1-5 alkyl), -O-CO-(C 1-5 alkyl), -CO-NH2, -CO-NH(C 1-5 Alkyl), -CO-N(C 1-5 Alkyl)(C 1-5 alkyl), -NH-CO-(C 1-5 Alkyl), -N(C 1-5alkyl)-CO-(C 1-5 alkyl), -SO2-NH2, -SO2-NH(C 1-5 Alkyl), -SO2-N(C 1-5 Alkyl)(C 1-5 Alkyl), -NH-SO2-(C 1-5 Alkyl), -N(C 1-5 alkyl)-SO2-(C 1-5 Alkyl), -SO-(C 1-5 alkyl), -SO2-(C 1-5 alkyl), cycloalkyl and heterocycloalkyl.

[0094] R X3 Selected from hydrogen, C 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, -(C 0-3 Alkylene)-OH, -(C 0-3 Alkylene)-O(C 1-5 Alkyl), -(C 0-3 Alkylene)-SH, -(C 0-3 Alkylene)-S(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH2, -(C 0-3 Alkylene)-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-halogen, -(C 0-3 alkylene)-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-O-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-CN,-(C 0-3 Alkylene)-CHO, -(C 0-3 alkylene)-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-COOH, -(C 0-3 Alkylene)-CO-O-(C 1-5 Alkyl), -(C 0-3 Alkylene)-O-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-CO-NH2, -(C 0-3 Alkylene)-CO-NH(C 1-5 Alkyl), -(C 0-3Alkylene)-CO-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 alkyl)-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO2-NH2, -(C 0-3 Alkylene)-SO2-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO2-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH-SO2-(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 alkyl)-SO2-(C 1-5 Alkyl), -(C 0-3 Alkylene)-aryl, -(C 0-3 Alkylene)-heteroaryl, -(C 0-3 alkylene)-cycloalkyl and -(C 0-3 alkylene)-heterocycloalkyl, wherein the -(C 0-3 Alkylene)-aryl in the aryl part, the -(C 0-3 The heteroaryl portion of the -(C 0-3 The cycloalkyl portion of the -(C 0-3 The heterocycloalkyl moieties of the alkylene)-heterocycloalkyl groups are each optionally substituted by one or more groups R X31 replace.

[0095] R X31 Each independently selected from C 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, -OH, -O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -NH2, -NH(C 1-5 Alkyl), -N(C 1-5 Alkyl)(C 1-5 alkyl), halogen, C 1-5 Haloalkyl, -O-(C 1-5 haloalkyl), -CN, -CHO, -CO-(C 1-5 alkyl), -COOH, -CO-O-(C 1-5alkyl), -O-CO-(C 1-5 alkyl), -CO-NH2, -CO-NH(C 1-5 Alkyl), -CO-N(C 1-5 Alkyl)(C 1-5 alkyl), -NH-CO-(C 1-5 Alkyl), -N(C 1-5 alkyl)-CO-(C 1-5 alkyl), -SO2-NH2, -SO2-NH(C 1-5 Alkyl), -SO2-N(C 1-5 Alkyl)(C 1-5 Alkyl), -NH-SO2-(C 1-5 Alkyl), -N(C 1-5 alkyl)-SO2-(C 1-5 alkyl), cycloalkyl and heterocycloalkyl.

[0096] R X4 Selected from hydrogen, C 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, -(C 0-3 Alkylene)-OH, -(C 0-3 Alkylene)-O(C 1-5 Alkyl), -(C 0-3 Alkylene)-SH, -(C 0-3 Alkylene)-S(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH2, -(C 0-3 Alkylene)-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-halogen, -(C 0-3 alkylene)-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-O-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-CN,-(C 0-3 Alkylene)-CHO, -(C 0-3 alkylene)-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-COOH, -(C 0-3 Alkylene)-CO-O-(C 1-5 Alkyl), -(C 0-3 Alkylene)-O-CO-(C 1-5Alkyl), -(C 0-3 Alkylene)-CO-NH2, -(C 0-3 Alkylene)-CO-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-CO-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 alkyl)-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO2-NH2, -(C 0-3 Alkylene)-SO2-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO2-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH-SO2-(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 alkyl)-SO2-(C 1-5 Alkyl), -(C 0-3 Alkylene)-aryl, -(C 0-3 Alkylene)-heteroaryl, -(C 0-3 alkylene)-cycloalkyl and -(C 0-3 alkylene)-heterocycloalkyl, wherein the -(C 0-3 Alkylene)-aryl in the aryl part, the -(C 0-3 The heteroaryl portion of the -(C 0-3 The cycloalkyl portion of the -(C 0-3 The heterocycloalkyl moieties of the alkylene)-heterocycloalkyl groups are each optionally substituted by one or more groups R X41 replace.

[0097] R X41 Each independently selected from C 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, -OH, -O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -NH2, -NH(C 1-5 Alkyl), -N(C 1-5 Alkyl)(C 1-5 alkyl), halogen, C1-5 Haloalkyl, -O-(C 1-5 haloalkyl), -CN, -CHO, -CO-(C 1-5 alkyl), -COOH, -CO-O-(C 1-5 alkyl), -O-CO-(C 1-5 alkyl), -CO-NH2, -CO-NH(C 1-5 Alkyl), -CO-N(C 1-5 Alkyl)(C 1-5 alkyl), -NH-CO-(C 1-5 Alkyl), -N(C 1-5 alkyl)-CO-(C 1-5 alkyl), -SO2-NH2, -SO2-NH(C 1-5 Alkyl), -SO2-N(C 1-5 Alkyl)(C 1-5 Alkyl), -NH-SO2-(C 1-5 Alkyl), -N(C 1-5 alkyl)-SO2-(C 1-5 alkyl), cycloalkyl and heterocycloalkyl.

[0098] According to the present invention, the following compounds are excluded from formula (I):

[0099] and

[0100] The present invention also relates to a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable excipient. Thus, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising any of the above entities and a pharmaceutically acceptable excipient for use as a medicament.

[0101] The present invention also relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising any of the aforementioned entities and a pharmaceutically acceptable excipient for use in the treatment or prevention of disorders associated with altered glutamatergic signaling and / or function and / or disorders that can be affected by alterations in glutamate levels or signaling.

[0102] Furthermore, the present invention relates to the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating or preventing disorders associated with altered glutamatergic signaling and / or function and / or disorders that can be affected by alterations in glutamate levels or signaling.

[0103] The present invention also relates to a method for treating or preventing a condition associated with altered glutamatergic signaling and / or function and / or a condition that can be affected by altered glutamate levels or signaling, the method comprising administering to an individual (preferably a human) in need thereof a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising any of the aforementioned entities and a pharmaceutically acceptable excipient. It will be understood that according to this method, a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition is administered.

[0104] Conditions that can be treated or prevented according to the present invention, i.e., conditions associated with altered glutamatergic signaling and / or function and / or conditions that can be affected by alterations in glutamate levels or signaling, include, in particular: epilepsy, including neonatal, infantile, childhood and adult syndromes, partial (related to localization) and generalized epilepsy, with partial and generalized, convulsive and non-convulsive seizures, with or without impaired consciousness and status epilepticus; dementias and related diseases, including dementias of the Alzheimer's type (DAT), Alzheimer's disease, Pick's disease, vascular dementia, Lewy-body disease, dementias due to metabolic, toxic and deficiency diseases (including alcoholism, hypothyroidism and vitamin B12 deficiency), AIDS-dementia complex, Creutzfeld-Jacob disease and atypical subacute spongiform encephalopathies; spongiformencephalopathy); parkinsonism and movement disorders, including Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, hepatolenticular degeneration, chorea (including Huntington's disease and hemishambulation), athetosis, dystonia (including spasmodic torticollis, occupational movement disorder, Gilles de la Tourette syndrome), tardive dyskinesia or drug-induced movement disorders (including levodopa-induced dyskinesia), tremor, and myoclonus; motor neuron disease or amyotrophic lateral sclerosis (ALS); other neurodegenerative and / or genetic disorders of the nervous system, including spinocerebellar degeneration such as Friedrich's ataxia Disorders of the peripheral nervous system, including trigeminal neuralgia, facial nerve disorders, other cranial nerve disorders, nerve root and plexus disorders, mononeuritis such as carpal tunnel syndrome and sciatica, hereditary and idiopathic peripheral neuropathies, and inflammatory and toxic neuropathies; Multiple sclerosis and other autoimmune diseases, including lupus (i.e., systemic lupus erythematosus) and psoriasis; Cerebral palsy (spastic), monoplegic, paraplegic, or quadriplegic; Hemiplegia and hemiparesis, flaccid or spastic, and other paralytic syndromes;Cerebrovascular disorders, including subarachnoid hemorrhage, intracerebral hemorrhage, anterior cerebral artery occlusion and stenosis, cerebral artery occlusion (including thrombosis and embolism), cerebral ischemia, stroke, transient ischemic attack, atherosclerosis, cerebrovascular dementia, aneurysm, brain defects caused by heart bypass surgery and transplantation (cerebral deficit); migraine, including classic migraine and variants such as cluster headache; headache; myoneural disorders, including myasthenia gravis, acute muscle spasms, myopathies, including muscular dystrophy, myotonia, and familial periodic paralysis; ocular and visual pathway disorders, including retinal disorders and visual disturbances; intracranial trauma / injury and its sequelae; trauma / injury to the nerves and spinal cord and its sequelae; intoxication and toxic effects of non-drug substances; accidental poisoning by drugs, pharmaceutical substances, and biological products acting on the central, peripheral, and autonomic nervous systems; neurological and psychiatric adverse effects of drugs, pharmaceutical substances, and biological substances; disorders of sphincter control and sexual function; social skills disorders, such as autism or autism spectrum disorder, or fragile X syndrome; psychiatric disorders usually diagnosed in infancy, childhood, or adolescence, including mental retardation, learning disabilities, motor skills disorders, communication disorders, combined mental developmental disorders, attention deficit disorder, and disruptive behavior disorder disorders, feeding and eating disorders, tic disorders, elimination disorders; delirium and other cognitive disorders; substance-related disorders, including alcohol-related disorders, nicotine-related disorders, disorders related to cocaine, opioids, cannabis, hallucinogens, and other drugs; schizophrenia and other psychotic disorders; mood disorders, including depressive disorders and bipolar disorder; anxiety disorders, including panic disorder, phobias, obsessive-compulsive disorder, stress disorder, and generalized anxiety disorder; eating disorders, including anorexia and bulimia; sleep disorders, including dyssomnia (insomnia, hypersomnia, narcolepsy, and breathing-related sleep disorders) and parasomnias; drug-induced movement disorders (including neuroleptic-induced parkinsonism and tardive dyskinesia); endocrine and metabolic diseases, including diabetes, endocrine gland disorders, and hypoglycemia; acute and chronic pain; nausea and vomiting; irritable bowel syndrome; or cancer.

[0105] Preferably, the condition to be treated or prevented according to the present invention is selected from the group consisting of dementia and related diseases, including dementia of the Alzheimer type (DAT), Alzheimer's disease, Pick's disease, vascular dementia, Lewy body disease, dementias caused by metabolic, toxic and deficiency diseases (including alcoholism, hypothyroidism and vitamin B12 deficiency), AIDS dementia complex, Creutzfeldt-Jakob disease and atypical subacute spongiform encephalopathies; parkinsonism and movement disorders, including Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, hepatolenticular degeneration, chorea (including Huntington's disease and hemishacitia), athetosis, dystonia (including spasmodic torticollis, occupational dyskinesia, Gilles de la Tourette syndrome), tardive dyskinesia or drug-induced movement disorders (including levodopa-induced dyskinesia), tremor and myoclonus; social skills disorders such as autism or autism spectrum disorder, or fragile X syndrome; acute and chronic pain; Anxiety disorders, including panic disorder, phobia, obsessive-compulsive disorder, stress disorder and generalized anxiety disorder; schizophrenia and other mental disorders; mood disorders, including depressive disorders and bipolar disorder; endocrine and metabolic diseases, including diabetes, endocrine gland disorders and hypoglycemia; or cancer. More preferably, the condition treated or prevented according to the present invention is Parkinson's disease.

[0106] The present invention also provides a method for identifying a test agent that binds to metabotropic glutamate receptor 4 (mGluR4), or in other words, a method for determining the ability of one or more test agents to bind to the receptor, the method comprising the steps of: (a) contacting mGluR4 with a compound of the present invention (i.e., a compound of formula (I) or a pharmaceutically acceptable salt thereof) that is labeled, preferably radioactively labeled or fluorescently labeled, under conditions that permit binding of the compound to mGluR4, thereby producing a bound, labeled compound; (b) detecting a signal corresponding to the amount of bound, labeled compound in the absence of the test agent; (c) contacting the bound, labeled compound with a test agent; (d) detecting a signal corresponding to the amount of bound, labeled compound in the presence of the test agent; and (e) comparing the signal detected in step (d) with the signal detected in step (b) to determine whether the test agent is bound to mGluR4. As can be understood, the signal detected in step (d) is substantially unchanged compared to the signal detected in step (b) indicating that the test substance is not bound to receptors or is lower than the compound of the present invention in terms of the intensity of receptor binding. The signal detected in step (d) is reduced or increased compared to the signal detected in step (b) indicating that the test substance is bound to receptors. Therefore, the substance that is combined with mGluR4 can be identified in the test substance used in the above method. It can also be understood that the compound of unbound labeling is preferably removed, for example, the compound of unbound labeling is removed in the washing step and then steps (b) and (d) are carried out.

[0107] The mGluR4 used in the above methods can be a human form (see, e.g., Flor PJ et al. Neuropharmacology. 1995. 34: 149-155; Makoff A et al. Brain Res. Mol. Brain Res. 1996. 37: 239-248; or Wu S et al. Brain Res. Mol. Brain Res. 1998. 53: 88-97), such as the protein with accession number NP_000832 or a protein having at least 80% (preferably at least 90%; more preferably at least 95%; even more preferably at least 99%) amino acid identity with accession number NP_000832, or a non-human form, including, e.g., a mouse form or a rat form (see, e.g., Tanabe Y et al. Neuron. 1992. 8: 169-179), or a homolog thereof found in a different species (e.g., in a different mammalian species), or a mutant protein of any of the above entities, wherein the mutant protein retains mGluR4 activity. The mutant protein can preferably be obtained by substituting, inserting, adding, and / or removing one or more (e.g., 1-20, including 1-10 or 1-3) amino acid residues of the above entities. The mGluR4 used in the above method can also be a functional fragment of any of the above entities (including the mutant protein), i.e., a fragment that retains the mGluR4 activity of each of the above entities, or in other words, a fragment that has substantially the same biological activity as each of the above entities (i.e., at least about 60% activity, preferably at least about 70% activity, more preferably at least about 80% activity, and even more preferably at least about 90% activity). Techniques known in the art, such as knockout and rescue experiments, can be readily used by those skilled in the art. Furthermore, the mGluR4 used in the above methods may also be a compound comprising any one or more of the above entities (including but not limited to the protein with accession number NP_000832, a protein having at least 80% amino acid identity with the protein with accession number NP_000832, or a functional fragment thereof), wherein mGluR4 activity is retained. Preferably, the mGluR4 used in the above methods is a human form.

[0108] The present invention also relates to the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof as a positive allosteric modulator of mGluR4 (i.e., as an mGluR4 PAM) in research, particularly as a research tool compound. Thus, the present invention relates to the in vitro use of a compound of formula (I) or a pharmaceutically acceptable salt thereof as an mGluR4 PAM, particularly to the in vitro use of a compound of formula (I) or a pharmaceutically acceptable salt thereof as a research tool compound, which functions as an mGluR4 PAM. The present invention also relates to methods, particularly in vitro methods, for achieving positive allosteric modulation of mGluR4, comprising applying a compound of formula (I) or a pharmaceutically acceptable salt thereof. The present invention further relates to methods for achieving positive allosteric modulation of mGluR4, comprising applying a compound of formula (I) or a pharmaceutically acceptable salt thereof to a test sample (e.g., a biological sample) or a test animal (i.e., a non-human test animal). The present invention also relates to methods, particularly in vitro methods, for achieving positive allosteric modulation of mGluR4 in a sample (e.g., a biological sample), comprising applying a compound of formula (I) or a pharmaceutically acceptable salt thereof to the sample. The present invention further provides a method for achieving positive allosteric modulation of mGluR4, comprising contacting a test sample (e.g., a biological sample) or a test animal (i.e., a non-human test animal) with a compound of formula (I) or a pharmaceutically acceptable salt thereof. The mGluR4 is preferably human mGluR4. The terms "sample," "test sample," and "biological sample" include, but are not limited to, cells, cell cultures, or cellular or subcellular extracts; biopsy material obtained from an animal (e.g., a human), or an extract thereof; or blood, serum, plasma, saliva, urine, feces, or any other body fluid or extract thereof. It should be understood that the term "in vitro" in the specific context herein is used to mean "outside a living human or animal," which specifically includes experiments performed with cells, cellular or subcellular extracts, and / or biomolecules in an artificial environment, such as an aqueous solution or culture medium, which can be provided, for example, in a flask, test tube, petri dish, or microtiter plate.

[0109] The compounds of formula (I) or pharmaceutically acceptable salts thereof provided by the present invention are described in more detail below:

[0110]

[0111] R 1 Any one selected from the following groups:

[0112]

[0113]

[0114] wherein each of the above groups is optionally replaced by one or more (eg one, two or three) groups R 11 replace.

[0115] R 1 Examples include each corresponding group R contained in any one of the specific compounds of the present invention disclosed in the Examples section 1 Any one of .

[0116] Preferably, R 1 Any one selected from the following groups:

[0117]

[0118] wherein each of the groups depicted above is optionally replaced by one or more groups R 11 replace.

[0119] or R 1 is a group It is optionally substituted by one or more groups R 11A replace.

[0120] More preferably, R 1 Selected from one of the following groups:

[0121]

[0122] wherein each of the groups depicted above is optionally replaced by one or more groups R 11 replace.

[0123] Even more preferably, R 1 Selected from one of the following groups:

[0124]

[0125] wherein each of the groups depicted above is optionally replaced by one or more groups R 11 replace.

[0126] Even more preferably, R 1 Selected from one of the following groups:

[0127]

[0128] wherein each of the groups depicted above is optionally replaced by one or more groups R 11 replace.

[0129] Even more preferably, R 1 Selected from one of the following groups:

[0130]

[0131] wherein each of the groups depicted above is optionally replaced by one or more groups R 11 replace.

[0132] Still more preferably, R 1 is a group:

[0133]

[0134] wherein the groups depicted above are optionally replaced by one or more groups R 11 replace.

[0135] R 11 Each independently selected from C 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, -(C 0-3 Alkylene)-OH, -(C 0-3 Alkylene)-O(C 1-5 Alkyl), -(C 0-3 Alkylene)-SH, -(C 0-3 Alkylene)-S(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH2, -(C 0-3 Alkylene)-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-halogen, -(C 0-3 alkylene)-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-O-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-CN,-(C 0-3 Alkylene)-CHO, -(C 0-3 alkylene)-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-COOH, -(C 0-3 Alkylene)-CO-O-(C 1-5 Alkyl), -(C 0-3 Alkylene)-O-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-CO-NH2, -(C 0-3 Alkylene)-CO-NH(C 1-5 Alkyl), -(C 0-3Alkylene)-CO-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 alkyl)-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO2-NH2, -(C 0-3 Alkylene)-SO2-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO2-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH-SO2-(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 alkyl)-SO2-(C 1-5 Alkyl), -(C 0-3 Alkylene)-aryl, -(C 0-3 Alkylene)-heteroaryl, -(C 0-3 alkylene)-cycloalkyl and -(C 0-3 alkylene)-heterocycloalkyl,

[0136] wherein said-(C 0-3 Alkylene)-aryl in the aryl part, the -(C 0-3 The heteroaryl portion of the -(C 0-3 The cycloalkyl portion of the -(C 0-3 Each heterocycloalkyl moiety in the heterocycloalkyl group is optionally replaced by one or more (eg, one, two, or three) groups R 12 replace,

[0137] And in addition, R 12 Each independently selected from C 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, -OH, -O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -NH2, -NH(C 1-5 Alkyl), -N(C 1-5 Alkyl)(C 1-5 alkyl), halogen, C 1-5 Haloalkyl, -O-(C 1-5 haloalkyl), -CN, -CHO, -CO-(C1-5 alkyl), -COOH, -CO-O-(C 1-5 alkyl), -O-CO-(C 1-5 alkyl), -CO-NH2, -CO-NH(C 1-5 Alkyl), -CO-N(C 1-5 Alkyl)(C 1-5 alkyl), -NH-CO-(C 1-5 Alkyl), -N(C 1-5 alkyl)-CO-(C 1-5 alkyl), -SO2-NH2, -SO2-NH(C 1-5 Alkyl), -SO2-N(C 1-5 Alkyl)(C 1-5 Alkyl), -NH-SO2-(C 1-5 Alkyl), -N(C 1-5 alkyl)-SO2-(C 1-5 alkyl), cycloalkyl and heterocycloalkyl.

[0138] Preferably, R 11 Each independently selected from C 1-5 Alkyl, -(C 0-3 Alkylene)-OH, -(C 0-3 Alkylene)-O(C 1-5 Alkyl), -(C 0-3 Alkylene)-SH, -(C 0-3 Alkylene)-S(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH2, -(C 0-3 Alkylene)-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-halogen, -(C 0-3 alkylene)-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-O-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-CN,-(C 0-3 Alkylene)-CHO, -(C 0-3 alkylene)-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-COOH, -(C 0-3 Alkylene)-CO-O-(C 1-5 Alkyl), -(C 0-3Alkylene)-O-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-CO-NH2, -(C 0-3 Alkylene)-CO-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-CO-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 alkyl)-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO2-NH2, -(C 0-3 Alkylene)-SO2-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO2-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH-SO2-(C 1-5 alkyl) and -(C 0-3 Alkylene)-N(C 1-5 alkyl)-SO2-(C 1-5 alkyl).

[0139] More preferably, R 11 Each independently selected from C 1-5 Alkyl, -(C 0-3 Alkylene)-OH, -(C 0-3 Alkylene)-O(C 1-5 Alkyl), -(C 0-3 Alkylene)-SH, -(C 0-3 Alkylene)-S(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH2, -(C 0-3 Alkylene)-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-halogen, -(C 0-3 alkylene)-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-O-(C 1-5 haloalkyl) and -(C 0-3 alkylene)-CN.

[0140] Even more preferably, R 11 Each independently selected from C 1-5 Alkyl (such as methyl or ethyl), -OH, -O(C 1-5 alkyl) (e.g., methoxy or ethoxy), halogen (e.g., -F or -Cl), C 1-5 Haloalkyl (e.g. -CF3), -O-(C 1-5 haloalkyl) (e.g., -OCF3) and -CN.

[0141] R 11A Each independently selected from C 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, -(C 0-3 Alkylene)-OH, -(C 0-3 Alkylene)-O(C 1-5 Alkyl), -(C 0-3 Alkylene)-SH, -(C 0-3 Alkylene)-S(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH2, -(C 0-3 Alkylene)-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-halogen, -(C 0-3 alkylene)-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-O-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-CN,-(C 0-3 Alkylene)-CHO, -(C 0-3 alkylene)-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-COOH, -(C 0-3 Alkylene)-CO-O-(C 1-5 Alkyl), -(C 0-3 Alkylene)-O-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-CO-NH2, -(C 0-3 Alkylene)-CO-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-CO-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C0-3 Alkylene)-NH-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 alkyl)-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO2-NH2, -(C 0-3 Alkylene)-SO2-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO2-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH-SO2-(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 alkyl)-SO2-(C 1-5 Alkyl), -(C 0-3 Alkylene)-heteroaryl, -(C 0-3 alkylene)-cycloalkyl and -(C 0-3 alkylene)-heterocycloalkyl,

[0142] wherein said-(C 0-3 The heteroaryl portion of the -(C 0-3 The cycloalkyl portion of the -(C 0-3 The heterocycloalkyl moieties of the alkylene)-heterocycloalkyl groups are each optionally substituted by one or more (eg one, two or three) groups R 12 replace,

[0143] And in addition, R 12 Each independently selected from C 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, -OH, -O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -NH2, -NH(C 1-5 Alkyl), -N(C 1-5 Alkyl)(C 1-5 alkyl), halogen, C 1-5 Haloalkyl, -O-(C 1-5 haloalkyl), -CN, -CHO, -CO-(C 1-5 alkyl), -COOH, -CO-O-(C 1-5 alkyl), -O-CO-(C 1-5 alkyl), -CO-NH2, -CO-NH(C 1-5Alkyl), -CO-N(C 1-5 Alkyl)(C 1-5 alkyl), -NH-CO-(C 1-5 Alkyl), -N(C 1-5 alkyl)-CO-(C 1-5 alkyl), -SO2-NH2, -SO2-NH(C 1-5 Alkyl), -SO2-N(C 1-5 Alkyl)(C 1-5 Alkyl), -NH-SO2-(C 1-5 Alkyl), -N(C 1-5 alkyl)-SO2-(C 1-5 alkyl), cycloalkyl and heterocycloalkyl.

[0144] Preferably, R 11A Each independently selected from C 1-5 Alkyl, -(C 0-3 Alkylene)-OH, -(C 0-3 Alkylene)-O(C 1-5 Alkyl), -(C 0-3 Alkylene)-SH, -(C 0-3 Alkylene)-S(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH2, -(C 0-3 Alkylene)-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-halogen, -(C 0-3 alkylene)-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-O-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-CN,-(C 0-3 Alkylene)-CHO, -(C 0-3 alkylene)-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-COOH, -(C 0-3 Alkylene)-CO-O-(C 1-5 Alkyl), -(C 0-3 Alkylene)-O-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-CO-NH2, -(C 0-3 Alkylene)-CO-NH(C 1-5 Alkyl), -(C0-3 Alkylene)-CO-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 alkyl)-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO2-NH2, -(C 0-3 Alkylene)-SO2-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO2-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH-SO2-(C 1-5 alkyl) and -(C 0-3 Alkylene)-N(C 1-5 alkyl)-SO2-(C 1-5 alkyl).

[0145] More preferably, R 11A Each independently selected from C 1-5 Alkyl, -(C 0-3 Alkylene)-OH, -(C 0-3 Alkylene)-O(C 1-5 Alkyl), -(C 0-3 Alkylene)-SH, -(C 0-3 Alkylene)-S(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH2, -(C 0-3 Alkylene)-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-halogen, -(C 0-3 alkylene)-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-O-(C 1-5 haloalkyl) and -(C 0-3 alkylene)-CN.

[0146] Even more preferably, R 11A Each independently selected from C 1-5 Alkyl (such as methyl or ethyl), -OH, -O(C 1-5alkyl) (e.g., methoxy or ethoxy), halogen (e.g., -F or -Cl), C 1-5 Haloalkyl (e.g. -CF3), -O-(C 1-5 haloalkyl) (e.g., -OCF3) and -CN.

[0147] As mentioned above, R 1 Can be a structure wherein the pyridin-2-yl group is optionally substituted by one or more groups R 11 replace.

[0148] In this case, it is preferred that the pyridin-2-yl group is a substituted pyridin-2-yl group selected from any one of the following groups:

[0149]

[0150] wherein each of the groups depicted above is optionally further substituted by one or more (eg one or two) groups R 11 replace.

[0151] More preferably, the pyridin-2-yl group is a substituted pyridin-2-yl group selected from any one of the following groups:

[0152]

[0153] wherein each of the groups depicted above is optionally further substituted by one or more groups (e.g., one group) R 11 replace.

[0154] Even more preferably, the pyridin-2-yl group is a trifluoromethyl- or methyl-substituted pyridin-2-yl group selected from any one of the following groups:

[0155]

[0156] Therefore, it is particularly preferred that R 1 Any one selected from the following groups:

[0157]

[0158] wherein each of the groups depicted above is optionally further substituted by one or more groups R 11 substituted (and wherein the groups depicted above are preferably not further substituted by any group R 11 replace).

[0159] Still more preferably, R 1 yes:

[0160]

[0161] wherein the groups depicted above are optionally replaced by one or more groups R 11 replace.

[0162] Most preferably, R 1 yes:

[0163]

[0164] The ring atoms X1, X2, X3 and X4 in formula (I) have the following meanings: X1 is C(R X1 ) or N; X2 is C(-LR X2 ) or N; X3 is C(R X3 ) or N; and X4 is C(R X4 ) or N; wherein at least one of the ring atoms X1, X2, X3 and X4 is not N.

[0165] Preferably, X1 is C(R X1 ) or N; X2 is C(-LR X2 ); X3 is C(R X3 ) or N; and X4 is C(R X4 ) or N.

[0166] More preferably, X1 is C(R X1 ) or N; X2 is C(-LR X2 ); X3 is C(R X3 ) or N; and X4 is C(R X4 ).

[0167] Even more preferably, X1 is C(R X1 ) or N; X2 is C(-LR X2 ); X3 is C(R X3 ) or N; and X4 is C(R X4 ); wherein one of X1 and X3 is N or both X1 and X3 are not N (ie, at least one of X1 and X3 is not N).

[0168] Even more preferably, X1 is C(R X1 ) or N; X2 is C(-LR X2 ); X3 is C(R X3 ); and X4 is C(R X4 ).

[0169] Still more preferably, X1 is C(R X1 ), X2 is C(-LR X2 ), X3 is C(R X3 ), and X4 is C(R X4 ).

[0170] Therefore, according to the above definitions of X1, X2, X3 and X4, it is particularly preferred that the compound of formula (I) has the following structure:

[0171]

[0172] Even more preferred are compounds of formula (I) having the structure:

[0173]

[0174] R X1 Selected from hydrogen, C 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, -(C 0-3 Alkylene)-OH, -(C 0-3 Alkylene)-O(C 1-5 Alkyl), -(C 0-3 Alkylene)-SH, -(C 0-3 Alkylene)-S(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH2, -(C 0-3 Alkylene)-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-halogen, -(C 0-3 alkylene)-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-O-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-CN,-(C 0-3 Alkylene)-CHO, -(C 0-3 alkylene)-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-COOH, -(C 0-3 Alkylene)-CO-O-(C 1-5 Alkyl), -(C 0-3 Alkylene)-O-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-CO-NH2, -(C 0-3 Alkylene)-CO-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-CO-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C0-3 Alkylene)-NH-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 alkyl)-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO2-NH2, -(C 0-3 Alkylene)-SO2-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO2-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH-SO2-(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 alkyl)-SO2-(C 1-5 Alkyl), -(C 0-3 Alkylene)-aryl, -(C 0-3 Alkylene)-heteroaryl, -(C 0-3 alkylene)-cycloalkyl and -(C 0-3 alkylene)-heterocycloalkyl,

[0175] wherein said-(C 0-3 Alkylene)-aryl in the aryl part, the -(C 0-3 The heteroaryl portion of the -(C 0-3 The cycloalkyl portion of the -(C 0-3 The heterocycloalkyl moieties of the alkylene)-heterocycloalkyl groups are each optionally substituted by one or more (eg one, two or three) groups R X11 replace,

[0176] And in addition, R X11 Each independently selected from C 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, -OH, -O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -NH2, -NH(C 1-5 Alkyl), -N(C 1-5 Alkyl)(C 1-5 alkyl), halogen, C 1-5 Haloalkyl, -O-(C 1-5 haloalkyl), -CN, -CHO, -CO-(C 1-5 alkyl), -COOH, -CO-O-(C 1-5alkyl), -O-CO-(C 1-5 alkyl), -CO-NH2, -CO-NH(C 1-5 Alkyl), -CO-N(C 1-5 Alkyl)(C 1-5 alkyl), -NH-CO-(C 1-5 Alkyl), -N(C 1-5 alkyl)-CO-(C 1-5 alkyl), -SO2-NH2, -SO2-NH(C 1-5 Alkyl), -SO2-N(C 1-5 Alkyl)(C 1-5 Alkyl), -NH-SO2-(C 1-5 Alkyl), -N(C 1-5 alkyl)-SO2-(C 1-5 alkyl), cycloalkyl and heterocycloalkyl.

[0177] Preferably, R X1 Selected from hydrogen, C 1-5 Alkyl, -(C 0-3 Alkylene)-OH, -(C 0-3 Alkylene)-O(C 1-5 Alkyl), -(C 0-3 Alkylene)-SH, -(C 0-3 Alkylene)-S(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH2, -(C 0-3 Alkylene)-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-halogen, -(C 0-3 alkylene)-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-O-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-CN, -(C 0-3 Alkylene)-CHO, -(C 0-3 alkylene)-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-COOH, -(C 0-3 Alkylene)-CO-O-(C 1-5 Alkyl), -(C 0-3 Alkylene)-O-CO-(C 1-5 Alkyl), -(C 0-3Alkylene)-CO-NH2, -(C 0-3 Alkylene)-CO-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-CO-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 alkyl)-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO2-NH2, -(C 0-3 Alkylene)-SO2-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO2-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH-SO2-(C 1-5 alkyl) and -(C 0-3 Alkylene)-N(C 1-5 alkyl)-SO2-(C 1-5 alkyl).

[0178] More preferably, R X1 Selected from hydrogen, C 1-5 Alkyl, -(C 0-3 Alkylene)-OH, -(C 0-3 Alkylene)-O(C 1-5 Alkyl), -(C 0-3 Alkylene)-SH, -(C 0-3 Alkylene)-S(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH2, -(C 0-3 Alkylene)-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-halogen, -(C 0-3 alkylene)-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-O-(C 1-5 haloalkyl) and -(C 0-3 alkylene)-CN.

[0179] Even more preferably, R X1 Selected from hydrogen, C 1-5Alkyl, -OH, -O(C 1-5 alkyl), -NH2, -NH(C 1-5 Alkyl), -N(C 1-5 Alkyl)(C 1-5 alkyl), halogen, C 1-5 Haloalkyl, -O-(C 1-5 haloalkyl) and -CN.

[0180] Even more preferably, R X1 It's hydrogen.

[0181] L is selected from covalent bond, C 1-10 Alkylene, C 2-10 Alkenylene and C 2-10 Alkynylidene,

[0182] wherein the C 1-10 Alkylene, the C 2-10 Alkenylene or the C 2-10 One or more (e.g., one or two) -CH2- units contained in the alkynylene group are each optionally replaced by a group independently selected from the group consisting of: -O-, -CO-, -C(=O)O-, -OC(=O)-, -NH-, -N(C 1-5 Alkyl)-、-NH-CO-、-N(C 1-5 Alkyl)-CO-, -CO-NH-, -CO-N(C 1-5 Alkyl)-、-S-、-SO-、-SO2-、-SO2-NH-、-SO2-N(C 1-5 Alkyl)-、-NH-SO2-、-N(C 1-5 alkyl)-SO2-, carbocyclylene (e.g., cycloalkylene or arylene) and heterocyclylene (e.g., heterocycloalkylene or heteroarylene), wherein the carbocyclylene (or the cycloalkylene or arylene) and the heterocyclylene (or the heterocycloalkylene or heteroarylene) are each optionally substituted by one or more groups independently selected from the following: C 1-4 Alkyl, -OH, -O(C 1-4 alkyl), -SH, -S(C 1-5 alkyl), -NH2, -NH(C 1-4 Alkyl), -N(C 1-4 Alkyl)(C 1-4 alkyl), halogen, C 1-5 Haloalkyl, -O-(C 1-5 haloalkyl) and -CN,

[0183] And further wherein said C 1-10 Alkylene, the C 2-10 Alkenylene and the C 2-10Each alkynylene group is optionally substituted with one or more (eg, one, two, or three) groups independently selected from the group consisting of halogen, C 1-5 Haloalkyl, -O-(C 1-5 haloalkyl), -CN, -OH, -O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -NH2, -NH(C 1-5 alkyl) and -N(C 1-5 Alkyl)(C 1-5 alkyl).

[0184] It should be understood that if X2 is C(-LR X2 ) and L is a covalent bond, then the group R X2 Directly attached to the corresponding ring carbon atom of the quinazolinone ring of the compound of formula (I) as shown below:

[0185]

[0186] Preferably, L is a covalent bond or C 1-10 Alkylene,

[0187] wherein the C 1-10 One or two -CH2- units contained in the alkylene group are each optionally replaced by a group independently selected from the group consisting of: -O-, -CO-, -C(=O)O-, -OC(=O)-, -NH-, -N(C 1-5 Alkyl)-, -NH-CO-, -N(C 1-5 Alkyl)-CO-, -CO-NH-, -CO-N(C 1-5 Alkyl)-、-S-、-SO-、-SO2-、 -SO2-NH-、-SO2-N(C 1-5 Alkyl)-、-NH-SO2-、-N(C 1-5 alkyl)-SO2-, cycloalkylene, arylene, heterocycloalkylene and heteroarylene, wherein the cycloalkylene, the arylene, the heterocycloalkylene and the heteroarylene are each optionally substituted by one or more (e.g., one, two or three) groups independently selected from the group consisting of: C 1-4 Alkyl, -OH, -O(C 1-4 alkyl), -SH, -S(C 1-5 alkyl), -NH2, -NH(C 1-4 Alkyl), -N(C 1-4 Alkyl)(C 1-4 alkyl), halogen, C 1-5 Haloalkyl, -O-(C 1-5 haloalkyl) and -CN,

[0188] And further wherein said C 1-10 The alkylene group is optionally substituted with one or more (eg, one, two, or three) groups independently selected from the group consisting of halogen, C 1-5 Haloalkyl, -O-(C 1-5 haloalkyl), -CN, -OH, -O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -NH2, -NH(C 1-5 alkyl) and -N(C 1-5 Alkyl)(C 1-5 alkyl).

[0189] More preferably, L is a covalent bond or C 1-8 Alkylene,

[0190] wherein the C 1-8 One -CH2- unit contained in the alkylene group is optionally replaced by a group selected from the group consisting of: -O-, -CO-, -NH- and -N(C 1-5 alkyl)-,

[0191] and further wherein said C 1-8 The alkylene group is optionally substituted with one or more (eg, one, two, or three) groups independently selected from the group consisting of halogen, C 1-5 Haloalkyl, -O-(C 1-5 haloalkyl), -CN, -OH, -O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -NH2, -NH(C 1-5 alkyl) and -N(C 1-5 Alkyl)(C 1-5 alkyl).

[0192] Even more preferably, L is selected from the group consisting of a covalent bond, C 1-5 Alkylene (e.g., -CH2-, -CH2CH2-, or -CH2CH2CH2-), -O-, -O-(C 1-5 Alkylene)-(e.g., -O-CH2-, -O-CH2CH2-, -O-CH2CH2CH2- or -O-CH2CH2CH2CH2-), -CO-, -(C 1-5 Alkylene)-CO-(e.g., -CH2-CO-), -NH-, -NH-(C 1-5 Alkylene)-, -N(C 1-5 alkyl)- and -N(C 1-5 alkyl)-(C 1-5 alkylene)-,

[0193] wherein the C1-5 Alkylene or the -O-(C 1-5 Alkylene)-, the -NH-(C 1-5 Alkylene)- and said-N(C 1-5 alkyl)-(C 1-5 C contained in any one of alkylene)- 1-5 The alkylene moiety is optionally substituted with one or more groups independently selected from the group consisting of halogen, -CF3, -CN, -OH, -O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -NH2, -NH(C 1-5 alkyl) and -N(C 1-5 Alkyl)(C 1-5 alkyl).

[0194] Even more preferably, L is selected from the group consisting of a covalent bond, C 1-5 Alkylene (e.g., -CH2-, -CH2CH2-, or -CH2CH2CH2-), -O-, -O-(C 1-5 Alkylene)-(e.g., -O-CH2-, -O-CH2CH2-, -O-CH2CH2CH2- or -O-CH2CH2CH2CH2-), -NH-, -NH-(C 1-5 Alkylene)-, -N(C 1-5 alkyl)- and -N(C 1-5 alkyl)-(C 1-5 alkylene)-,

[0195] wherein the C 1-5 Alkylene or the -O-(C 1-5 Alkylene)-, the -NH-(C 1-5 Alkylene)- and said-N(C 1-5 alkyl)-(C 1-5 C contained in any one of alkylene)- 1-5 The alkylene moiety is optionally substituted with one or more groups independently selected from the group consisting of halogen, -CF3, -CN, -OH, -O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -NH2, -NH(C 1-5 alkyl) and -N(C 1-5 Alkyl)(C 1-5 alkyl).

[0196] Still more preferably, L is selected from the group consisting of a covalent bond, C 1-5 Alkylene (e.g., -CH2-, -CH2CH2-, or -CH2CH2CH2-), -O-, and -O-(C 1-5alkylene)-(e.g., -O-CH2-, -O-CH2CH2-, -O-CH2CH2CH2-, or -O-CH2CH2CH2CH2-).

[0197] R X2 Selected from C 2-10 Alkyl, carbocyclic (eg, cycloalkyl or aryl), heterocyclic (eg, heterocycloalkyl or heteroaryl), and -L 1 -R X21 , wherein the C 2-10 The alkyl group, the carbocyclyl group and the heterocyclyl group are each optionally substituted by one or more (eg one, two or three) groups R X22 replace.

[0198] For example, R X2 Can be selected from C 2-10 alkyl, carbocyclyl (eg, cycloalkyl or aryl), heterocycloalkyl, and heteroaryl, wherein the heterocycloalkyl is a monocyclic heterocycloalkyl or a spirocyclic heterocycloalkyl, and further wherein the C 2-10 The alkyl, carbocyclyl, heterocycloalkyl and heteroaryl groups are each optionally substituted by one or more (eg, one, two or three) groups R X22 replace.

[0199] Preferably, R X2 Selected from C 2-10 Alkyl, cycloalkyl, aryl, heterocycloalkyl and heteroaryl, wherein the C 2-10 The alkyl, cycloalkyl, aryl, heterocycloalkyl and heteroaryl groups are each optionally substituted by one or more (eg, one, two or three) groups R X22 Substitution; the heterocycloalkyl group may be, for example, a monocyclic heterocycloalkyl group or a spirocyclic heterocycloalkyl group.

[0200] More preferably, R X2 is selected from cycloalkyl, aryl, heterocycloalkyl and heteroaryl, wherein the cycloalkyl, the aryl, the heterocycloalkyl and the heteroaryl are each optionally substituted by one or more (eg, one, two or three) groups R X22 replace.

[0201] Even more preferably, R X2selected from azetidinyl (e.g. azetidin-3-yl), oxetanyl (e.g. oxetan-3-yl), pyrrolidinyl (e.g. pyrrolidin-1-yl or pyrrolidin-3-yl), oxopyrrolidinyl (e.g. 2-oxo-pyrrolidin-1-yl or 5-oxo-pyrrolidin-3-yl), tetrahydrofuranyl (e.g. tetrahydrofuran-3-yl), piperidinyl (e.g. piperidin-1-yl, piperidin-3-yl or piperidin-4-yl), oxopiperidin ... oxo-piperidin-4-yl or 6-oxo-piperidin-3-yl), piperazinyl (e.g., piperazin-1-yl), oxopiperazinyl (e.g., 3-oxo-piperazin-1-yl), morpholinyl (e.g., morpholin-4-yl), thiomorpholinyl (e.g., thiomorpholin-4-yl), dioxythiomorpholinyl (e.g., 1,1-dioxythiomorpholin-4-yl), tetrahydropyranyl (e.g., tetrahydropyran-4-yl), oxazepanyl (e.g., [1,4]oxazepan-4-yl), 2-oxa-6-aza-spiro[3.3]heptane (e.g., 2-oxa-6-aza-spiro[3.3]heptane-6-yl), 2-oxa-7-aza-spiro[3.5]nonyl (e.g., 2-oxa-7-aza-spiro[3.5]nonane). ]nonan-7-yl), 6-oxa-2-aza-spiro[3.4]octyl (e.g., 6-oxa-2-aza-spiro[3.4]oct-2-yl), 3-oxa-9-aza-spiro[5.5]undecyl (e.g., 3-oxa-9-aza-spiro[5.5]undec-9-yl), 7-oxa-2-aza-spiro[4.5]decyl (e.g., 7-oxa-2-aza-spiro[4.5]dec-2-yl), 8-oxa-2-aza-spiro[4.5]decyl (e.g., 8-oxa-2-aza-spiro[4.5]dec-2-yl), 3-oxa-8-aza-bicyclo[3.2.1]octyl (e.g., 3-oxa- oxa-8-aza-bicyclo[3.2.1]oct-8-yl), 8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl (e.g. 8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl), phenyl, oxazolyl (e.g. oxazol-4-yl), pyridinyl (e.g. pyridin-3-yl or pyridin-4-yl), pyrazinyl (e.g. pyrazin-2-yl) and pyrimidinyl (e.g. pyrimidin-5-yl), wherein each of the above cyclic groups is optionally substituted by one or more radicals R X22 replace.

[0202] Even more preferably, R X2is selected from azetidinyl (e.g. azetidin-3-yl), oxetanyl (e.g. oxetan-3-yl), pyrrolidinyl (e.g. pyrrolidin-3-yl), oxopyrrolidinyl (e.g. 2-oxo-pyrrolidin-1-yl), tetrahydrofuranyl (e.g. tetrahydrofuran-3-yl), piperidinyl (e.g. piperidin-3-yl or piperidin-4-yl), oxopiperidinyl (e.g. 6-oxo-piperidin-3-yl), piperazinyl (e.g. piperazin-1-yl), morpholinyl (e.g. morpholin-4-yl), tetrahydropyranyl (e.g. tetrahydropyran-4-yl), 2-oxa-7-aza-spiro[3.5]nonyl (e.g. 2-oxa-7-aza-spiro[3.5]non-7-yl), 6-oxa-2-aza-spiro[3.4]octyl (e.g. 6-oxa-2-aza-spiro[3.4]octyl). [3.4]octan-2-yl), 3-oxa-9-aza-spiro[5.5]undecyl (e.g. 3-oxa-9-aza-spiro[5.5]undec-9-yl), 7-oxa-2-aza-spiro[4.5]decyl (e.g. 7-oxa-2-aza-spiro[4.5]dec-2-yl), 8-oxa-2-aza-spiro[4.5]decyl (e.g. 8-oxa-2-aza-spiro[4.5]dec-2-yl), phenyl, oxazolyl (e.g. oxazol-4-yl), pyridinyl (e.g. pyridin-3-yl or pyridin-4-yl), pyrazinyl (e.g. pyrazin-2-yl) and pyrimidinyl (e.g. pyrimidin-5-yl), wherein each of the above cyclic groups is optionally substituted by one or more radicals R X22 replace.

[0203] L 1 Selected from covalent bonds, C 1-10 Alkylene, C 2-10 Alkenylene and C 2-10 Alkynylidene, wherein the C 1-10 Alkylene, the C 2-10 Alkenylene or the C 2-10 One or more (e.g., one or two) -CH2- units contained in the alkynylene group are each optionally replaced by a group independently selected from the group consisting of: -O-, -CO-, -C(=O)O-, -OC(=O)-, -NH-, -N(C 1-5 Alkyl)-、-NH-CO-、-N(C 1-5 Alkyl)-CO-, -CO-NH-, -CO-N(C 1-5 Alkyl)-、-S-、-SO-、-SO2-、-SO2-NH-、-SO2-N(C 1-5 alkyl)-, -NH-SO2- and -N(C 1-5 alkyl)-SO2-, and further wherein said C 1-10 Alkylene, the C 2-10 Alkenylene and the C2-10 Each alkynylene group is optionally substituted with one or more (eg, one, two, or three) groups independently selected from the group consisting of halogen, C 1-5 Haloalkyl, -O-(C 1-5 haloalkyl), -CN, -OH, -O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -NH2, -NH(C 1-5 alkyl) and -N(C 1-5 Alkyl)(C 1-5 alkyl).

[0204] Preferably, L 1 Is a covalent bond or C 1-10 Alkylene, wherein the C 1-10 One or two -CH2- units contained in the alkylene group are each optionally replaced by a group independently selected from the group consisting of: -O-, -CO-, -C(=O)O-, -OC(=O)-, -NH-, -N(C 1-5 Alkyl)-、-NH-CO-、-N(C 1-5 Alkyl)-CO-, -CO-NH-, -CO-N(C 1-5 Alkyl)-、-S-、-SO-、-SO2-、-SO2-NH-、-SO2-N(C 1-5 alkyl)-, -NH-SO2- and -N(C 1-5 alkyl)-SO2-, and further wherein said C 1-10 The alkylene group is optionally substituted with one or more (eg, one, two, or three) groups independently selected from the group consisting of halogen, C 1-5 Haloalkyl, -O-(C 1-5 haloalkyl), -CN, -OH, -O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -NH2, -NH(C 1-5 alkyl) and -N(C 1-5 Alkyl)(C 1-5 alkyl).

[0205] More preferably, L 1 Is a covalent bond or C 1-8 Alkylene, wherein the C 1-8 One -CH2- unit contained in the alkylene group is optionally replaced by a group selected from the group consisting of: -O-, -CO-, -NH- and -N(C 1-5 alkyl)-, and further wherein said C 1-8 The alkylene group is optionally substituted with one or more (eg, one, two, or three) groups independently selected from the group consisting of halogen, C1-5 Haloalkyl, -O-(C 1-5 haloalkyl), -CN, -OH, -O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -NH2, -NH(C 1-5 alkyl) and -N(C 1-5 Alkyl)(C 1-5 alkyl).

[0206] Even more preferably, L 1 Selected from covalent bonds, C 1-5 Alkylene (e.g., -CH2-, -CH2CH2-, or -CH2CH2CH2-), -O-, -O-(C 1-5 Alkylene)-(e.g., -O-CH2-, -O-CH2CH2-, -O-CH2CH2CH2- or -O-CH2CH2CH2CH2-), -NH-, -NH-(C 1-5 Alkylene)-, -N(C 1-5 alkyl)- and -N(C 1-5 alkyl)-(C 1-5 Alkylene)-, wherein the C 1-5 Alkylene or the -O-(C 1-5 Alkylene)-, the -NH-(C 1-5 Alkylene)- and said-N(C 1-5 alkyl)-(C 1-5 C contained in any one of alkylene)- 1-5 The alkylene moiety is optionally substituted with one or more groups independently selected from the group consisting of halogen, -CF3, -CN, -OH, -O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -NH2, -NH(C 1-5 alkyl) and -N(C 1-5 Alkyl)(C 1-5 alkyl).

[0207] Even more preferably, L 1 Selected from covalent bonds, C 1-5 Alkylene (e.g., -CH2-, -CH2CH2-, or -CH2CH2CH2-), -O-, and -O-(C 1-5 alkylene)-(e.g., -O-CH2-, -O-CH2CH2-, -O-CH2CH2CH2-, or -O-CH2CH2CH2CH2-).

[0208] R X21 Selected from C 2-5alkyl, carbocyclyl (e.g. cycloalkyl or aryl) and heterocyclyl (e.g. heterocycloalkyl or heteroaryl), wherein the carbocyclyl and the heterocyclyl are each optionally substituted by one or more (e.g. one, two or three) groups R X22 replace.

[0209] Preferably, R X21 Selected from C 2-5 alkyl, cycloalkyl, aryl, heterocycloalkyl and heteroaryl, wherein the cycloalkyl, the aryl, the heterocycloalkyl and the heteroaryl are each optionally substituted by one or more (e.g., one, two or three) groups R X22 replace.

[0210] R X22 Each independently selected from C 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, -(C 0-3 Alkylene)-OH, -(C 0-3 Alkylene)-O(C 1-5 Alkyl), -(C 0-3 Alkylene)-SH, -(C 0-3 Alkylene)-S(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH2, -(C 0-3 Alkylene)-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-halogen, -(C 0-3 alkylene)-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-O-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-CN,-(C 0-3 Alkylene)-CHO, -(C 0-3 alkylene)-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-COOH, -(C 0-3 Alkylene)-CO-O-(C 1-5 Alkyl), -(C 0-3 Alkylene)-O-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-CO-NH2, -(C 0-3 Alkylene)-CO-NH(C 1-5 Alkyl), -(C 0-3Alkylene)-CO-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 alkyl)-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO2-NH2, -(C 0-3 Alkylene)-SO2-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO2-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH-SO2-(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 alkyl)-SO2-(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO2-(C 1-5 Alkyl), -(C 0-3 Alkylene)-aryl, -(C 0-3 Alkylene)-heteroaryl, -(C 0-3 alkylene)-cycloalkyl and -(C 0-3 alkylene)-heterocycloalkyl,

[0211] wherein said-(C 0-3 Alkylene)-aryl in the aryl part, the -(C 0-3 The heteroaryl portion of the -(C 0-3 The cycloalkyl portion of the -(C 0-3 The heterocycloalkyl moieties of the alkylene)-heterocycloalkyl groups are each optionally substituted by one or more (eg one, two or three) groups R X23 replace,

[0212] And in addition, R X23 Each independently selected from C 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, -OH, -O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -NH2, -NH(C 1-5 Alkyl), -N(C1-5 Alkyl)(C 1-5 alkyl), halogen, C 1-5 Haloalkyl, -O-(C 1-5 haloalkyl), -CN, -CHO, -CO-(C 1-5 alkyl), -COOH, -CO-O-(C 1-5 alkyl), -O-CO-(C 1-5 alkyl), -CO-NH2, -CO-NH(C 1-5 Alkyl), -CO-N(C 1-5 Alkyl)(C 1-5 alkyl), -NH-CO-(C 1-5 Alkyl), -N(C 1-5 alkyl)-CO-(C 1-5 alkyl), -SO2-NH2, -SO2-NH(C 1-5 Alkyl), -SO2-N(C 1-5 Alkyl)(C 1-5 Alkyl), -NH-SO2-(C 1-5 Alkyl), -N(C 1-5 alkyl)-SO2-(C 1-5 Alkyl), -SO-(C 1-5 alkyl), -SO2-(C 1-5 alkyl), cycloalkyl and heterocycloalkyl.

[0213] Preferably, R X22 Each independently selected from C 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, -(C 0-3 Alkylene)-OH, -(C 0-3 Alkylene)-O(C 1-5 Alkyl), -(C 0-3 Alkylene)-SH, -(C 0-3 Alkylene)-S(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH2, -(C 0-3 Alkylene)-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-halogen, -(C 0-3 alkylene)-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-O-(C 1-5 haloalkyl), -(C0-3 Alkylene)-CN,-(C 0-3 Alkylene)-CHO, -(C 0-3 alkylene)-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-COOH, -(C 0-3 Alkylene)-CO-O-(C 1-5 Alkyl), -(C 0-3 Alkylene)-O-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-CO-NH2, -(C 0-3 Alkylene)-CO-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-CO-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 alkyl)-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO2-NH2, -(C 0-3 Alkylene)-SO2-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO2-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH-SO2-(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 alkyl)-SO2-(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO2-(C 1-5 Alkyl), -(C 0-3 Alkylene)-aryl, -(C 0-3 Alkylene)-heteroaryl, -(C 0-3 alkylene)-cycloalkyl and -(C 0-3 alkylene)-heterocycloalkyl.

[0214] More preferably, R X22 Each independently selected from C 1-5 Alkyl, -(C 0-3 Alkylene)-OH, -(C 0-3Alkylene)-O(C 1-5 Alkyl), -(C 0-3 Alkylene)-SH, -(C 0-3 Alkylene)-S(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH2, -(C 0-3 Alkylene)-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-halogen, -(C 0-3 alkylene)-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-O-(C 1-5 haloalkyl) and -(C 0-3 alkylene)-CN.

[0215] Even more preferably, R X22 Each independently selected from C 1-5 Alkyl, -OH, -O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -NH2, -NH(C 1-5 Alkyl), -N(C 1-5 Alkyl)(C 1-5 alkyl), halogen, C 1-5 Haloalkyl, -O-(C 1-5 haloalkyl) and -CN.

[0216] -LR X2 Examples include the various groups -LR contained in the specific compounds of the present invention disclosed in the Examples section. X2 Any one of .

[0217] According to L and R X2 The above definition, particularly preferred is the group -LR in the compound of formula (I) X2 Yes-R X2 or -(C 1-8 Alkylene)-R X2 , wherein the C 1-8 One -CH2- unit contained in the alkylene group is optionally replaced by a group selected from the group consisting of: -O-, -CO-, -NH- and -N(C 1-5 alkyl)-, wherein the C 1-8 The alkylene group is optionally substituted with one or more (eg, one, two, or three) groups independently selected from the group consisting of halogen, C 1-5 Haloalkyl, -O-(C1-5 haloalkyl), -CN, -OH, -O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -NH2, -NH(C 1-5 alkyl) and -N(C 1-5 Alkyl)(C 1-5 alkyl), and in addition wherein R X2 is selected from cycloalkyl, aryl, heterocycloalkyl and heteroaryl, wherein the cycloalkyl, the aryl, the heterocycloalkyl and the heteroaryl are each optionally substituted by one or more (e.g., one, two or three) groups R X22 replace.

[0218] More preferably, the group -LR X2 Selected from -R X2 、-(C 1-5 Alkylene)-R X2 、-OR X2 and -O-(C 1-5 Alkylene)-R X2 , where R X2 is selected from cycloalkyl, aryl, heterocycloalkyl and heteroaryl, wherein the cycloalkyl, the aryl, the heterocycloalkyl and the heteroaryl are each optionally substituted by one or more (eg, one, two or three) groups R X22 replace.

[0219] In Group-LR X2 In the above definition, even more preferably, R X2is selected from azetidinyl (e.g. azetidin-3-yl), oxetanyl (e.g. oxetan-3-yl), pyrrolidinyl (e.g. pyrrolidin-3-yl), oxopyrrolidinyl (e.g. 2-oxo-pyrrolidin-1-yl), tetrahydrofuranyl (e.g. tetrahydrofuran-3-yl), piperidinyl (e.g. piperidin-3-yl or piperidin-4-yl), oxopiperidinyl (e.g. 6-oxo-piperidin-3-yl), piperazinyl (e.g. piperazin-1-yl), morpholinyl (e.g. morpholin-4-yl), tetrahydropyranyl (e.g. tetrahydropyran-4-yl), 2-oxa-7-aza-spiro[3.5]nonyl (e.g. 2-oxa-7-aza-spiro[3.5]non-7-yl), 6-oxa-2- aza-spiro[3.4]octyl (e.g. 6-oxa-2-aza-spiro[3.4]octyl-2-yl), 3-oxa-9-aza-spiro[5.5]undecyl (e.g. 3-oxa-9-aza-spiro[5.5]undec-9-yl), 7-oxa-2-aza-spiro[4.5]decyl (e.g. 7-oxa-2-aza-spiro[4.5]dec-2-yl), 8-oxa-2-aza-spiro[4.5]decyl (e.g. 8-oxa-2-aza-spiro[4.5]dec-2-yl), phenyl, oxazolyl (e.g. oxazol-4-yl), pyridinyl (e.g. pyridin-3-yl or pyridin-4-yl), pyrazinyl (e.g. pyrazin-2-yl) and pyrimidinyl (e.g. pyrimidin-5-yl), wherein each of the above cyclic groups is optionally substituted by one or more radicals R X22 replace.

[0220] Still more preferably, -LR X2 Any one selected from the following groups:

[0221]

[0222]

[0223] wherein the cyclic portion in each of the groups depicted above is optionally further substituted by one or more (eg, one or two) groups R X22 replace.

[0224] Even more preferably, -LR X2 Any one selected from the following groups:

[0225]

[0226] wherein the cyclic portion in each of the groups depicted above is optionally further substituted by one or more (eg, one or two) groups R X22 replace.

[0227] Still more preferably, -LR X2Any one selected from the following groups:

[0228]

[0229] wherein the cyclic portion in each of the groups depicted above is optionally further substituted by one or more (eg, one or two) groups R X22 replace.

[0230] Most preferably, -LR X2 yes:

[0231]

[0232] wherein the cyclic portion of the groups depicted above is optionally further substituted by one or more (eg, one or two) groups R X22 replace.

[0233] R X3 Selected from hydrogen, C 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, -(C 0-3 Alkylene)-OH, -(C 0-3 Alkylene)-O(C 1-5 Alkyl), -(C 0-3 Alkylene)-SH, -(C 0-3 Alkylene)-S(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH2, -(C 0-3 Alkylene)-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-halogen, -(C 0-3 alkylene)-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-O-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-CN,-(C 0-3 Alkylene)-CHO, -(C 0-3 alkylene)-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-COOH, -(C 0-3 Alkylene)-CO-O-(C 1-5 Alkyl), -(C 0-3 Alkylene)-O-CO-(C 1-5 Alkyl), -(C 0-3Alkylene)-CO-NH2, -(C 0-3 Alkylene)-CO-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-CO-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 alkyl)-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO2-NH2, -(C 0-3 Alkylene)-SO2-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO2-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH-SO2-(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 alkyl)-SO2-(C 1-5 Alkyl), -(C 0-3 Alkylene)-aryl, -(C 0-3 Alkylene)-heteroaryl, -(C 0-3 alkylene)-cycloalkyl and -(C 0-3 alkylene)-heterocycloalkyl,

[0234] wherein said-(C 0-3 Alkylene)-aryl in the aryl part, the -(C 0-3 The heteroaryl portion of the -(C 0-3 The cycloalkyl portion of the -(C 0-3 The heterocycloalkyl moieties of the alkylene)-heterocycloalkyl groups are each optionally substituted by one or more (eg one, two or three) groups R X31 replace,

[0235] And in addition, R X31 Each independently selected from C 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, -OH, -O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -NH2, -NH(C 1-5 Alkyl), -N(C 1-5 Alkyl)(C1-5 alkyl), halogen, C 1-5 Haloalkyl, -O-(C 1-5 haloalkyl), -CN, -CHO, -CO-(C 1-5 alkyl), -COOH, -CO-O-(C 1-5 alkyl), -O-CO-(C 1-5 alkyl), -CO-NH2, -CO-NH(C 1-5 Alkyl), -CO-N(C 1-5 Alkyl)(C 1-5 alkyl), -NH-CO-(C 1-5 Alkyl), -N(C 1-5 alkyl)-CO-(C 1-5 alkyl), -SO2-NH2, -SO2-NH(C 1-5 Alkyl), -SO2-N(C 1-5 Alkyl)(C 1-5 Alkyl), -NH-SO2-(C 1-5 Alkyl), -N(C 1-5 alkyl)-SO2-(C 1-5 alkyl), cycloalkyl and heterocycloalkyl.

[0236] The above group -(C 0-3 The heterocycloalkyl portion of the (alkylene)-heterocycloalkyl group may be, for example, a monocyclic heterocycloalkyl group or a spirocyclic heterocycloalkyl group.

[0237] Preferably, R X3 Selected from hydrogen, C 1-5 Alkyl, -(C 0-3 Alkylene)-OH, -(C 0-3 Alkylene)-O(C 1-5 Alkyl), -(C 0-3 Alkylene)-SH, -(C 0-3 Alkylene)-S(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH2, -(C 0-3 Alkylene)-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-halogen, -(C 0-3 alkylene)-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-O-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-CN, -(C0-3 Alkylene)-CHO, -(C 0-3 alkylene)-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-COOH, -(C 0-3 Alkylene)-CO-O-(C 1-5 Alkyl), -(C 0-3 Alkylene)-O-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-CO-NH2, -(C 0-3 Alkylene)-CO-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-CO-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 alkyl)-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO2-NH2, -(C 0-3 Alkylene)-SO2-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO2-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH-SO2-(C 1-5 alkyl) and -(C 0-3 Alkylene)-N(C 1-5 alkyl)-SO2-(C 1-5 alkyl).

[0238] More preferably, R X3 Selected from hydrogen, C 1-5 Alkyl, -(C 0-3 Alkylene)-OH, -(C 0-3 Alkylene)-O(C 1-5 Alkyl), -(C 0-3 Alkylene)-SH, -(C 0-3 Alkylene)-S(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH2, -(C 0-3 Alkylene)-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C0-3 Alkylene)-halogen, -(C 0-3 alkylene)-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-O-(C 1-5 haloalkyl) and -(C 0-3 alkylene)-CN.

[0239] Even more preferably, R X3 Selected from hydrogen, C 1-5 Alkyl (such as methyl or ethyl), -OH, -O(C 1-5 alkyl) (e.g., methoxy or ethoxy), halogen (e.g., -F or -Cl), and C 1-5 Haloalkyl (eg, -CF3).

[0240] Additionally and even more preferably, R X3 is selected from hydrogen, -OH and -OCH3. Particularly preferred is R X3 It's hydrogen.

[0241] R X4 Selected from hydrogen, C 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, -(C 0-3 Alkylene)-OH, -(C 0-3 Alkylene)-O(C 1-5 Alkyl), -(C 0-3 Alkylene)-SH, -(C 0-3 Alkylene)-S(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH2, -(C 0-3 Alkylene)-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-halogen, -(C 0-3 alkylene)-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-O-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-CN,-(C 0-3 Alkylene)-CHO, -(C 0-3 alkylene)-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-COOH, -(C 0-3 Alkylene)-CO-O-(C 1-5Alkyl), -(C 0-3 Alkylene)-O-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-CO-NH2, -(C 0-3 Alkylene)-CO-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-CO-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 alkyl)-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO2-NH2, -(C 0-3 Alkylene)-SO2-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO2-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH-SO2-(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 alkyl)-SO2-(C 1-5 Alkyl), -(C 0-3 Alkylene)-aryl, -(C 0-3 Alkylene)-heteroaryl, -(C 0-3 alkylene)-cycloalkyl and -(C 0-3 alkylene)-heterocycloalkyl,

[0242] wherein said-(C 0-3 Alkylene)-aryl in the aryl part, the -(C 0-3 The heteroaryl portion of the -(C 0-3 The cycloalkyl portion of the -(C 0-3 The heterocycloalkyl moieties of the alkylene)-heterocycloalkyl groups are each optionally substituted by one or more (eg one, two or three) groups R X41 replace,

[0243] And in addition, R X41 Each independently selected from C 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, -OH, -O(C 1-5 alkyl), -SH, -S(C1-5 alkyl), -NH2, -NH(C 1-5 Alkyl), -N(C 1-5 Alkyl)(C 1-5 alkyl), halogen, C 1-5 Haloalkyl, -O-(C 1-5 haloalkyl), -CN, -CHO, -CO-(C 1-5 alkyl), -COOH, -CO-O-(C 1-5 alkyl), -O-CO-(C 1-5 alkyl), -CO-NH2, -CO-NH(C 1-5 Alkyl), -CO-N(C 1-5 Alkyl)(C 1-5 alkyl), -NH-CO-(C 1-5 Alkyl), -N(C 1-5 alkyl)-CO-(C 1-5 alkyl), -SO2-NH2, -SO2-NH(C 1-5 Alkyl), -SO2-N(C 1-5 Alkyl)(C 1-5 Alkyl), -NH-SO2-(C 1-5 Alkyl), -N(C 1-5 alkyl)-SO2-(C 1-5 alkyl), cycloalkyl and heterocycloalkyl.

[0244] Preferably, R X4 Selected from hydrogen, C 1-5 Alkyl, -(C 0-3 Alkylene)-OH, -(C 0-3 Alkylene)-O(C 1-5 Alkyl), -(C 0-3 Alkylene)-SH, -(C 0-3 Alkylene)-S(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH2, -(C 0-3 Alkylene)-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-halogen, -(C 0-3 alkylene)-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-O-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-CN, -(C 0-3Alkylene)-CHO, -(C 0-3 alkylene)-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-COOH, -(C 0-3 Alkylene)-CO-O-(C 1-5 Alkyl), -(C 0-3 Alkylene)-O-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-CO-NH2, -(C 0-3 Alkylene)-CO-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-CO-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 alkyl)-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO2-NH2, -(C 0-3 Alkylene)-SO2-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO2-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH-SO2-(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 alkyl)-SO2-(C 1-5 alkyl), aryl, heteroaryl, cycloalkyl and heterocycloalkyl,

[0245] wherein the aryl, the heteroaryl, the cycloalkyl and the heterocycloalkyl are each optionally substituted by one or more (eg, one, two or three) groups independently selected from the following: 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, -OH, -O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -NH2, -NH(C 1-5 Alkyl), -N(C 1-5 Alkyl)(C 1-5 alkyl), halogen, C 1-5 Haloalkyl, -O-(C 1-5 haloalkyl), -CN, -CHO, -CO-(C1-5 alkyl), -COOH, -CO-O-(C 1-5 alkyl), -O-CO-(C 1-5 alkyl), -CO-NH2, -CO-NH(C 1-5 Alkyl), -CO-N(C 1-5 Alkyl)(C 1-5 alkyl), -NH-CO-(C 1-5 Alkyl), -N(C 1-5 alkyl)-CO-(C 1-5 alkyl), -SO2-NH2, -SO2-NH(C 1-5 Alkyl), -SO2-N(C 1-5 Alkyl)(C 1-5 Alkyl), -NH-SO2-(C 1-5 Alkyl), -N(C 1-5 alkyl)-SO2-(C 1-5 alkyl), cycloalkyl and heterocycloalkyl.

[0246] More preferably, R X4 Selected from hydrogen, C 1-5 Alkyl, -(C 0-3 Alkylene)-OH, -(C 0-3 Alkylene)-O(C 1-5 Alkyl), -(C 0-3 Alkylene)-SH, -(C 0-3 Alkylene)-S(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH2, -(C 0-3 Alkylene)-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-halogen, -(C 0-3 alkylene)-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-O-(C 1-5 haloalkyl), -(C 0-3 alkylene)-CN, cycloalkyl and heterocycloalkyl.

[0247] Even more preferably, R X4 Selected from hydrogen, C 1-5 Alkyl (such as methyl or ethyl), -OC 1-5 Alkyl (such as methoxy or ethoxy), halogen (such as -F or -Cl), C 1-5 Haloalkyl (e.g. -CF3) and C3-7 Cycloalkyl (eg, cyclopropyl).

[0248] Even more preferably, R X4 is selected from hydrogen, methyl, -OCH3, halogen (e.g., -F or -Cl) and cyclopropyl. X4 It can be methyl, -OCH3, halogen or cyclopropyl.

[0249] Additionally and even more preferably, R X4 is selected from hydrogen, methyl, halogen (such as -F or -Cl) and cyclopropyl. Particularly preferred is R X4 is selected from methyl, -F and -Cl.

[0250] Still more preferably, R X4 It's methyl.

[0251] According to the present invention, the following compounds are excluded from formula (I):

[0252] and

[0253] Therefore, the above-depicted compounds and pharmaceutically acceptable salts thereof are excluded from the present invention.

[0254] It is further preferred to exclude the following compounds from the present invention:

[0255]

[0256] It is particularly preferred that the compound of formula (I) of the present invention is one of the specific compounds of formula (I) further described below in the Examples section of this specification, which is in a non-salt form (e.g. free base / acid form) or a pharmaceutically acceptable salt form of the corresponding compound.

[0257] Therefore, it is particularly preferred that the compound of formula (I) is selected from:

[0258] 6-(3-pyridin-4-yl-propoxy)-2-pyrrolo[1,2-c]pyrimidin-3-yl-3H-quinazolin-4-one;

[0259] 2-Isoquinolin-3-yl-6-(3-pyridin-4-yl-propoxy)-3H-quinazolin-4-one;

[0260] 6-(3-pyridin-4-yl-propoxy)-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one;

[0261] 6-(3-pyridin-4-yl-propoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0262] 2-pyridin-2-yl-6-(3-pyridin-4-yl-propoxy)-3H-quinazolin-4-one;

[0263] 2-(4-Methoxy-pyridin-2-yl)-6-(3-pyridin-4-yl-propoxy)-3H-quinazolin-4-one;

[0264] 2-(5-Fluoro-pyridin-2-yl)-6-(3-pyridin-4-yl-propoxy)-3H-quinazolin-4-one;

[0265] 6-(3-Pyridin-4-yl-propoxy)-2-(5-trifluoromethyl-pyridin-3-yl)-3H-quinazolin-4-one;

[0266] 6-[3-(4-pyridinyl)propoxy]-2-[5-(trifluoromethyl)-2-pyridinyl]-3H-quinazolin-4-one;

[0267] 2-(4-methyl-2-pyridinyl)-6-[3-(4-pyridinyl)propoxy]-3H-quinazolin-4-one;

[0268] 2-(6-methyl-2-pyridinyl)-6-[3-(4-pyridinyl)propoxy]-3H-quinazolin-4-one;

[0269] 2-(5-methylpyrazin-2-yl)-6-[3-(4-pyridinyl)propoxy]-3H-quinazolin-4-one;

[0270] 2-[5-chloro-4-(trifluoromethyl)-2-pyridinyl]-6-[3-(4-pyridinyl)propoxy]3H-quinazolin-4-one;

[0271] 2-(4-chloro-2-pyridinyl)-6-[3-(4-pyridinyl)propoxy]-3H-quinazolin-4-one;

[0272] 2-(4-ethyl-2-pyridinyl)-6-[3-(4-pyridinyl)propoxy]-3H-quinazolin-4-one;

[0273] 6-[3-(4-pyridinyl)propoxy]-2-[6-(trifluoromethyl)-2-pyridinyl]-3H-quinazolin-4-one;

[0274] 2-(4-bromo-2-pyridinyl)-6-[3-(4-pyridinyl)propoxy]-3H-quinazolin-4-one;

[0275] 2-(4-cyclopropyl-2-pyridyl)-6-[3-(4-pyridyl)propoxy]-3H-quinazolin-4-one;

[0276] 2-(2-Methyl-oxazol-4-yl)-6-(3-pyridin-4-yl-propoxy)-3H-quinazolin-4-one;

[0277] 6-(2-pyridin-3-yl-ethoxy)-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one;

[0278] 6-(4-Bromo-benzyloxy)-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one;

[0279] tert-Butyl 3-(4-hydroxy-2-pyrrolo[1,2-c]pyrimidin-3-yl-quinazolin-6-yl)oxyazetidine-1-carboxylate;

[0280] 6-(azetidin-3-yloxy)-2-pyrrolo[1,2-c]pyrimidin-3-yl-3H-quinazolin-4-one;

[0281] 6-(1-pyrimidin-4-yl-azetidin-3-yloxy)-2-pyrrolo[1,2-c]pyrimidin-3-yl-3H-quinazolin-4-one;

[0282] 3-(4-Hydroxy-2-thieno[2,3-c]pyridin-5-yl-quinazolin-6-yloxy)-azetidine-1-carboxylic acid tert-butyl ester;

[0283] 6-(azetidin-3-yloxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0284] 6-(1-propionyl-azetidin-3-yloxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0285] 6-(piperidin-4-yloxy)-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one;

[0286] 6-(1-propionyl-piperidin-4-yloxy)-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one;

[0287] 6-(2-morpholin-4-yl-ethoxy)-2-pyrrolo[1,2-c]pyrimidin-3-yl-3H-quinazolin-4-one;

[0288] 6-(2-methoxy-ethoxy)-2-pyrrolo[1,2-c]pyrimidin-3-yl-3H-quinazolin-4-one;

[0289] 6-(2-morpholin-4-yl-ethoxy)-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one;

[0290] 6-(2-methoxy-ethoxy)-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one;

[0291] 6-(3-pyridin-3-yl-propoxy)-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one;

[0292] 4-(4-Oxo-2-pyridin-2-yl-3,4-dihydro-quinazolin-6-yloxy)-piperidine-1-carboxylic acid tert-butyl ester;

[0293] 6-(piperidin-4-yloxy)-2-pyridin-2-yl-3H-quinazolin-4-one;

[0294] 6-(1-Acetyl-piperidin-4-yloxy)-2-pyridin-2-yl-3H-quinazolin-4-one;

[0295] 4-[4-Oxo-2-(4-trifluoromethyl-pyridin-2-yl)-3,4-dihydro-quinazolin-6-yloxymethyl]-piperidine-1-carboxylic acid tert-butyl ester;

[0296] 6-(Piperidin-4-ylmethoxy)-2-(4-trifluoromethyl-pyridin-2-yl)-3H-quinazolin-4-one;

[0297] 6-(1-Acetyl-piperidin-4-ylmethoxy)-2-(4-trifluoromethyl-pyridin-2-yl)-3H-quinazolin-4-one;

[0298] tert-Butyl 4-[(4-oxo-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-6-yl)oxymethyl]piperidine-1-carboxylate;

[0299] 6-(4-Piperidinylmethoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0300] 6-(1-acetyl-piperidin-4-ylmethoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0301] 6-(1-propionyl-piperidin-4-ylmethoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0302] 3-(4-Oxo-2-thieno[2,3-c]pyridin-5-yl-3,4-dihydro-quinazolin-6-yloxy)-pyrrolidine-1-carboxylic acid tert-butyl ester;

[0303] 6-(Pyrrolidin-3-yloxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0304] 6-(1-acetyl-pyrrolidin-3-yloxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0305] 4-[4-Oxo-2-(4-trifluoromethyl-pyridin-2-yl)-3,4-dihydro-quinazolin-6-yl]-piperazine-1-carboxylic acid tert-butyl ester;

[0306] 6-Piperazin-1-yl-2-(4-trifluoromethyl-pyridin-2-yl)-3H-quinazolin-4-one;

[0307] 6-(4-Propanyl-piperazin-1-yl)-2-(4-trifluoromethyl-pyridin-2-yl)-3H-quinazolin-4-one;

[0308] 4-(4-Oxo-2-thieno[2,3-c]pyridin-5-yl-3,4-dihydro-quinazolin-6-yl)-piperidine-1-carboxylic acid tert-butyl ester;

[0309] 6-Piperidin-4-yl-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0310] 6-(1-acetyl-piperidin-4-yl)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0311] 6-[2-(Tetrahydro-pyran-4-yl)-ethoxy]-2-(4-trifluoromethyl-pyridin-2-yl)-3H-quinazolin-4-one;

[0312] 6-[3-(3-Fluoro-pyridin-4-yl)-propoxy]-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0313] 6-[3-(4-Methanesulfonyl-phenyl)-propyloxy]-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0314] 6-(3-Pyrazin-2-yl-propyloxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0315] 6-[3-(3-Methoxy-pyridin-4-yl)-propoxy]-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0316] 6-[3-(2-methyl-pyridin-4-yl)-propoxy]-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0317] 6-(3-oxazol-4-yl-propoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0318] 8-methyl-6-(3-pyridin-4-yl-propoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0319] 6-(3-pyridin-4-yl-propoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-pyrido[3,2-d]pyrimidin-4-one;

[0320] 6-(3-Pyridin-4-yl-propoxy)-2-(4-trifluoromethyl-pyridin-2-yl)-3H-pyrido[3,2-d]pyrimidin-4-one;

[0321] 6-(3-Pyridin-4-yl-propoxy)-2-(4-trifluoromethyl-pyridin-2-yl)-3H-pyrido[2,3-d]pyrimidin-4-one;

[0322] 6-(3-Pyridin-4-yl-propoxy)-2-(4-trifluoromethyl-pyridin-2-yl)-3H-pyrido[3,4-d]pyrimidin-4-one;

[0323] 6-(3-pyridin-4-yl-propoxy)-2-thieno[2,3-c]pyridin-5-yl-7-trifluoromethyl-3H-quinazolin-4-one;

[0324] 5-chloro-6-(3-pyridin-4-yl-propoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0325] 8-Chloro-6-(3-pyridin-4-yl-propoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0326] 8-cyclopropyl-6-(3-pyridin-4-yl-propoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0327] 8-ethyl-6-(3-pyridin-4-yl-propoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0328] 8-Fluoro-6-(3-pyridin-4-yl-propoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0329] 8-methyl-6-(tetrahydro-pyran-4-ylmethoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0330] 8-methyl-6-(2-oxetan-3-yl-ethoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0331] 8-methyl-6-[2-(tetrahydro-furan-3-yl)-ethoxy]-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0332] 8-Methyl-6-[2-(tetrahydro-pyran-4-yl)-ethoxy]-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0333] 8-methyl-6-(tetrahydro-furan-3-ylmethoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0334] R-8-methyl-6-(tetrahydro-furan-3-ylmethoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0335] S-8-methyl-6-(tetrahydro-furan-3-ylmethoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0336] 8-methyl-6-(1-methyl-6-oxo-piperidin-3-yloxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0337] R-8-methyl-6-((1-methyl-6-oxopiperidin-3-yl)oxy)-2-(thieno[2,3-c]pyridin-5-yl)quinazolin-4(3H)-one;

[0338] S-8-methyl-6-((1-methyl-6-oxopiperidin-3-yl)oxy)-2-(thieno[2,3-c]pyridin-5-yl)quinazolin-4(3H)-one;

[0339] 8-methyl-6-(1-propionyl-pyrrolidin-3-yloxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0340] R-8-methyl-6-(1-propionyl-pyrrolidin-3-yloxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0341] S-8-methyl-6-(1-propionyl-pyrrolidin-3-yloxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0342] 8-methyl-6-(1-oxetan-3-ylpyrrolidin-3-yloxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0343] R-8-methyl-6-(1-oxetan-3-ylpyrrolidin-3-yloxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0344] S-8-methyl-6-(1-oxetan-3-ylpyrrolidin-3-yloxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0345] 8-Methyl-6-[2-(2-oxa-7-aza-spiro[3.5]non-7-yl)-ethoxy]-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0346] 8-methyl-6-(piperidin-4-ylmethoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0347] 8-methyl-6-(1-oxetan-3-yl-piperidin-4-ylmethoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0348] 8-methyl-6-(1-propionyl-piperidin-4-ylmethoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0349] 6-(1-methylsulfonyl-piperidin-4-ylmethoxy)-8-methyl-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0350] 8-methyl-6-(2-oxa-7-aza-spiro[3.5]non-7-yl)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0351] 8-methyl-6-(6-oxa-2-aza-spiro[3.4]octan-2-yl)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0352] 8-methyl-6-(3-oxa-9-aza-spiro[5.5]undec-9-yl)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0353] 8-methyl-6-(7-oxa-2-aza-spiro[4.5]dec-2-yl)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0354] 8-Methyl-6-(8-oxa-2-aza-spiro[4.5]dec-2-yl)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0355] 6-(2-Hydroxy-2-methyl-propylamino)-8-methyl-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0356] 8-Methyl-6-(2-piperidin-3-yl-ethoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0357] 6-[2-(1-acetyl-piperidin-3-yl)-ethoxy]-8-methyl-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0358] 6-[2-(4-Acetyl-piperazin-1-yl)-ethoxy]-8-methyl-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0359] 3-(8-Methyl-4-oxo-2-thieno[2,3-c]pyridin-5-yl-3,4-dihydro-quinazolin-6-yl)-propanal;

[0360] 8-methyl-6-(3-morpholin-4-yl-propyl)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0361] 8-methyl-6-(2-morpholin-4-yl-ethyl)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0362] 8-Methyl-6-(3-pyridin-4-yl-propoxy)-2-(4-trifluoromethyl-pyridin-2-yl)-3H-quinazolin-4-one;

[0363] 8-Methyl-6-(tetrahydro-furan-3-ylmethoxy)-2-(4-trifluoromethyl-pyridin-2-yl)-3H-quinazolin-4-one;

[0364] 8-Methyl-6-(1-propionyl-azetidin-yloxy)-2-(4-trifluoromethyl-pyridin-2-yl)-3H-quinazolin-4-one;

[0365] 8-Methyl-6-(1-oxetan-3-yl-piperidin-4-yloxy)-2-(4-trifluoromethyl-pyridin-2-yl)-3H-quinazolin-4-one;

[0366] 8-Methyl-6-(3-oxa-9-aza-spiro[5.5]undec-9-yl)-2-(4-trifluoromethyl-pyridin-2-yl)-3H-quinazolin-4-one;

[0367] 8-methyl-6-(3-pyridin-4-yl-propoxy)-2-pyrrolo[1,2-c]pyrimidin-3-yl-3H-quinazolin-4-one;

[0368] 8-methyl-2-pyrrolo[1,2-c]pyrimidin-3-yl-6-(tetrahydro-furan-3-ylmethoxy)-3H-quinazolin-4-one;

[0369] 8-methyl-6-(3-oxa-9-aza-spiro[5.5]undec-9-yl)-2-pyrrolo[1,2-c]pyrimidin-3-yl-3H-quinazolin-4-one;

[0370] 8-methyl-6-(1-oxetan-3-yl-piperidin-4-yloxy)-2-pyrrolo[1,2-c]pyrimidin-3-yl-3H-quinazolin-4-one;

[0371] 8-methyl-6-[1-(tetrahydro-pyran-4-yl)-ethoxy]-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0372] R-8-methyl-6-[1-(tetrahydro-pyran-4-yl)-ethoxy]-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0373] S-8-Methyl-6-[1-(tetrahydro-pyran-4-yl)-ethoxy]-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0374] 8-Methyl-6-[1-(tetrahydro-pyran-4-yl)-ethoxy]-2-(4-trifluoromethyl-pyridin-2-yl)-3H-quinazolin-4-one;

[0375] R-8-Methyl-6-[1-(tetrahydro-pyran-4-yl)-ethoxy]-2-(4-trifluoromethyl-pyridin-2-yl)-3H-quinazolin-4-one;

[0376] S-8-Methyl-6-[1-(tetrahydro-pyran-4-yl)-ethoxy]-2-(4-trifluoromethyl-pyridin-2-yl)-3H-quinazolin-4-one;

[0377] 6-[(3-fluorotetrahydrofuran-3-yl)methoxy]-8-methyl-2-[4-(trifluoromethyl)-2-pyridinyl]-3H-quinazolin-4-one;

[0378] 8-methyl-6-(3-oxa-9-azaspiro[5.5]undec-9-yl)-2-thieno[2,3-c]pyridin-5-yl-3-(2-trimethylsilylethoxymethyl)pyrido[3,2-d]pyrimidin-4-one;

[0379] 8-methyl-6-(morpholinomethyl)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0380] 8-methyl-6-(morpholinomethyl)-2-[4-(trifluoromethyl)-2-pyridinyl]-3H-quinazolin-4-one;

[0381] 8-methyl-6-(1-propionylazetidin-3-yl)oxy-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0382] 8-methyl-6-(2-morpholinoethyl)-2-[4-(trifluoromethyl)-2-pyridinyl]-3H-quinazolin-4-one;

[0383] 8-methyl-6-[(1-methyl-6-oxo-3-piperidinyl)oxy]-2-pyrrolo[1,2-c]pyrimidin-3-yl-3H-quinazolin-4-one;

[0384] 8-methyl-6-(morpholinomethyl)-2-(thieno[3,2-c]pyridin-6-yl)quinazolin-4(3H)-one;

[0385] 8-methyl-6-(3-oxa-9-azaspiro[5.5]undec-9-yl)-2-(thieno[3,2-c]pyridin-6-yl)quinazolin-4(3H)-one;

[0386] 8-methyl-6-(2-[1,4]oxazepan-4-yl-ethyl)-2-thieno[2,3-b]pyridin-5-yl-3H-quinazolin-4-one;

[0387] 8-methyl-6-(2-[1,4]oxazepan-4-yl-ethyl)-2-thieno[3,2-b]pyridin-6-yl-3H-quinazolin-4-one;

[0388] 8-methyl-6-(2-morpholin-4-yl-ethyl)-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one;

[0389] 8-Methyl-6-(2-morpholin-4-yl-ethyl)-2-pyrrolo[1,2-c]pyrimidin-3-yl-3H-quinazolin-4-one;

[0390] 8-methyl-6-(morpholinomethyl)-2-pyrrolo[1,2-c]pyrimidin-3-yl-3H-quinazolin-4-one;

[0391] 8-methyl-6-(2-morpholino-2-oxoethyl)-2-(thieno[3,2-c]pyridin-6-yl)quinazolin-4(3H)-one;

[0392] 8-methyl-6-(2-morpholino-2-oxo-ethyl)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0393] 8-methyl-6-(2-piperidin-1-yl-ethyl)-2-thieno[2,3-b]pyridin-5-yl-3H-quinazolin-4-one;

[0394] 8-methyl-6-(1-methyl-6-oxo-piperidin-3-yloxy)-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one;

[0395] 8-Methyl-6-(1-methyl-2-oxo-piperidin-4-ylmethoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one

[0396] 8-methyl-6-(1-piperidinylmethyl)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0397] 8-methyl-6-(2-morpholino-2-oxo-ethyl)-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one;

[0398] 8-methyl-6-[(4-methylpiperazin-1-yl)methyl]-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0399] 8-methyl-6-(pyrrolidin-1-ylmethyl)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0400] 8-methyl-6-(2-morpholino-2-oxo-ethyl)-2-pyrrolo[1,2-c]pyrimidin-3-yl-3H-quinazolin-4-one;

[0401] 8-methyl-6-(morpholine-4-carbonyl)-2-pyrrolo[1,2-c]pyrimidin-3-yl-3H-quinazolin-4-one;

[0402] 8-Methyl-6-(1-methyl-6-oxo-piperidin-3-yloxy)-2-(4-trifluoromethyl-pyridin-2-yl)-3H-quinazolin-4-one;

[0403] 8-methyl-2-thieno[2,3-c]pyridin-5-yl-6-(thiomorpholinomethyl)-3H-quinazolin-4-one;

[0404] 8-methyl-6-[2-(1,4-oxazepan-4-yl)-2-oxo-ethyl]-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0405] 8-methyl-6-(pyrrolidin-1-ylmethyl)-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one;

[0406] 8-methyl-6-(1-methyl-5-oxo-pyrrolidin-3-yl)oxy-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one;

[0407] 8-methyl-6-[(3R)-1-methyl-5-oxo-pyrrolidin-3-yl]oxy-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one;

[0408] 8-methyl-6-[(3S)-1-methyl-5-oxo-pyrrolidin-3-yl]oxy-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one;

[0409] benzyl 3-[(8-methyl-4-oxo-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-6-yl)oxy]pyrrolidine-1-carboxylate;

[0410] benzyl (3S)-3-[(8-methyl-4-oxo-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-6-yl)oxy]pyrrolidine-1-carboxylate;

[0411] benzyl (3R)-3-[(8-methyl-4-oxo-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-6-yl)oxy]pyrrolidine-1-carboxylate;

[0412] 8-methyl-6-[2-(4-methyl-3-oxo-piperazin-1-yl)ethyl]-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0413] 8-methyl-6-[2-(4-methyl-3-oxo-piperazin-1-yl)ethyl]-2-[4-(trifluoromethyl)-2-pyridinyl]-3H-quinazolin-4-one;

[0414] 8-methyl-6-[2-(2-oxa-6-azaspiro[3.3]heptane-6-yl)ethyl]-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0415] 8-methyl-6-[2-(2-oxa-6-azaspiro[3.3]heptane-6-yl)ethyl]-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one;

[0416] 8-methyl-6-[(4-methyl-3-oxo-piperazin-1-yl)methyl]-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one;

[0417] 6-(2-((2-methoxyethyl)(methyl)amino)ethyl)-8-methyl-2-(thieno[3,2-c]pyridin-6-yl)quinazolin-4(3H)-one;

[0418] 6-(2-(1,1-dioxythiomorpholino)ethyl)-8-methyl-2-(thieno[3,2-c]pyridin-6-yl)quinazolin-4(3H)-one;

[0419] 6-[(1,1-dioxo-1,4-thiazinane-4-yl)methyl]-8-methyl-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one;

[0420] 6-(((2-methoxyethyl)(methyl)amino)methyl)-8-methyl-2-(thieno[3,2-c]pyridin-6-yl)quinazolin-4(3H)-one;

[0421] 6-[(4-methoxy-1-piperidinyl)methyl]-8-methyl-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one;

[0422] 6-[(2,2-dimethylmorpholin-4-yl)methyl]-8-methyl-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one;

[0423] 8-chloro-6-(2-morpholinoethyl)-2-(4-(trifluoromethyl)pyridin-2-yl)quinazolin-4(3H)-one;

[0424] 8-methyl-6-(2-oxa-7-azaspiro[3.5]nonan-7-ylmethyl)-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one;

[0425] N,N-dimethyl-1-((8-methyl-4-oxo-2-(thieno[3,2-c]pyridin-6-yl)-3,4-dihydroquinazolin-6-yl)methyl)piperidine-4-carboxamide;

[0426] 6-((4-(methoxymethyl)piperidin-1-yl)methyl)-8-methyl-2-(thieno[3,2-c]pyridin-6-yl)quinazolin-4(3H)-one;

[0427] 8-methoxy-6-(2-morpholinoethyl)-2-(4-(trifluoromethyl)pyridin-2-yl)quinazolin-4(3H)-one;

[0428] 8-Bromo-6-(2-morpholinoethyl)-2-(4-(trifluoromethyl)pyridin-2-yl)quinazolin-4(3H)-one;

[0429] 6-(2-(2,2-dimethylmorpholino)ethyl)-8-methyl-2-(4-(trifluoromethyl)pyridin-2-yl)quinazolin-4(3H)-one;

[0430] 8-methyl-6-((4-methyl-3-oxopiperazin-1-yl)methyl)-2-(4-(trifluoromethyl)pyridin-2-yl)quinazolin-4(3H)-one;

[0431] 6-(2-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)ethyl)-8-methyl-2-(4-(trifluoromethyl)pyridin-2-yl)quinazolin-4(3H)-one;

[0432] 6-(2-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)ethyl)-8-methyl-2-(4-(trifluoromethyl)pyridin-2-yl)quinazolin-4(3H)-one;

[0433] 6-(2-(4-hydroxypiperidin-1-yl)ethyl)-8-methyl-2-(4-(trifluoromethyl)pyridin-2-yl)quinazolin-4(3H)-one;

[0434] 6-(2-(4,4-difluoropiperidin-1-yl)ethyl)-8-methyl-2-(4-(trifluoromethyl)pyridin-2-yl)quinazolin-4(3H)-one;

[0435] 6-(2-(4-methoxypiperidin-1-yl)ethyl)-8-methyl-2-(4-(trifluoromethyl)pyridin-2-yl)quinazolin-4(3H)-one;

[0436] 8-methyl-6-(2-morpholinoethyl)-2-(4-(trifluoromethyl)pyridin-2-yl)pyrido[3,2-d]pyrimidin-4(3H)-one; and a pharmaceutically acceptable salt of any one of the foregoing compounds.

[0437] The present invention also relates to each intermediate further described below in the Examples section of this specification, including any of these intermediates in non-salt form or salt form (e.g., pharmaceutically acceptable salts). Such intermediates can be particularly useful in the synthesis of compounds of formula (I).

[0438] For those skilled in the art of synthetic chemistry, various methods for preparing compounds of formula (I) will be readily apparent. For example, compounds of formula (I) can be prepared as described below, and in particular, they can be prepared according to or in a manner similar to the synthetic routes described in the Examples section.

[0439]

[0440] When-LR X2 =-OR, compounds of formula (I) can be prepared as follows: starting from the corresponding o-aminobenzamide and carboxylic acid of formula (A) under peptide coupling conditions, typically using BOP (benzotriazol-1-yloxy-tris(dimethylamino)-phosphonium hexafluorophosphate) as a coupling reagent (Valeur et al. (2009) Chem. Soc. Rev., 38: 606–631), followed by a cyclization step under alkaline conditions at elevated temperature. The o-aminobenzoic acid of formula (A) can be prepared by reducing the corresponding nitro derivative of formula (B). Typical conditions are the use of hydrogen with palladium on carbon, or the use of a metal such as iron (Orlandi et al. (2018) Org. Process Res. Dev., 22: 430-445). The -OR chain can be introduced from fluorinated derivatives of formula (C) and alcohols by nucleophilic aromatic substitution. Typical conditions are the use of a base at elevated temperature (Bunnett et al. (1951) Chem. Rev., 49:273-412). Group -LR X2 Can be introduced directly from the corresponding alcohol, or the -OR chain can be subsequently modified to form -LR X2For example, a deprotection step and / or further functionalization may be performed. Finally, anthranilamides of formula (C) can be obtained from the corresponding anthranilic acids of formula (D) under peptide coupling conditions, typically using BOP as coupling reagent in the presence of ammonia.

[0441]

[0442] Or, when -LR X2 =-OR, the compound of formula (I) can be prepared from the compound of formula (F) and an alcohol by a nucleophilic substitution reaction or a cross-coupling reaction such as an Ullmann-type reaction (Altman et al., (2008) J. Org. Chem., 73: 284–286) or a palladium-catalyzed coupling reaction (Bruno et al., (2013) Org. Lett., 15: 2876–2879) or by a photoredox-nickel catalyzed C–O coupling reaction (Terrett et al. (2015) Nature, 524: 330). X2 Can be introduced directly from the corresponding alcohol, or the -OR chain can be subsequently modified to form -LR X2 For example, deprotection steps and / or further functionalizations may be performed.

[0443] Or, when -LR X2 =-OR, compounds of formula (I) can be prepared from compounds of formula (E) by Mitsunobu reaction with alcohols (Swamy et al. (2009) Chem. Rev., 109:2551-265) or by nucleophilic substitution from halide or pseudohalide derivatives. Group -LR X2 The -OR chain can be introduced directly from the corresponding alcohol or halide or pseudohalide, or the -OR chain can be subsequently modified to form -LR X2 For example, deprotection steps and / or further functionalizations may be performed.

[0444] When-LR X2 =-N-RR', compounds of formula (I) can be prepared from compounds of formula (F) by Buchwald-Hartwig reaction with amines (Heravi et al. (2018) J. Organomet. Chem., 861:17). Group -LR X2 Can be introduced directly from the corresponding amine, or the -N-RR' chain can be subsequently modified to form -LR X2 For example, deprotection steps and / or further functionalizations may be performed.

[0445] When-LR X2 =-CRR'R" or -CR=R'R" or C≡R, compounds of formula (I) can be prepared from compounds of formula (F) using organometallic reagents, for example, by Suzuki (Maluenda et al. (2015) Molecules, 20:7528) or Neigishi (Haas et al. (2016) ACS Catal., 6:1540) coupling or by palladium-catalyzed aminocarbonylation (Wannberg et al. (2003) J. Org. Chem., 14:5750). Group -LR X2 It can be introduced directly from the corresponding organometallic reagent, or the -CRR'R" or -CR=R'R" or C≡R chain can be subsequently modified to form -LR X2 For example, hydroboration and / or deprotection and / or further functionalization may be performed.

[0446] Compounds of formula (F) can be prepared starting from the corresponding formula (G) and an anthranilamide and a carboxylic acid under peptide coupling conditions, typically using BOP as a coupling reagent, followed by cyclization under basic conditions and heating.

[0447]

[0448] The anthranilamides of formula (G) are prepared from the corresponding acids of formula (H) under peptide coupling conditions, typically using BOP as coupling reagent in the presence of ammonia.

[0449] Alternatively, anthranilamides of formula (G) can be prepared from the corresponding nitrile derivatives of formula (J) by hydration reaction.

[0450]

[0451] When-LR X2=-CH2-CH2-NRR', the compound of formula (I) can be prepared from the compound of formula (K) by cyclization under alkaline heating conditions. The compound of formula (K) can be prepared from the nitrile derivative of formula (M) by hydration and peptide coupling reaction with acid, regardless of the order of the steps. Typical hydration conditions are the use of strong acids such as hydrochloric acid or sulfuric acid or strong bases such as potassium carbonate or milder conditions such as aqueous hydrogen peroxide and dimethyl sulfoxide in the presence of bases such as potassium carbonate or sodium hydroxide. The peptide coupling reaction can be carried out using various methods of activating carboxylic acids, such as BOP, T3P (propylphosphonic anhydride), oxalyl chloride or phosphoryl chloride (Valeur et al. (2009) Chem. Soc. Rev., 38: 606–631). The amine HNRR' can be introduced as follows to obtain a compound of formula (M): Activate the alcohol derivative of formula (O) to form a leaving group such as mesylate, tosylate, triflate or halide, and then perform nucleophilic substitution. Typical conditions use a base such as triethylamine or potassium carbonate.Compounds of formula (O) may be prepared by halogenating compounds of formula (P), typically using N-bromosulfenyl imide or iodine as the halogenating agent.

[0452] The group -R X4 Modification is performed, for example, by electrophilic halogenation of compounds of formula (O) or (M) or by palladium-catalyzed coupling such as Suzuki coupling of compounds of formula (O) or (M) to introduce an alkyl group from the halogen to the group -R X4 Modified (Maluenda et al. (2015) Molecules, 20: 7528).

[0453]

[0454] When-LR X2 =-CH2-C(O)-NRR', compounds of formula (I) can be prepared by starting from an anthranilamide of formula (Q) and a carboxylic acid under peptide coupling conditions (Valeur et al. (2009) Chem. Soc. Rev., 38:606–631), typically using BOP as a coupling reagent, followed by a cyclization step at elevated temperature under alkaline conditions. One possible method for synthesizing compounds of formula (Q) is to decarboxylate the compound of formula (R), followed by reduction of the resulting nitro derivative and amide coupling with an amine NRR', typically using BOP as a coupling reagent. Compounds of formula (R) can be prepared by nucleophilic aromatic substitution of a fluorinated derivative or a compound of formula (C) with a dialkyl malonate in the presence of a base at elevated temperature.

[0455] Additionally, compounds of formula (I) may be further functionalized to provide further compounds of formula (I), for example, by cross-coupling reactions when X1, X3 and / or X4 = C-Hal.

[0456] While all of the above syntheses are being carried out, the lactam NH bond can be temporarily protected, for example with a SEM protecting group.

[0457] For importing -LR X2 Various reactants and starting materials are commercially available or can be prepared by typical organic chemical reactions as described in the examples.

[0458] The following definitions apply to the entire text of this specification, unless otherwise specified.

[0459] The term "hydrocarbyl" refers to a group consisting of carbon and hydrogen atoms.

[0460] The term "alkyl" as used herein refers to a monovalent saturated acyclic (i.e., non-cyclic) hydrocarbon group which may be straight-chain or branched. Thus, an "alkyl" group does not contain any carbon-carbon double bonds or any carbon-carbon triple bonds. 1-5 "Alkyl" means an alkyl group having 1 to 5 carbon atoms. Preferred exemplary alkyl groups are methyl, ethyl, propyl (e.g., n-propyl or isopropyl) or butyl (e.g., n-butyl, isobutyl, sec-butyl or tert-butyl). Unless otherwise defined, the term "alkyl" preferably refers to a C 1-4 Alkyl more preferably refers to methyl or ethyl, even more preferably refers to methyl.

[0461] As used herein, the term "alkenyl" refers to a monovalent unsaturated acyclic hydrocarbon group which may be linear or branched and contains one or more (e.g., one or two) carbon-carbon double bonds, while it does not contain any carbon-carbon triple bonds. 2-5 "Alkenyl" means an alkenyl group having 2 to 5 carbon atoms. Preferred exemplary alkenyl groups are ethenyl, propenyl (e.g., prop-1-en-1-yl, prop-1-en-2-yl or prop-2-en-1-yl), butenyl, butadienyl (e.g., buta-1,3-dien-1-yl or buta-1,3-dien-2-yl), pentenyl or pentadienyl (e.g., isoprenyl). Unless otherwise defined, the term "alkenyl" preferably refers to a C 2-4 Alkenyl.

[0462] As used herein, the term "alkynyl" refers to a monovalent unsaturated acyclic hydrocarbon group which may be linear or branched and contains one or more (e.g., one or two) carbon-carbon triple bonds and optionally one or more (e.g., one or two) carbon-carbon double bonds. 2-5"Alkynyl" means an alkynyl group having 2 to 5 carbon atoms. Preferred exemplary alkynyl groups are ethynyl, propynyl (eg, propargyl) or butynyl. Unless otherwise defined, the term "alkynyl" preferably refers to a C 2-4 Alkynyl.

[0463] The term "alkylene" as used herein refers to an alkanediyl group, i.e., a divalent saturated acyclic hydrocarbon group which may be straight-chain or branched. 1-5 "Alkylene" means an alkylene group having 1 to 5 carbon atoms. 0-3 "Alkylene" means there is a covalent bond (equivalent to selecting "C0 alkylene") or C 1-3 Alkylene. Preferred exemplary alkylene groups are methylene (-CH2-), ethylene (e.g., -CH2-CH2- or -CH(-CH3)-), propylene (e.g., -CH2-CH2-CH2-, -CH(-CH2-CH3)-, -CH2-CH(-CH3)- or -CH(-CH3)-CH2-), or butylene (e.g., -CH2-CH2-CH2-CH2-). Unless otherwise defined, the term "alkylene" preferably refers to a C 1-4 Alkylene (especially, including straight chain C 1-4 Alkylene), more preferably refers to methylene or ethylene.

[0464] The term "alkenylene" as used herein refers to an alkenediyl group, i.e., a divalent unsaturated acyclic hydrocarbon group which may be linear or branched and contains one or more (e.g., one or two) carbon-carbon double bonds, while it does not contain any carbon-carbon triple bonds. 2-8 "Alkenylene" means an alkenylene group having 2 to 8 carbon atoms. Unless otherwise defined, the term "alkenylene" preferably refers to a C 2-4 Alkenylene (especially, including straight chain C 2-4 alkenylene).

[0465] The term "alkynylene" as used herein refers to an alkynediyl group, i.e., a divalent unsaturated acyclic hydrocarbon group, which may be linear or branched, containing one or more (e.g., one or two) carbon-carbon triple bonds, and optionally containing one or more (e.g., one or two) carbon-carbon double bonds. 2-8 "Alkyne" means an alkynyl group having 2 to 8 carbon atoms. Unless otherwise defined, the term "alkynyl" preferably refers to a C 2-4 Alkynylidene (especially, including straight chain C 2-4 alkynylene).

[0466] The term "carbocyclyl" as used herein refers to a hydrocarbon ring group, including monocyclic and bridged, spirocyclic and / or fused ring systems (which may, for example, be composed of two or three rings), wherein the ring group may be saturated, partially unsaturated (i.e., unsaturated, but not aromatic) or aromatic. Unless otherwise defined, "carbocyclyl" preferably refers to an aryl, cycloalkyl or cycloalkenyl group.

[0467] The term "carbocyclylene" as used herein refers to a carbocyclyl as defined above, but having two points of attachment, i.e., a divalent hydrocarbon ring group, including monocyclic and bridged, spirocyclic and / or fused ring systems (which may, for example, consist of two or three rings), wherein the ring group may be saturated, partially unsaturated (i.e., unsaturated, but not aromatic) or aromatic. Unless otherwise defined, "carbocyclylene" preferably refers to arylene, cycloalkylene or cycloalkenylene.

[0468] As used herein, the term "heterocyclyl" refers to a cyclic group, including monocyclic and bridged, spirocyclic and / or fused ring systems (which may be composed of, for example, two or three rings), wherein the cyclic group contains one or more (e.g., one, two, three or four) ring heteroatoms independently selected from O, S and N, the remaining ring atoms being carbon atoms, wherein one or more S ring atoms (if present) and / or one or more N ring atoms (if present) may be optionally oxidized, wherein one or more carbon ring atoms may be optionally oxidized (i.e., to form an oxo group), and further wherein the cyclic group may be saturated, partially unsaturated (i.e., unsaturated but not aromatic) or aromatic. For example, each heteroatom-containing ring contained in the cyclic group may contain one or two O atoms and / or one or two S atoms (which may be optionally oxidized) and / or one, two, three or four N atoms (which may be optionally oxidized), provided that the total number of heteroatoms in the corresponding heteroatom-containing ring is 1-4 and that there is at least one carbon ring atom (which may be optionally oxidized) in the corresponding heteroatom-containing ring. Unless defined otherwise, "heterocyclyl" preferably refers to heteroaryl, heterocycloalkyl or heterocycloalkenyl.

[0469] The term "heterocyclylene" as used herein refers to a heterocyclyl as defined above, but having two points of attachment, i.e., a divalent ring group, including monocyclic as well as bridged, spiro and / or fused ring systems (which may, for example, consist of two or three rings), wherein the ring group contains one or more (e.g., one, two, three or four) ring heteroatoms independently selected from O, S and N, the remaining ring atoms being carbon atoms, wherein one or more S ring atoms (if present) and / or one or more N ring atoms (if present) may be optionally oxidized, wherein one or more carbon ring atoms may be optionally oxidized (i.e., to form an oxo group), and further wherein the ring group may be saturated, partially unsaturated (i.e., unsaturated but not aromatic) or aromatic. For example, each heteroatom-containing ring included in the cyclic group may contain one or two O atoms and / or one or two S atoms (which may be optionally oxidized) and / or one, two, three or four N atoms (which may be optionally oxidized), provided that the total number of heteroatoms in the corresponding heteroatom-containing ring is 1-4 and that there is at least one carbon ring atom (which may be optionally oxidized) in the corresponding heteroatom-containing ring. Unless otherwise defined, "heterocyclylene" preferably refers to heteroarylene, heterocycloalkylene or heterocycloalkenylene.

[0470] The term "aryl" as used herein refers to an aromatic hydrocarbon ring group, including monocyclic aromatic rings and bridged and / or fused ring systems having at least one aromatic ring (e.g., a ring system consisting of two or three fused rings, wherein at least one of the fused rings is aromatic; or a bridged ring system consisting of two or three rings, wherein at least one of the bridged rings is aromatic). "Aryl" may, for example, refer to phenyl, naphthyl, dihydronaphthyl (dialinyl) (i.e., 1,2-dihydronaphthyl), tetrahydronaphthyl (i.e., 1,2,3,4-tetrahydronaphthyl), indanyl, indenyl (e.g., 1H-indenyl), anthracenyl, phenanthrenyl, 9H-fluorenyl or azulenyl. Unless otherwise defined, "aryl" preferably has 6-14 ring atoms, more preferably 6-10 ring atoms, even more preferably refers to phenyl or naphthyl, and most preferably refers to phenyl.

[0471] As used herein, the term "arylene" refers to an aryl group as defined above, but having two points of attachment, i.e., a divalent aromatic hydrocarbon ring radical, including monocyclic aromatic rings and bridged and / or fused ring systems containing at least one aromatic ring (e.g., a ring system consisting of two or three fused rings, wherein at least one of the fused rings is aromatic; or a bridged ring system consisting of two or three rings, wherein at least one of the bridged rings is aromatic). “Arylene” may, for example, refer to a phenylene group (e.g., benzene-1,2-diyl, benzene-1,3-diyl, or benzene-1,4-diyl), a naphthylene group (e.g., naphthalene-1,2-diyl, naphthalene-1,3-diyl, naphthalene-1,4-diyl, naphthalene-1,5-diyl, naphthalene-1,6-diyl, naphthalene-1,7-diyl, naphthalene-2,3-diyl, naphthalene-2,5-diyl, naphthalene-2,6-diyl, naphthalene-2,7-diyl, or naphthalene-2,8-diyl), a 1,2-dihydronaphthylene group, a 1,2,3,4-tetrahydronaphthylene group, an indanylene group, an indenylene group, an anthrylene group, a phenanthrenylene group, a 9H-fluorenylene group, or an azulenylene group. Unless otherwise defined, "arylene" preferably has 6-14 ring atoms, more preferably 6-10 ring atoms, even more preferably refers to phenylene or naphthylene, most preferably refers to phenylene (especially benzene-1,4-diyl).

[0472] As used herein, the term "heteroaryl" refers to aromatic ring groups, including monocyclic aromatic rings and bridged and / or fused ring systems containing at least one aromatic ring (e.g., a ring system consisting of two or three fused rings, wherein at least one of the fused rings is aromatic; or a bridged ring system consisting of two or three rings, wherein at least one of the bridged rings is aromatic), wherein the aromatic ring group contains one or more (e.g., one, two, three or four) ring heteroatoms independently selected from O, S and N, the remaining ring atoms being carbon atoms, wherein one or more S ring atoms (if present) and / or one or more N ring atoms (if present) may be optionally oxidized, and further wherein one or more carbon ring atoms may be optionally oxidized (i.e., to form an oxo group). For example, each heteroatom-containing ring contained in the aromatic cyclic group can contain one or two O atoms and / or one or two S atoms (which can be optionally oxidized) and / or one, two, three or four N atoms (which can be optionally oxidized), provided that the total number of heteroatoms in the corresponding heteroatom-containing ring is 1-4 and there is at least one carbon ring atom (which can be optionally oxidized) in the corresponding heteroatom-containing ring."Heteroaryl" can be, for example, thienyl (i.e., thienyl), benzo[b]thienyl, naphtho[2,3-b]thienyl, thianthrenyl, furyl (i.e., furanyl), benzofuranyl, isobenzofuranyl, chromanyl, chromenyl (e.g., 2H-1-benzopyranyl or 4H-1-benzopyranyl), isochromenyl (e.g., 1H-2-benzopyranyl), chromonyl, xanthenyl, phenoxathiinyl, pyrrolyl ( 1H-pyrrolyl), imidazolyl, pyrazolyl, pyridinyl (i.e., pyridinyl; e.g., 2-pyridinyl, 3-pyridinyl, or 4-pyridinyl), pyrazinyl, pyrimidinyl, pyridazinyl, indolyl (e.g., 3H-indolyl), isoindolyl, indazolyl, indolizinyl, purinyl, quinolyl, isoquinolyl, phthalazinyl, naphthyridinyl, quinoxalinyl, cinnolinyl, pteridinyl, carbazolyl, β-carbolinyl, phenanthridinyl, acridinyl, permidinyl, phenanthrolinyl (e.g., [1,10]phenanthrolinyl, [1,7]phenanthrolinyl, or [4,7]phenanthrolinyl), phenazinyl, thiazolyl, isothiazolyl, phenothiazinyl, oxazolyl, isoxazolyl, oxadiazolyl (e.g., For example, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl (i.e., furazanyl) or 1,3,4-oxadiazolyl), thiadiazolyl (e.g., 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl or 1,3,4-thiadiazolyl), phenoxazinyl, pyrazolo[1,5-a]pyrimidinyl (e.g., pyrazolo[1,5-a]pyrimidin-3-yl), 1,2-benzisoxazol-3-yl, benzothiazolyl, benzothiadiazolyl, benzoxazolyl, benzisoxazolyl, benzimidazolyl, benzo[b]thienyl (i.e., benzothienyl), triazolyl (e.g., 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, 1H-1,2,4-triazolyl or 4H-1,2 ,4-triazolyl), benzotriazolyl, 1H-tetrazolyl, 2H-tetrazolyl, triazinyl (e.g., 1,2,3-triazinyl, 1,2,4-triazinyl or 1,3,5-triazinyl), furo[2,3-c]pyridinyl, dihydrofuropyridinyl (e.g., 2,3-dihydrofuropyridinyl or 1,3-dihydrofuropyridinyl), imidazopyridinyl ( For example, imidazo[1,2-a]pyridinyl or imidazo[3,2-a]pyridinyl), quinazolinyl, thienopyridinyl, tetrahydrothienopyridinyl (e.g., 4,5,6,7-tetrahydrothieno[3,2-c]pyridinyl), dibenzofuranyl, 1,3-benzodioxolyl, benzodioxanyl (e.g., 1,3-benzodioxanyl or 1,4-benzodioxanyl), or coumarinyl.Unless otherwise defined, the term "heteroaryl" preferably refers to a 5-14 membered (more preferably a 5-10 membered) monocyclic or fused ring system comprising one or more (e.g., one, two, three or four) ring heteroatoms independently selected from O, S and N, wherein one or more S ring atoms (if present) and / or one or more N ring atoms (if present) are optionally oxidized, and wherein one or more carbon ring atoms are optionally oxidized; even more preferably, "heteroaryl" refers to a 5- or 6-membered monocyclic ring comprising one or more (e.g., one, two or three) ring heteroatoms independently selected from O, S and N, wherein one or more S ring atoms (if present) and / or one or more N ring atoms (if present) are optionally oxidized, and wherein one or more carbon ring atoms are optionally oxidized.

[0473] As used herein, the term "heteroarylene" refers to a heteroaryl group as defined above, but having two points of attachment, i.e., a divalent aromatic ring group, including monocyclic aromatic rings and bridged and / or fused ring systems further comprising at least one aromatic ring (e.g., a ring system consisting of two or three fused rings, wherein at least one of the fused rings is aromatic; or a bridged ring system consisting of two or three rings, wherein at least one of the bridged rings is aromatic), wherein the aromatic ring group comprises one or more (e.g., one, two, three, or four) ring heteroatoms independently selected from O, S, and N, the remaining ring atoms being carbon atoms, wherein one or more S ring atoms (if present) and / or one or more N ring atoms (if present) may be optionally oxidized, and further wherein one or more carbon ring atoms may be optionally oxidized (i.e., to form an oxo group). For example, each heteroatom-containing ring contained in the aromatic cyclic group can contain one or two O atoms and / or one or two S atoms (which can be optionally oxidized) and / or one, two, three or four N atoms (which can be optionally oxidized), provided that the total number of heteroatoms in the corresponding heteroatom-containing ring is 1-4 and there is at least one carbon ring atom (which can be optionally oxidized) in the corresponding heteroatom-containing ring. "Heteroarylene" may refer to, for example, a thiophenylene group (i.e., a thiophenylene group; for example, thiophene-2,3-diyl, thiophene-2,4-diyl, or thiophene-2,5-diyl), a benzo[b]thiophenylene group, a naphtho[2,3-b]thiophenylene group, a thianthrenylene group, a furanylene group (i.e., a furanylene group; for example, furan-2,3-diyl, furan-2,4-diyl, or furan-2,5-diyl group), a benzofuranylene group, an isobenzofuranylene group, a chromanylene group, a chromenylene group, an isochromenylene group, a chromonylene group, a xanthenylene group, an oxythioanthenylene group, a pyrrolylene group, an imidazolylene group, a pyrazolylene group, a pyridylene group (i.e., a pyridylene group), a pyrazinylene group, a pyrimidinylene group, Pyridazinyl, indolyl, isoindolyl, indazolyl, indolizinyl, purinyl, quinolyl, isoquinolyl, phthalazinyl, naphthyridinyl, quinoxalinyl, cinnolinyl, pteridinyl, carbazolylene, β-carbolylene, phenanthridinylene, acridinylene, perimidinylene, phenanthrolinylene, phenazinylene, thiazolylene (e.g., thiazol-2,4-diyl, thiazol-2,5-diyl, or thiazol-4,5-diyl), isothiazolylene (e.g., isothiazol-3,4-diyl, isothiazol-3,5-diyl, or isothiazol-4,5-diyl), phenothiazinylene, oxazolylene (e.g., oxazol-2,4-diyl, oxazol-2,5-diyl, or oxazol-4,5-diyl), isoxazolylene (e.g., isoxazol-3,4-diyl, isoxazol-3,5-diyl, or isoxazol-4,5-diyl), oxadiazolylene (e.g., 1,2,4- Oxadiazole-3,5-diyl, 1,2,5-oxadiazole-3,4-diyl or 1,3,4-oxadiazole-2,5-diyl), thiadiazolylidene (e.g. 1,2,4-thiadiazole-3,5-diyl, 1,2,5-thiadiazole-3,4-diyl or 1,3,4-thiadiazole-2,5-diyl), phenoxazinylene, pyrazolo[1,5-a]pyrimidinylene, 1,2-benzoxazolylene, benzothiazolylene, benzothiadiazolylene, benzoxazolylene, benzisoxazolylene, benzimidazolylene, benzo[b]thienylene (i.e., benzothienylene), triazolylene (e.g., 1H-1,2,3-triazolylene, 2H-1,2,3-triazolylene, 1H-1,2,4-triazolylene or 4H-1,2,4-triazolylene), benzotriazolylene, 1H-tetrazolylene, 2H-tetrazolylene, triazinylene (e.g., 1,2,3-triazinylene, 1,2 ,4-triazinyl or 1,3,5-triazinyl), furano[2,3-c]pyridylene, dihydrofuropyridylene (e.g., 2,3-dihydrofuro[2,3-c]pyridylene or 1,3-dihydrofuro[3,4-c]pyridylene), imidazopyridylene (e.g., imidazo[1,2-a]pyridylene or imidazo[3,2-a]pyridylene), quinazolinylene, thienopyridylene, tetrahydrothienopyridylene (e.g., 4,5,6,7-tetrahydrothieno[3,2-c]pyridylene), dibenzofuranylene, 1,3-benzodioxolylene, benzodioxanylene (e.g., 1,3-benzodioxanylene or 1,4-benzodioxanylene), or coumarinylene. Unless otherwise defined, the term "heteroarylene" preferably refers to a divalent 5-14 membered (more preferably 5-10 membered) monocyclic or fused ring system comprising one or more (e.g., one, two, three or four) ring heteroatoms independently selected from O, S and N, wherein one or more S ring atoms (if present) and / or one or more N ring atoms (if present) are optionally oxidized, and wherein one or more carbon ring atoms are optionally oxidized; even more preferably, "heteroarylene" refers to a divalent 5- or 6-membered monocyclic ring comprising one or more (e.g., one, two or three) ring heteroatoms independently selected from O, S and N, wherein one or more S ring atoms (if present) and / or one or more N ring atoms (if present) are optionally oxidized, and wherein one or more carbon ring atoms are optionally oxidized. "Heteroarylene" including any specific heteroarylene described herein may be linked via two carbon ring atoms, in particular via two carbon ring atoms within a single ring or within the complete ring system of the corresponding heteroarylene that are at the maximum distance from each other (the number of ring atoms separating them by the shortest possible link).

[0474] The term "cycloalkyl" as used herein refers to a saturated hydrocarbon ring group, including a monocyclic ring as well as a bridged ring, a spirocyclic ring and / or a fused ring system (which may be composed of, for example, two or three rings, for example, a fused ring system composed of two or three fused rings). "Cycloalkyl" may, for example, refer to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, decahydronaphthyl (i.e., decahydronaphthyl) or adamantyl. Unless otherwise defined, "cycloalkyl" preferably refers to a C 3-11 Cycloalkyl, more preferably refers to C 3-7 Cycloalkyl. Particularly preferred "cycloalkyl" is a monocyclic saturated hydrocarbon ring having 3 to 7 ring members.

[0475] The term "cycloalkylene" as used herein refers to a cycloalkyl group as defined above, but having two points of attachment, i.e., a divalent saturated hydrocarbon ring group, including monocyclic rings as well as bridged, spirocyclic and / or fused ring systems (which may consist of, for example, two or three rings; e.g., a fused ring system consisting of two or three fused rings). "Cycloalkylene" may refer to, for example, cyclopropylene (e.g., cyclopropane-1,1-diyl or cyclopropane-1,2-diyl), cyclobutylene (e.g., cyclobutane-1,1-diyl, cyclobutane-1,2-diyl or cyclobutane-1,3-diyl), cyclopentylene (e.g., cyclopentane-1,1-diyl, cyclopentane-1,2-diyl or cyclopentane-1,3-diyl), cyclohexylene (e.g., cyclohexane-1,1-diyl, cyclohexane-1,2-diyl, cyclohexane-1,3-diyl or cyclohexane-1,4-diyl), cycloheptylene, decahydronaphthylene (i.e., decahydronaphthylene) or adamantylene. Unless otherwise defined, "cycloalkylene" preferably refers to C 3-11 Cycloalkylene, more preferably refers to C 3-7 Cycloalkylene. Particularly preferred "cycloalkylene" is a divalent monocyclic saturated hydrocarbon ring having 3 to 7 ring members.

[0476] As used herein, the term "heterocycloalkyl" refers to a saturated cyclic group, including monocyclic and bridged, spirocyclic and / or fused ring systems (which can be composed of two or three rings, for example, a fused ring system composed of two or three fused rings), wherein the cyclic group contains one or more (e.g., one, two, three, or four) ring heteroatoms independently selected from O, S, and N, the remaining ring atoms being carbon atoms, wherein one or more S ring atoms (if present) and / or one or more N ring atoms (if present) can be optionally oxidized, and further wherein one or more carbon ring atoms can be optionally oxidized (i.e., to form an oxo group). For example, each heteroatom-containing ring contained in the saturated cyclic group can contain one or two O atoms and / or one or two S atoms (which can be optionally oxidized) and / or one, two, three, or four N atoms (which can be optionally oxidized), provided that the total number of heteroatoms in the corresponding heteroatom-containing ring is 1-4 and that there is at least one carbon ring atom (which can be optionally oxidized) in the corresponding heteroatom-containing ring. "Heterocycloalkyl" may refer, for example, to aziridinyl, azetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, azepanyl, diazepanyl (e.g., 1,4-diazepanyl), oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, morpholinyl (e.g., morpholin-4-yl), thiomorpholinyl (e.g., thiomorpholin-4-yl), oxazepanyl, oxirane, oxetanyl, tetrahydrofuranyl, 1,3-dioxolanyl, tetrahydropyranyl, 1,4-dioxanyl, oxepanyl, thiirane, thietanyl, tetrahydrothiophenyl (i.e., thiolanyl), 1,3-dithiolanyl, thianyl, thietanyl, decahydroquinolinyl, decahydroisoquinolinyl or 2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl. Unless otherwise defined, "heterocycloalkyl" preferably refers to a 3-11 membered saturated ring group that is a monocyclic or fused ring system (e.g., a fused ring system consisting of two fused rings), wherein the ring group contains one or more (e.g., one, two, three, or four) ring heteroatoms independently selected from O, S, and N, wherein one or more S ring atoms (if present) and / or one or more N ring atoms (if present) are optionally oxidized, and wherein one or more carbon ring atoms are optionally oxidized; more preferably, "heterocycloalkyl" refers to a 5-7 membered saturated monocyclic group that contains one or more (e.g., one, two, or three) heteroatoms independently selected from O, S, and N, wherein one or more S ring atoms (if present) and / or one or more N ring atoms (if present) are optionally oxidized, and wherein one or more carbon ring atoms are optionally oxidized.

[0477] The term "heterocycloalkylene" as used herein refers to a heterocycloalkyl group as defined above, but having two points of attachment, i.e., a divalent saturated ring group, including monocyclic rings as well as bridged, spirocyclic and / or fused ring systems (which may be composed of two or three rings; for example, a fused ring system composed of two or three fused rings), wherein the ring group contains one or more (e.g., one, two, three or four) ring heteroatoms independently selected from O, S and N, the remaining ring atoms being carbon atoms, wherein one or more S ring atoms (if present) and / or one or more N ring atoms (if present) may be optionally oxidized, and further wherein one or more carbon ring atoms may be optionally oxidized (i.e., to form an oxo group). For example, each heteroatom-containing ring contained in the saturated cyclic group may contain one or two O atoms and / or one or two S atoms (which may be optionally oxidized) and / or one, two, three or four N atoms (which may be optionally oxidized), provided that the total number of heteroatoms in the corresponding heteroatom-containing ring is 1-4 and there is at least one carbon ring atom (which may be optionally oxidized) in the corresponding heteroatom-containing ring. "Heterocycloalkylene" may, for example, refer to aziridinyl, azetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, azepanyl, diazepanyl (e.g., 1,4-diazepanyl), oxazolidinylene, isoxazolidinylene, thiazolidinylene, isothiazolidinylene, morpholinylene, thiomorpholinylene, oxazepanylene, oxiranylene, oxetaneylene, tetrahydrofuranylene, 1,3-dioxolanylene, tetrahydropyranylene, 1,4-dioxanylene, oxepanylene, thiiraneylene, thietanylene, tetrahydrothiophenylene (i.e., thiolanylene), 1,3-dithiolanylene, thianylene, thiepanylene, decahydroquinolinylene, decahydroisoquinolinylene or 2-oxa-5-aza-bicyclo[2.2.1]heptan-5-ylene. Unless otherwise defined, "heterocycloalkylene" preferably refers to a divalent 3-11 membered saturated cyclic group which is a monocyclic or fused ring system (e.g., a fused ring system consisting of two fused rings), wherein the cyclic group contains one or more (e.g., one, two, three, or four) ring heteroatoms independently selected from O, S, and N, wherein one or more S ring atoms (if present) and / or one or more N ring atoms (if present) may be optionally oxidized, and wherein one or more carbon ring atoms are optionally oxidized; more preferably, "heterocycloalkylene" refers to a divalent 5-7 membered saturated monocyclic group which contains one or more (e.g., one, two, or three) ring heteroatoms independently selected from O, S, and N, wherein one or more S ring atoms (if present) and / or one or more N ring atoms (if present) are optionally oxidized, and wherein one or more carbon ring atoms are optionally oxidized.

[0478] The term "cycloalkenyl" as used herein refers to an unsaturated alicyclic (i.e., non-aromatic) hydrocarbon ring group, including monocyclic and bridged rings, spirocyclic and / or fused ring systems (which can be composed of, for example, two or three rings; for example, a fused ring system composed of two or three fused rings), wherein the hydrocarbon ring group contains one or more (e.g., one or two) carbon-carbon double bonds and does not contain any carbon-carbon triple bonds. "Cycloalkenyl" can, for example, refer to cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl or cycloheptadienyl. Unless otherwise defined, "cycloalkenyl" preferably refers to C 3-11 Cycloalkenyl, more preferably C 3-7 Cycloalkenyl. A particularly preferred "cycloalkenyl" group is a monocyclic unsaturated alicyclic hydrocarbon ring having 3 to 7 ring members and containing one or more (eg, one or two; preferably one) carbon-carbon double bonds.

[0479] The term "cycloalkenylene" as used herein refers to a cycloalkenyl group as defined above, but with two points of attachment, i.e., a divalent unsaturated alicyclic (i.e., non-aromatic) hydrocarbon ring group, including monocyclic as well as bridged, spirocyclic and / or fused ring systems (which may consist of, for example, two or three rings; for example, a fused ring system consisting of two or three fused rings), wherein the hydrocarbon ring group contains one or more (e.g., one or two) carbon-carbon double bonds, and does not contain any carbon-carbon triple bonds. "Cycloalkenylene" may, for example, refer to cyclopropenylene, cyclobutenylene, cyclopentenylene, cyclohexenylene, cyclohexadienylene, cycloheptenylene or cycloheptadienylene. Unless otherwise defined, "cycloalkenylene" preferably refers to C 3-11 Cycloalkenylene, more preferably refers to C 3-7 Cycloalkenylene. A particularly preferred "cycloalkenylene" is a divalent monocyclic unsaturated alicyclic hydrocarbon ring having 3 to 7 ring members and containing one or more (eg, one or two; preferably one) carbon-carbon double bonds.

[0480] As used herein, the term "heterocyclenyl" refers to an unsaturated alicyclic (i.e., non-aromatic) ring group, including monocyclic as well as bridged, spirocyclic and / or fused ring systems (which may be composed of two or three rings; for example, a fused ring system composed of two or three fused rings), wherein the ring group contains one or more (e.g., one, two, three or four) ring heteroatoms independently selected from O, S and N, the remaining ring atoms being carbon atoms, wherein one or more S ring atoms (if present) and / or one or more N ring atoms (if present) may be optionally oxidized, wherein one or more carbon ring atoms may be optionally oxidized (i.e., to form an oxo group), and further wherein the ring group contains at least one double bond between adjacent ring atoms and does not contain any triple bonds between adjacent ring atoms. For example, each heteroatom-containing ring contained in the unsaturated alicyclic ring group can contain one or two O atoms and / or one or two S atoms (which can be optionally oxidized) and / or one, two, three or four N atoms (which can be optionally oxidized), provided that the total number of heteroatoms in the corresponding heteroatom-containing ring is 1-4 and there is at least one carbon ring atom in the corresponding heteroatom-containing ring. "Heterocycloalkenyl" may refer, for example, to imidazolidinyl (e.g., 2-imidazolidinyl (i.e., 4,5-dihydro-1H-imidazolyl), 3-imidazolidinyl, or 4-imidazolidinyl), tetrahydropyridinyl (e.g., 1,2,3,6-tetrahydropyridinyl), dihydropyridinyl (e.g., 1,2-dihydropyridinyl, or 2,3-dihydropyridinyl), pyranyl (e.g., 2H-pyranyl, or 4H-pyranyl), thiopyranyl (e.g., 2H-thiopyranyl, or 4H-thiopyranyl), dihydropyranyl, dihydrofuranyl, dihydropyrazolyl, dihydropyrazinyl, dihydroisoindolyl, octahydroquinolinyl (e.g., 1,2,3,4,4a,5,6,7-octahydroquinolinyl), or octahydroisoquinolinyl (e.g., 1,2,3,4,5,6,7,8-octahydroisoquinolinyl).Unless otherwise defined, "heterocycloalkenyl" preferably refers to a 3-11 membered unsaturated alicyclic ring group, which is a monocyclic ring or a fused ring system (e.g., a fused ring system consisting of two fused rings), wherein the ring group contains one or more (e.g., one, two, three or four) ring heteroatoms independently selected from O, S and N, wherein one or more S ring atoms (if present) and / or one or more N ring atoms (if present) are is optionally oxidized, wherein one or more carbon ring atoms are optionally oxidized, and wherein the ring group contains at least one double bond between adjacent ring atoms and does not contain any triple bonds between adjacent ring atoms; more preferably, "heterocycloalkenyl" refers to a 5-7 membered monocyclic, saturated, non-aromatic ring group containing one or more (e.g., one, two or three) ring heteroatoms independently selected from O, S and N, wherein one or more S ring atoms (if present) and / or one or more N ring atoms (if present) are optionally oxidized, wherein one or more carbon ring atoms are optionally oxidized, and wherein the ring group contains at least one double bond between adjacent ring atoms and does not contain any triple bonds between adjacent ring atoms.

[0481] As used herein, the term "heterocycloalkenylene" refers to a heterocycloalkenyl group as defined above, but having two points of attachment, i.e., a divalent unsaturated alicyclic (i.e., non-aromatic) ring group, including monocyclic as well as bridged, spirocyclic and / or fused ring systems (which may consist of, for example, two or three rings, e.g., a fused ring system consisting of two or three fused rings), wherein the ring group contains one or more (e.g., one, two, three or four) ring heteroatoms independently selected from O, S and N, the remaining ring atoms being carbon atoms, wherein one or more S ring atoms (if present) and / or one or more N ring atoms (if present) may be optionally oxidized, wherein one or more carbon ring atoms may be optionally oxidized (i.e., to form an oxo group), and further wherein the ring group contains at least one double bond between adjacent ring atoms and does not contain any triple bonds between adjacent ring atoms. For example, each heteroatom-containing ring contained in the unsaturated alicyclic ring group may contain one or two O atoms and / or one or two S atoms (which may be optionally oxidized) and / or one, two, three or four N atoms (which may be optionally oxidized), provided that the total number of heteroatoms in the corresponding heteroatom-containing ring is 1-4 and there is at least one carbon ring atom in the corresponding heteroatom-containing ring. "Heterocycloalkenylene" may, for example, refer to imidazolidinylene, tetrahydropyridylene, dihydropyridylene, pyranylene, thiopyranylene, dihydropyranylene, dihydrofuranylene, dihydropyrazolylene, dihydropyrazinylene, dihydroisoindolylene, octahydroquinolinylene or octahydroisoquinolinylene. Unless otherwise defined, "heterocycloalkenylene" preferably refers to a 3-11 membered, divalent, unsaturated, alicyclic ring group which is a monocyclic or fused ring system (e.g., a fused ring system consisting of two fused rings), wherein the ring group contains one or more (e.g., one, two, three, or four) ring heteroatoms independently selected from O, S, and N, wherein one or more S ring atoms (if present) and / or one or more N ring atoms (if present) are optionally oxidized, wherein one or more carbon ring atoms are optionally oxidized, and wherein the ring group contains at least one double bond between adjacent ring atoms and does not contain any triple bonds between adjacent ring atoms; More preferably, "heterocycloalkenylene" refers to a divalent 5-7 membered monocyclic unsaturated non-aromatic ring group containing one or more (e.g., one, two or three) ring heteroatoms independently selected from O, S and N, wherein one or more S ring atoms (if present) and / or one or more N ring atoms (if present) are optionally oxidized, wherein one or more carbon ring atoms are optionally oxidized, and wherein the ring group contains at least one double bond between adjacent ring atoms and does not contain any triple bonds between adjacent ring atoms.

[0482] As used herein, the term "halogen" refers to fluorine (-F), chlorine (-Cl), bromine (-Br), or iodine (-I).

[0483] As used herein, the term "haloalkyl" refers to an alkyl group that is independently selected from the group consisting of fluorine, chlorine, bromine, and iodine, and preferably all fluorine atoms. It should be understood that the maximum number of halogen atoms is limited by the number of available attachment sites and therefore depends on the number of carbon atoms included in the alkyl portion of the haloalkyl group. "haloalkyl" can, for example, refer to -CF3, -CHF2, -CH2F, -CF2-CH3, -CH2-CF3, -CH2-CHF2, -CH2-CF2-CH3, -CH2-CF2-CF3, or -CH(CF3)2. Particularly preferred "haloalkyl" is -CF3.

[0484] As used herein, the terms "optional," "optionally," "optionally," and "may" indicate that a given feature may or may not be present. Whenever the terms "optional," "optionally," and "may" are used, the present invention specifically contemplates both possibilities, i.e., the presence of the corresponding feature or the absence of the corresponding feature. For example, the expression "X is optionally substituted by Y" (or "X may be substituted by Y") means that X is substituted by Y or that X is unsubstituted. Similarly, if a component of a composition is stated as "optional," the present invention specifically contemplates both possibilities, i.e., the presence of the corresponding component (included in the composition) or the absence of the corresponding component in the composition.

[0485] In this specification various groups are referred to as "optionally substituted", "optionally substituted by...". Typically, these groups may carry one or more substituents, for example one, two, three or four substituents. It will be understood that the maximum number of substituents is limited by the number of available attachment sites on the substituted group. Unless otherwise defined, the "optionally substituted", "optionally substituted by..." groups mentioned in this specification preferably carry no more than two substituents, in particular may only carry one substituent. Furthermore, unless otherwise defined, it is preferred that there are no optional substituents, i.e. the corresponding group is unsubstituted.

[0486] It will be appreciated by those skilled in the art that the substituents included in the compounds of the present invention can be connected to the remainder of the corresponding compound through many different positions of the corresponding specific substituents. Unless otherwise defined, the preferred connection positions of the various specific substituents are as shown in the examples.

[0487] As used herein, the terms "a," "an," and "the" are used interchangeably with "one or more" and "at least one," unless expressly stated otherwise or contradicted by context. Thus, for example, a composition comprising "a" compound of Formula (I) can be interpreted to mean a composition comprising "one or more" compounds of Formula (I).

[0488] As used herein, the term "about" preferably refers to ±10% of a given value, more preferably ±5% of a given value, and particularly refers to the exact value given.

[0489] Unless expressly stated otherwise or contradicted by the context, the term "comprising" (or "including", "containing", "containing") has the meaning of "especially containing", that is, "containing in addition to other optional elements...". In addition, the term also includes the narrower meanings of "essentially consisting of" and "consisting of". For example, the term "A comprises B and C" has the meaning "A especially contains B and C", where A may contain additional optional elements (for example, "A contains B, C and D" may also be covered), but the term also includes the meaning "A essentially consists of B and C" and the meaning "A consists of B and C" (i.e., A does not contain other components besides B and C).

[0490] The scope of the present invention includes all pharmaceutically acceptable salt forms of the compounds of formula (I), which can be formed, for example, by protonating an atom carrying a lone electron pair susceptible to protonation, such as an amino group, with an inorganic or organic acid or as a salt of an acid group (e.g. a carboxylic acid group) with a physiologically acceptable cation.

[0491] Exemplary base addition salts include, for example, alkali metal salts, such as sodium or potassium salts; alkaline earth metal salts, such as calcium or magnesium salts; zinc salts; ammonium salts; aliphatic amine salts, such as trimethylamine salts, triethylamine salts, dicyclohexylamine salts, ethanolamine salts, diethanolamine salts, triethanolamine salts, procaine salts, meglumine salts, ethylenediamine salts, or choline salts; arylalkylamine salts, such as N,N-dibenzylethylenediamine salts, benzathine salts, benethamine salts; heterocyclic aromatic amine salts, such as pyridinium salts, picoline salts, quinolinium salts, or isoquinolinium salts; quaternary ammonium salts, such as tetramethylammonium salts, tetraethylammonium salts, benzyltrimethylammonium salts, benzyltriethylammonium salts, benzyltributylammonium salts, methyltrioctylammonium salts, or tetrabutylammonium salts; and basic amino acid salts, such as arginine salts, lysine salts, or histidine salts.

[0492] Exemplary acid addition salts include, for example, inorganic acid salts such as hydrochlorides, hydrobromides, hydroiodides, salts of sulfuric acid (e.g., sulfates or bisulfates), nitrates, salts of phosphoric acid (e.g., phosphates, hydrogenphosphates, or dihydrogenphosphates), carbonates, bicarbonates, perchlorates, borates, or thiocyanates; organic acid salts such as acetates, propionates, butyrates, valerates, hexanoates, heptanoates, octanoates, cyclopentanepropionates, decanoates, undecanoates, oleates, stearates, lactates, maleates, Oxalate, fumarate, tartrate, malate, citrate, succinate, adipate, gluconate, glycolate, nicotinate, benzoate, salicylate, ascorbate, pamoate (enbolate), camphorate, glucoheptonate or pivalate; sulfonates, such as methanesulfonate (mesylate), ethanesulfonate (ethanesulfonate), 2-hydroxyethanesulfonate (isethionate), benzenesulfonate (phenylsulfonate), p-toluenesulfonate (toluenesulfonate), 2-naphthalenesulfonate (naphthalenesulfonate), 3-phenylsulfonate or camphorsulfonate; glycerophosphate; and acidic amino acid salts, such as aspartate or glutamate.

[0493] Preferred pharmaceutically acceptable salts of compounds of formula (I) include hydrochlorides, hydrobromides, methanesulfonates, sulfuric acid salts, tartaric acid salts, fumaric acid salts, acetates, citric acid salts and phosphoric acid salts. Particularly preferred pharmaceutically acceptable salts of compounds of formula (I) are hydrochlorides. Therefore, it is preferred that the compounds of formula (I), including any one of the specific compounds of formula (I) described herein, are in the form of hydrochlorides, hydrobromides, methanesulfonates, sulfuric acid salts, tartaric acid salts, fumaric acid salts, acetates, citric acid salts or phosphoric acid salts, and it is particularly preferred that the compounds of formula (I) are in the form of hydrochlorides.

[0494] It will be understood that the present invention also relates to compounds of formula (I), including any of the specific compounds described herein, in non-salt form.

[0495] In addition, the scope of the present invention includes any solvated form of the compound of formula (I), including, for example, solvates with water (i.e., hydrates) or solvates with organic solvents such as methanol, ethanol or acetonitrile (e.g., methanolates, ethanolates or acetonitrile). All physical forms of the compound of formula (I), including any amorphous or crystalline form (i.e., polymorphs), are also included within the scope of the present invention. It should be understood that the present invention also includes such solvates and physical forms of pharmaceutically acceptable salts of the compound of formula (I).

[0496] In addition, the compounds of formula (I) may exist in different isomeric forms, in particular stereoisomers (including, for example, geometric isomers (or cis / trans isomers), enantiomers, atropisomers and diastereomers) or tautomers (especially including prototropic tautomers). All such isomers of the compounds of formula (I) are considered to be part of the present invention, either as a mixture or in pure or substantially pure form.

[0497] With respect to stereoisomers, the present invention includes the isolated optical isomers of the compounds of the present invention as well as any mixtures thereof (particularly including racemic mixtures / racemates). The racemates can be resolved by physical methods, such as fractional crystallization, separation or crystallization of diastereomeric derivatives, or separation by chiral column chromatography. Individual optical isomers can also be obtained from the racemates by forming a salt with an optically active acid followed by crystallization.

[0498] The present invention also includes any tautomers (e.g., keto / enol tautomers or lactam / lactim tautomers) of the compounds provided herein, particularly including the following tautomers of compounds of formula (I):

[0499]

[0500] The scope of the present invention also includes compounds of formula (I) wherein one or more atoms are replaced by specific isotopes of corresponding atoms.

[0501] For example, the present invention includes compounds wherein one or more hydrogen atoms (or, for example, all hydrogen atoms) are replaced by deuterium atoms (i.e. 2 H; also referred to as "D") substituted for the compound of formula (I). Therefore, the present invention also includes the compound of formula (I) enriched with deuterium. Naturally occurring hydrogen is a compound containing about 99.98 mol-% of hydrogen-1 ( 1 H) and about 0.0156 mol-% deuterium ( 2H or D) isotopic mixtures. Deuteration techniques known in the art can be used to increase the deuterium content in one or more hydrogen positions in the compound of formula (I). For example, the compound of formula (I) or the reactants or precursors for synthesizing the compound of formula (I) can use, for example, heavy water (DO) to perform an H / D exchange reaction. Other suitable deuteration techniques are described in Atzrodt J et al. Bioorg Med Chem, 20 (18), 5658-5667, 2012; William JS et al. Journal of Labelled Compounds and Radiopharmaceuticals, 53 (11-12), 635-644, 2010; Modvig A et al. J Org Chem, 79, 5861-5868, 2014. The deuterium content can be determined, for example, using mass spectrometry or NMR spectroscopy. Unless otherwise specified, it is preferred that the compound of formula (I) is not enriched in deuterium. Therefore, it is preferred that naturally occurring hydrogen atoms or 1 H hydrogen atom.

[0502] The present invention also includes the case where one or more atoms are replaced by a positron-emitting isotope of the corresponding atom, e.g. 18 F. 11 C. 13 N. 15 O. 76 Br, 77 Br, 120 I and / or 124 I substituted compounds of formula (I). Such compounds are useful as tracers, tracking agents or imaging probes in positron emission tomography (PET). Thus, the present invention includes (i) wherein one or more fluorine atoms (or, for example, all fluorine atoms) are replaced by 18 F atom substituted compounds of formula (I), (ii) wherein one or more carbon atoms (or, for example, all carbon atoms) are replaced by 11 C substituted compounds of formula (I), (iii) wherein one or more nitrogen atoms (or, for example, all nitrogen atoms) are replaced by 13 A compound of formula (I) wherein one or more oxygen atoms (or, for example, all oxygen atoms) are replaced by 15 O atom replaced by a compound of formula (I), (v) wherein one or more bromine atoms (or, for example, all bromine atoms) are replaced by 76 A compound of formula (I) wherein one or more iodine atoms (or, for example, all iodine atoms) are replaced by 120 I atom replaced by a compound of formula (I), and (viii) wherein one or more iodine atoms (or, for example, all iodine atoms) are replaced by 124I atom substituted compounds of formula (I).

[0503] In general, it is preferred that the compounds of formula (I) do not have any atoms replaced by a specific isotope.

[0504] The compound of formula (I) can also be used in the form of a pharmaceutically acceptable prodrug, i.e., a derivative of a compound of formula (I) that has a chemically or metabolically cleavable group and becomes a pharmaceutically active compound of formula (I) in vivo by solvolysis or under physiological conditions. The prodrug of the compound of the present invention can be formed in a conventional manner with the functional group of the compound, for example, with an amino, hydroxyl or carboxyl group. Prodrug forms generally provide advantages in terms of solubility, tissue compatibility or delayed release in mammalian organisms (see Bundgaard, H., Design of Prodrugs, pp.7-9, 21-24, Elsevier, Amsterdam 1985). Prodrugs include acid derivatives, such as esters prepared by reacting a parent acidic compound with a suitable alcohol or amides prepared by reacting a parent acidic compound with a suitable amine. If the compound of the present invention has a carboxyl group, an ester derivative prepared by reacting a carboxyl group with a suitable alcohol or an amide derivative prepared by reacting a carboxyl group with a suitable amine is used as a specific example of a prodrug. Particularly preferred ester derivatives as prodrugs are methyl ester, ethyl ester, n-propyl ester, isopropyl ester, n-butyl ester, isobutyl ester, tert-butyl ester, morpholinoethyl ester, N,N-diethylglycolamidoester or α-acetoxyethyl ester. If the compound of the present invention has a hydroxyl group, an acyloxy derivative prepared by reacting the hydroxyl group with a suitable acyl halide or a suitable acid anhydride is a specific example of a prodrug. Particularly preferred acyloxy derivatives as prodrugs are -OC(=O)-CH3, -OC(=O)-C2H5, -OC(=O)-(tert-Bu), -OC(=O)-C 15 H 31 , -OC(=O)-(m-COONa-Ph), -OC(=O)-CH2CH2COONa, -O(C=O)-CH(NH2)CH3 or -OC(=O)-CH2-N(CH3)2. If the compound of the present invention has an amino group, an amide derivative prepared by reacting the amino group with a suitable acyl halide or a suitable mixed acid anhydride is a specific example of a prodrug. An amide derivative particularly preferred as a prodrug is -NHC(=O)-(CH2)2OCH3 or -NHC(=O)-CH(NH2)CH3.

[0505] The compounds provided by the present invention, i.e., compounds of formula (I) and / or pharmaceutically acceptable salts thereof, can be administered as the compounds themselves or can be formulated for administration as medicaments. Medicaments / pharmaceutical compositions can optionally contain one or more pharmaceutically acceptable excipients, such as carriers, diluents, fillers, disintegrants, lubricants, binders, colorants, pigments, stabilizers, preservatives, antioxidants, and / or solubility enhancers.

[0506] The pharmaceutical composition may include one or more dissolution enhancers, for example, poly(ethylene glycol), including poly(ethylene glycol) having a molecular weight of about 200 to about 5,000 Da (e.g., PEG 200, PEG 300, PEG 400, or PEG 600), ethylene glycol, propylene glycol, glycerol, nonionic surfactants, tyloxapol, polysorbate 80, polyethylene glycol-15-hydroxystearate (e.g., HS 15,CAS 70142-34-6), phospholipids, lecithin, dimyristoyl phosphatidylcholine, dipalmitoylphosphatidylcholine, distearoyl phosphatidylcholine, cyclodextrin, α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, hydroxyethyl-β-cyclodextrin, hydroxypropyl-β-cyclodextrin, hydroxyethyl-γ-cyclodextrin, hydroxypropyl-γ-cyclodextrin, dihydroxypropyl-β-cyclodextrin, Sulfobutyl ether-β-cyclodextrin, sulfobutyl ether-γ-cyclodextrin, glucosyl-α-cyclodextrin, glucosyl-β-cyclodextrin, diglucosyl-β-cyclodextrin, maltosyl-α-cyclodextrin, maltosyl-β-cyclodextrin, maltosyl-γ-cyclodextrin, maltotriosyl-β-cyclodextrin, maltotriosyl-γ-cyclodextrin, dimaltosyl-β-cyclodextrin, methyl-β-cyclodextrin, carboxyalkyl sulfide, hydroxypropyl methylcellulose, hydroxypropyl cellulose, polyvinyl pyrrolidone, vinyl acetate copolymer, vinyl pyrrolidone, sodium lauryl sulfate, dioctyl sodium sulfosuccinate, or any combination thereof.

[0507] The pharmaceutical composition can be formulated by techniques known to those skilled in the art, such as those disclosed in "Remington: The Science and Practice of Pharmacy", Pharmaceutical Press, 22nd edition. The pharmaceutical composition can be formulated into dosage forms for oral, parenteral, such as intramuscular, intravenous, subcutaneous, intradermal, intraarterial, intracardiac, rectal, nasal, topical, aerosol or vaginal administration. Oral dosage forms include coated and uncoated tablets, soft gelatin capsules, hard gelatin capsules, lozenges, tablets, solutions, emulsions, suspensions, syrups, elixirs, powders and granules for reconstitution, dispersible powders and granules, medicated gums, chewable tablets and effervescent tablets. Dosage forms for parenteral administration include solutions, emulsions, suspensions, dispersants and powders and granules for reconstitution. Emulsions are preferred dosage forms for parenteral administration. Dosage forms for rectal and vaginal administration include suppositories and ovulas. Dosage forms for nasal administration can be administered by inhalation or insufflation, for example, by a metered dose inhaler.Dosage forms for topical administration include creams, gels, ointments, salves, patches and transdermal delivery systems.

[0508] The compounds of the invention or the pharmaceutical compositions described above comprising the compounds of the invention may be administered to a subject by any convenient route of administration, whether systemically / peripherally or at the desired site of action, including, but not limited to, one or more of the following: oral (e.g., in tablet, capsule form, or ingestible solution), topical (e.g., transdermal, intranasal, ophthalmic, buccal, and sublingual), parenteral (e.g., using injection or infusion techniques, including, for example, by injection, e.g., subcutaneous, intradermal, intramuscular, intravenous, intraarterial, intracardiac, intrathecal, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal, intratracheal, subcuticular, intraarticular, subarachnoid, or intrasternal, via, for example, a reservoir implant, e.g., subcutaneous or intramuscular), pulmonary (e.g., by inhalation or insufflation therapy, using, for example, an aerosol, e.g., through the mouth or nose), gastrointestinal, intrauterine, intraocular, subcutaneous, ophthalmic (including intravitreal or intracameral), rectal, or vaginal administration.

[0509] If the compound or pharmaceutical composition is administered parenterally, the example of such administration includes one or more of the following: intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, ​​intrasternal, intracardial, intracranial, intramuscular or subcutaneous administration of the compound or pharmaceutical composition, and / or the use of an infusion technique. For parenteral administration, it is best to use these compounds in the form of a sterile aqueous solution that may contain other substances, such as enough salt or glucose, to make the solution isotonic with the blood. If necessary, the aqueous solution should be appropriately buffered (preferably at a pH of 3 to 9). Suitable parenteral formulations can be easily prepared under sterile conditions by standard pharmaceutical techniques well known to those skilled in the art.

[0510] The compound or pharmaceutical composition may also be administered orally in the form of tablets, capsules, pessaries, elixirs, solutions or suspensions, which may contain flavorings or colorings for immediate-, delayed-, modified-, sustained-, pulsed- or controlled-release applications.

[0511] Tablets may contain excipients such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, calcium hydrogen phosphate, and glycine, disintegrants such as starch (preferably corn starch, potato starch, or tapioca starch), sodium starch glycolate, cross-linked sodium carboxymethyl cellulose, and certain complex silicates, and granulation binders such as polyvinyl pyrrolidone, hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellulose (HPC), sucrose, gelatin, and gum arabic. In addition, lubricants such as magnesium stearate, stearic acid, glyceryl behenate, and talc may also be included. Similar types of solid compositions may also be used as fillers in gelatin capsules. Preferred excipients in this regard include lactose, starch, cellulose, or high molecular weight polyethylene glycols. For aqueous suspensions and / or elixirs, the active agent may be combined with various sweeteners or flavorings, colorants, or dyes, with emulsifiers and / or suspending agents, and with diluents such as water, ethanol, propylene glycol, and glycerol, and combinations thereof.

[0512] Alternatively, the compound or pharmaceutical composition can be administered in the form of a suppository or pessary, or can be administered topically in the form of a gel, hydrogel, lotion, solution, cream, ointment, or dusting powder. The compounds of the invention can also be administered dermally or transdermally, for example, by using a skin patch.

[0513] The compound or pharmaceutical composition can also be used by sustained release system.The applicable example of sustained release composition comprises the semi-permeable polymer matrix of shaped article (shaped article) such as membrane or microcapsule form.Sustained release matrix comprises the copolymer of for example polylactide, L-glutamic acid and γ-ethyl-L-glutamic acid, poly-(2-hydroxyethyl methacrylate), ethylene vinyl acetate or poly-D-(-)-3-hydroxybutyric acid.Sustained release pharmaceutical composition also comprises the compound of liposome encapsulation.Therefore, the present invention still further relates to the liposome containing compound of the present invention.

[0514] The compounds or pharmaceutical compositions may also be administered via the pulmonary, rectal or ophthalmic routes. For ophthalmic use, they may be formulated as micronized suspensions in isotonic, pH-adjusted, sterile saline, or preferably as solutions in isotonic, pH-adjusted, sterile saline, optionally in combination with a preservative such as benzalkonium chloride. Alternatively, they may be formulated as ointments such as petrolatum.

[0515] It is also contemplated to prepare dry powder formulations of compounds of formula (I) for pulmonary administration, particularly inhalation. Such dry powders can be prepared by spray drying under conditions that result in a substantially amorphous glassy or substantially crystalline biologically active powder. Thus, dry powders of compounds of the present invention can be prepared according to an emulsification / spray drying process.

[0516] For topical application on the skin, the compound or pharmaceutical composition can be formulated into a suitable ointment containing the active compound suspended or dissolved in, for example, a mixture of one or more of the following: mineral oil, liquid petrolatum, white petrolatum, propylene glycol, emulsifying wax, and water. Alternatively, they can be formulated into a suitable lotion or cream suspended or dissolved in a mixture of one or more of the following: mineral oil, sorbitan monostearate, polyethylene glycol, liquid paraffin, polysorbate 60, cetyl ester wax, 2-octyldodecanol, benzyl alcohol, and water.

[0517] Therefore, the present invention relates to the compounds or pharmaceutical compositions provided herein, wherein the corresponding compounds or pharmaceutical compositions are administered by any of the following routes: oral route; topical route, including transdermal, intranasal, ocular, buccal or sublingual route; parenteral route using injection techniques or infusion techniques, including subcutaneous, intradermal, intramuscular, intravenous, intraarterial, intracardiac, intrathecal, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal, intratracheal, subcutaneous, intraarticular, subarachnoid, intrasternal, intraventricular, intraurethral or intracranial route; pulmonary route, including by inhalation or insufflation therapy; gastrointestinal route; intrauterine route; intraocular route; subcutaneous route; ophthalmic route, including by intravitreal or intracameral route; rectal route; or vaginal route. The preferred route of administration is oral administration or parenteral administration, particularly preferred oral administration. Therefore, it is particularly preferred to administer the compound or pharmaceutical composition of the present invention orally (particularly by oral ingestion or swallowing).

[0518] Typically, the clinician will determine the actual dosage that is most suitable for an individual subject. The specific dosage level and frequency of administration for any particular individual can vary depending on a variety of factors, including the activity of the specific compound used, the metabolic stability and duration of action of the compound, age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, severity of the specific condition, and the individual being treated.

[0519] A suggested, but non-limiting, dosage of the compounds of the present invention for oral administration to humans (approximately 70 kg body weight) may be 0.05 to 2000 mg, preferably 0.1 mg to 1000 mg, of active ingredient per unit dose. The unit dose may be administered 1-3 times per day. The unit dose may also be administered 1-7 times per week, for example, not more than once per day. It will be understood that it may be necessary to routinely vary the dosage depending on the age and weight of the patient / individual and the severity of the condition being treated. The exact dosage and route of administration will ultimately be determined by the attending physician or veterinarian.

[0520] The compound of formula (I) or its pharmaceutically acceptable salt or the pharmaceutical composition comprising the compound of formula (I) or its pharmaceutically acceptable salt can be applied as a monotherapy (e.g., without the concomitant administration of any other therapeutic agent, or without the concomitant administration of any other therapeutic agent for the same disease treated or prevented with the compound of formula (I)). However, the compound of formula (I) or its pharmaceutically acceptable salt or the pharmaceutical composition comprising the compound of formula (I) or its pharmaceutically acceptable salt can also be applied in combination with one or more other therapeutic agents. If the compound of formula (I) or its pharmaceutically acceptable salt is used in combination with a second therapeutic agent that is active against the same disease or condition, the dosage of each compound may be different from the dosage when the corresponding compound is used alone, and in particular, each individual compound of a lower dosage can be used. The combination of the compound of formula (I) or its pharmaceutically acceptable salt and one or more other therapeutic agents can include the compound of formula (I) or its pharmaceutically acceptable salt and one or more other therapeutic agents (in the same pharmaceutical preparation or in the pharmaceutical preparation separated) or successively / separately the compound of formula (I) or its pharmaceutically acceptable salt and one or more other therapeutic agents used simultaneously / concomitantly.If used successively, then the compound of formula (I) of the present invention or its pharmaceutically acceptable salt or one or more other therapeutic agents can be first used.If used simultaneously, then one or more other therapeutic agents can be included in the same pharmaceutical preparation with the compound of formula (I) or its pharmaceutically acceptable salt, or they can be used in two or more different (separating) pharmaceutical preparations.

[0521] Preferably, the one or more additional therapeutic agents administered in combination with the compounds of the present invention are selected from levodopa, levodopa and a selective extracerebral decarboxylase inhibitor, carbidopa, entacapone, COMT inhibitors, dopamine agonists, dopamine receptor agonists, apomorphine, anticholinergics, cholinergic agonists, butyrophenone neuroleptics, diphenylbutyl neuroleptics, heterocyclic dibenzazepines, Neuroleptics, indolone neuroleptics, phenothiazine neuroleptics, thioxanthene neuroleptics, NMDA receptor antagonists, MAO-B inhibitors, mGluR3 PAMs or agonists, mGluR4 PAMs or agonists, mGluR5 antagonists, and A2A antagonists.

[0522] In particular, for the treatment or prevention of Parkinson's disease, the compound of formula (I) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising the compound of formula (I) or a pharmaceutically acceptable salt thereof may also be administered in combination with one or more additional anti-Parkinson's disease drugs. Such additional anti-Parkinson's disease drugs may, for example, be selected from the group consisting of levodopa, methyl levodopa, ethyl levodopa, droxidopa, alindore, apomorphine, bromocriptine, cabergoline, ciradopa, dihydroergocryptine, lisuride, pardoprunox, pergolide, piribedil, pramipexole, ropinirole, rotigotine, ladostinil, ladostinil, lazabemide, mofegiline, pargyline, rasagiline, selegiline, entacapone, Niticapone, tolcapone, benserazide, carbidopa, methyldopa, benztropine, biperiden, bonapril, chlorphenoxamine, cyclamine, dexbenzyltamide, dimenhydrinate, diphenhydramine, ethylbenzyltamine (etanautine), ethylbenzyltropine, mazatik, methixene, orphenadrine, fenagluamide, pyroheptine, procyclidine, profenamide, trihexyphenidyl, tripatepine, amantadine, budipine, memantine, methylxanthine (methylxanthine), rimantadine, UWA-101 and pharmaceutically acceptable salts of any one of these drugs. Preferred anti-Parkinson's disease drugs include levodopa, carbidopa and / or biperiden, especially levodopa.

[0523] For the treatment or prevention of Parkinson's disease, combined administration of a compound or pharmaceutical composition of the present invention and one or more additional antiparkinsonian agents can be achieved, for example, by simultaneous / concomitant administration (e.g. in the same pharmaceutical formulation or in separate pharmaceutical formulations) or by sequential / separate administration.

[0524] The individual or patient to be treated according to the present invention can be an animal (e.g., a non-human animal). Preferably, the individual / patient is a mammal. More preferably, the individual / patient is a human (e.g., male or female) or a non-human mammal (e.g., a guinea pig, hamster, rat, mouse, rabbit, dog, cat, horse, monkey, ape, marmoset, baboon, gorilla, chimpanzee, orangutan, gibbon, sheep, cattle, or pig). Most preferably, the individual / patient to be treated according to the present invention is a human.

[0525] As used herein, the terms "treating" a condition, disorder, or disease or "treatment" of a condition, disorder, or disease are well known in the art. "Treatment" of a condition, disorder, or disease or "treatment" of a condition, disorder, or disease means that a condition, disorder, or disease is suspected or has been diagnosed in a patient / individual. A patient / individual suspected of having a condition, disorder, or disease typically exhibits specific clinical and / or pathological symptoms that can be readily attributed to a specific pathological condition (i.e., diagnosed condition, disorder, or disease) by one skilled in the art.

[0526] "Treatment" of a condition, disorder or disease or "treatment" of a condition, disorder or disease can, for example, result in a cessation of the progression of the condition, disorder or disease (e.g., no worsening of symptoms) or a delay in the progression of the condition, disorder or disease (where the cessation of progression is only temporary). "Treatment" of a condition, disorder or disease or "treatment" of a condition, disorder or disease can also result in a partial response (e.g., improvement of symptoms) or a complete response (e.g., disappearance of symptoms) in the individual / patient suffering from the condition, disorder or disease. Thus, "treating" a condition, disorder or disease or "treatment" of a condition, disorder or disease can also refer to an improvement in the condition, disorder or disease, which can, for example, result in a cessation of the progression of the disease, disorder or disease or a delay in the progression of the condition, disorder or disease. Relapse may occur after such a partial or complete response. It should be understood that an individual / patient may experience a wide range of responses to treatment (e.g., the exemplary responses described above). Treatment of a condition, disorder or disease can particularly include curative treatment (preferably resulting in a complete response and ultimately resulting in a cure of the condition, disorder or disease) and palliative treatment (including symptom relief).

[0527] As used herein, the term "prevention" of a condition, disorder or disease or "prevention" of a condition, disorder or disease is also well known in the art. For example, a patient / individual suspected of being susceptible to a condition, disorder or disease may particularly benefit from the prevention of the condition, disorder or disease. The individual / patient may have a sensitivity or predisposition to the condition, disorder or disease, including but not limited to a genetic predisposition. This predisposition may be determined by standard methods or assays, for example, using genetic markers or phenotypic indicators. It should be understood that the condition, disorder or disease to be prevented by the present invention has not yet been diagnosed or cannot be diagnosed in the patient / individual (for example, the patient / individual does not show any clinical or pathological symptoms). Therefore, the term "prevention" includes using the compound of the present invention before any clinical and / or pathological symptoms are diagnosed or determined or can be diagnosed or determined by the attending physician.

[0528] It will be understood that the present invention specifically relates to each combination of features and embodiments described herein, including any combination of general and / or preferred features / embodiments. In particular, the present invention specifically relates to each combination of the meanings (including general and / or preferred meanings) given for the various groups and variables included in formula (I).

[0529] Throughout this specification, numerous references are cited, including patents, patent applications, and scientific literature. The disclosures of these references are incorporated herein by reference in their entireties, but they are not considered relevant to the patentability of the present invention. More specifically, all references are incorporated herein by reference to the same extent as if each individual reference were specifically and individually listed.

[0530] Reference to any prior publication (or information derived therefrom) in this specification is not or should not be taken as an admission or endorsement or as implying in any form that the corresponding prior publication (or information derived therefrom) constitutes part of the common general knowledge in the technical field to which this specification relates.

[0531] The present invention particularly relates to the following items:

[0532] 1. Compounds of formula (I)

[0533]

[0534] in:

[0535] R 1 Any one selected from the following groups:

[0536]

[0537]

[0538] wherein each of the groups depicted above is optionally replaced by one or more groups R 11 Replace; R 11 Each independently selected from C 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, -(C 0-3 Alkylene)-OH, -(C 0-3 Alkylene)-O(C 1-5 Alkyl), -(C 0-3 Alkylene)-SH, -(C 0-3 Alkylene)-S(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH2, -(C 0-3 Alkylene)-NH(C 1-5Alkyl), -(C 0-3 Alkylene)-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-halogen, -(C 0-3 alkylene)-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-O-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-CN,-(C 0-3 Alkylene)-CHO, -(C 0-3 alkylene)-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-COOH, -(C 0-3 Alkylene)-CO-O-(C 1-5 Alkyl), -(C 0-3 Alkylene)-O-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-CO-NH2, -(C 0-3 Alkylene)-CO-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-CO-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 alkyl)-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO2-NH2, -(C 0-3 Alkylene)-SO2-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO2-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH-SO2-(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 alkyl)-SO2-(C 1-5 Alkyl), -(C 0-3 Alkylene)-aryl, -(C 0-3 Alkylene)-heteroaryl, -(C 0-3 alkylene)-cycloalkyl and -(C 0-3 alkylene)-heterocycloalkyl, wherein the -(C 0-3Alkylene)-aryl in the aryl part, the -(C 0-3 The heteroaryl portion of the -(C 0-3 The cycloalkyl portion of the -(C 0-3 The heterocycloalkyl moieties of the alkylene)-heterocycloalkyl groups are each optionally substituted by one or more groups R 12 replace;

[0539] R 12 Each independently selected from C 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, -OH, -O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -NH2, -NH(C 1-5 Alkyl), -N(C 1-5 Alkyl)(C 1-5 alkyl), halogen, C 1-5 Haloalkyl, -O-(C 1-5 haloalkyl), -CN, -CHO, -CO-(C 1-5 alkyl), -COOH, -CO-O-(C 1-5 alkyl), -O-CO-(C 1-5 alkyl), -CO-NH2, -CO-NH(C 1-5 Alkyl), -CO-N(C 1-5 Alkyl)(C 1-5 alkyl), -NH-CO-(C 1-5 Alkyl), -N(C 1-5 alkyl)-CO-(C 1-5 alkyl), -SO2-NH2, -SO2-NH(C 1-5 Alkyl), -SO2-N(C 1-5 Alkyl)(C 1-5 Alkyl), -NH-SO2-(C 1-5 Alkyl), -N(C 1-5 alkyl)-SO2-(C 1-5 alkyl), cycloalkyl, and heterocycloalkyl;

[0540] X1 is C(R X1 ) or N;

[0541] X2 is C(-LR X2 ) or N;

[0542] X3 is C(R X3 ) or N;

[0543] X4 is C(R X4) or N;

[0544] wherein at least one of the ring atoms X1, X2, X3 and X4 is not N;

[0545] R X1 Selected from hydrogen, C 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, -(C 0-3 Alkylene)-OH, -(C 0-3 Alkylene)-O(C 1-5 Alkyl), -(C 0-3 Alkylene)-SH, -(C 0-3 Alkylene)-S(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH2, -(C 0-3 Alkylene)-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-halogen, -(C 0-3 alkylene)-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-O-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-CN,-(C 0-3 Alkylene)-CHO, -(C 0-3 alkylene)-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-COOH, -(C 0-3 Alkylene)-CO-O-(C 1-5 Alkyl), -(C 0-3 Alkylene)-O-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-CO-NH2, -(C 0-3 Alkylene)-CO-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-CO-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 alkyl)-CO-(C 1-5 Alkyl), -(C 0-3Alkylene)-SO2-NH2, -(C 0-3 Alkylene)-SO2-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO2-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH-SO2-(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 alkyl)-SO2-(C 1-5 Alkyl), -(C 0-3 Alkylene)-aryl, -(C 0-3 Alkylene)-heteroaryl, -(C 0-3 alkylene)-cycloalkyl and -(C 0-3 alkylene)-heterocycloalkyl, wherein the -(C 0-3 Alkylene)-aryl in the aryl part, the -(C 0-3 The heteroaryl portion of the -(C 0-3 The cycloalkyl portion of the -(C 0-3 The heterocycloalkyl moieties of the alkylene)-heterocycloalkyl groups are each optionally substituted by one or more groups R X11 replace;

[0546] R X11 Each independently selected from C 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, -OH, -O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -NH2, -NH(C 1-5 Alkyl), -N(C 1-5 Alkyl)(C 1-5 alkyl), halogen, C 1-5 Haloalkyl, -O-(C 1-5 haloalkyl), -CN, -CHO, -CO-(C 1-5 alkyl), -COOH, -CO-O-(C 1-5 alkyl), -O-CO-(C 1-5 alkyl), -CO-NH2, -CO-NH(C 1-5 Alkyl), -CO-N(C 1-5 Alkyl)(C 1-5 alkyl), -NH-CO-(C 1-5 Alkyl), -N(C 1-5 alkyl)-CO-(C 1-5alkyl), -SO2-NH2, -SO2-NH(C 1-5 Alkyl), -SO2-N(C 1-5 Alkyl)(C 1-5 Alkyl), -NH-SO2-(C 1-5 Alkyl), -N(C 1-5 alkyl)-SO2-(C 1-5 alkyl), cycloalkyl, and heterocycloalkyl;

[0547] L is selected from covalent bond, C 1-10 Alkylene, C 2-10 Alkenylene and C 2-10 Alkynylidene, wherein the C 1-10 Alkylene, the C 2-10 Alkenylene or the C 2-10 One or more -CH2- units contained in the alkynylene group are each optionally replaced by a group independently selected from the group consisting of: -O-, -CO-, -C(=O)O-, -OC(=O)-, -NH-, -N(C 1-5 Alkyl)-、-NH-CO-、-N(C 1-5 Alkyl)-CO-, -CO-NH-, -CO-N(C 1-5 Alkyl)-、-S-、-SO-、-SO2-、-SO2-NH-、 -SO2-N(C 1-5 Alkyl)-、-NH-SO2-、-N(C 1-5 alkyl)-SO2-, carbocyclylene and heterocyclylene, wherein the carbocyclylene and the heterocyclylene are each optionally substituted by one or more groups independently selected from the following: C 1-4 Alkyl, -OH, -O(C 1-4 alkyl), -SH, -S(C 1-5 alkyl), -NH2, -NH(C 1-4 Alkyl), -N(C 1-4 Alkyl)(C 1-4 alkyl), halogen, C 1-5 Haloalkyl, -O-(C 1-5 haloalkyl) and -CN, wherein said C 1-10 Alkylene, the C 2-10 Alkenylene and the C 2-10 Each alkynylene group is optionally substituted with one or more groups independently selected from the group consisting of halogen, C 1-5 Haloalkyl, -O-(C 1-5 haloalkyl), -CN, -OH, -O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -NH2, -NH(C1-5 alkyl) and -N(C 1-5 Alkyl)(C 1-5 alkyl);

[0548] R X2 Selected from C 2-10 Alkyl, carbocyclic, heterocyclic and -L 1 -R X21 , wherein the C 2-10 The alkyl group, the carbocyclyl group and the heterocyclyl group are each optionally substituted by one or more groups R X22 Replace; L 1 Selected from covalent bonds, C 1-10 Alkylene, C 2-10 Alkenylene and C 2-10 Alkynylidene, wherein the C 1-10 Alkylene, the C 2-10 Alkenylene or the C 2-10 One or more -CH2- units contained in the alkynylene group are each optionally replaced by a group independently selected from the group consisting of: -O-, -CO-, -C(=O)O-, -OC(=O)-, -NH-, -N(C 1-5 Alkyl)-、-NH-CO-、-N(C 1-5 Alkyl)-CO-, -CO-NH-, -CO-N(C 1-5 Alkyl)-、-S-、-SO-、-SO2-、-SO2-NH-、 -SO2-N(C 1-5 alkyl)-, -NH-SO2- and -N(C 1-5 Alkyl)-SO2-, in addition wherein the C 1-10 Alkylene, the C 2-10 Alkenylene and the C 2-10 Each alkynylene group is optionally substituted with one or more groups independently selected from the group consisting of halogen, C 1-5 Haloalkyl, -O-(C 1-5 haloalkyl), -CN, -OH, -O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -NH2, -NH(C 1-5 alkyl) and -N(C 1-5 Alkyl)(C 1-5 alkyl);

[0549] R X21 Selected from C 2-5 Alkyl, carbocyclyl and heterocyclyl, wherein the carbocyclyl and heterocyclyl are each optionally substituted by one or more groups R X22 replace;

[0550] RX22 Each independently selected from C 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, -(C 0-3 Alkylene)-OH, -(C 0-3 Alkylene)-O(C 1-5 Alkyl), -(C 0-3 Alkylene)-SH, -(C 0-3 Alkylene)-S(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH2, -(C 0-3 Alkylene)-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-halogen, -(C 0-3 alkylene)-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-O-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-CN,-(C 0-3 Alkylene)-CHO, -(C 0-3 alkylene)-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-COOH, -(C 0-3 Alkylene)-CO-O-(C 1-5 Alkyl), -(C 0-3 Alkylene)-O-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-CO-NH2, -(C 0-3 Alkylene)-CO-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-CO-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 alkyl)-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO2-NH2, -(C 0-3 Alkylene)-SO2-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO2-N(C1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH-SO2-(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 alkyl)-SO2-(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO2-(C 1-5 Alkyl), -(C 0-3 Alkylene)-aryl, -(C 0-3 Alkylene)-heteroaryl, -(C 0-3 alkylene)-cycloalkyl and -(C 0-3 alkylene)-heterocycloalkyl, wherein the -(C 0-3 Alkylene)-aryl in the aryl part, the -(C 0-3 The heteroaryl portion of the -(C 0-3 The cycloalkyl portion of the -(C 0-3 The heterocycloalkyl moieties of the alkylene)-heterocycloalkyl groups are each optionally substituted by one or more groups R X23 replace;

[0551] R X23 Each independently selected from C 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, -OH, -O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -NH2, -NH(C 1-5 Alkyl), -N(C 1-5 Alkyl)(C 1-5 alkyl), halogen, C 1-5 Haloalkyl, -O-(C 1-5 haloalkyl), -CN, -CHO, -CO-(C 1-5 alkyl), -COOH, -CO-O-(C 1-5 alkyl), -O-CO-(C 1-5 alkyl), -CO-NH2, -CO-NH(C 1-5 Alkyl), -CO-N(C 1-5 Alkyl)(C 1-5 alkyl), -NH-CO-(C 1-5 Alkyl), -N(C 1-5 alkyl)-CO-(C 1-5alkyl), -SO2-NH2, -SO2-NH(C 1-5 Alkyl), -SO2-N(C 1-5 Alkyl)(C 1-5 Alkyl), -NH-SO2-(C 1-5 Alkyl), -N(C 1-5 alkyl)-SO2-(C 1-5 Alkyl), -SO-(C 1-5 alkyl), -SO2-(C 1-5 alkyl), cycloalkyl, and heterocycloalkyl;

[0552] R X3 Selected from hydrogen, C 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, -(C 0-3 Alkylene)-OH, -(C 0-3 Alkylene)-O(C 1-5 Alkyl), -(C 0-3 Alkylene)-SH, -(C 0-3 Alkylene)-S(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH2, -(C 0-3 Alkylene)-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-halogen, -(C 0-3 alkylene)-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-O-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-CN,-(C 0-3 Alkylene)-CHO, -(C 0-3 alkylene)-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-COOH, -(C 0-3 Alkylene)-CO-O-(C 1-5 Alkyl), -(C 0-3 Alkylene)-O-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-CO-NH2, -(C 0-3 Alkylene)-CO-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-CO-N(C 1-5Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 alkyl)-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO2-NH2, -(C 0-3 Alkylene)-SO2-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO2-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH-SO2-(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 alkyl)-SO2-(C 1-5 Alkyl), -(C 0-3 Alkylene)-aryl, -(C 0-3 Alkylene)-heteroaryl, -(C 0-3 alkylene)-cycloalkyl and -(C 0-3 alkylene)-heterocycloalkyl, wherein the -(C 0-3 Alkylene)-aryl in the aryl part, the -(C 0-3 The heteroaryl portion of the -(C 0-3 The cycloalkyl portion of the -(C 0-3 The heterocycloalkyl moieties of the alkylene)-heterocycloalkyl groups are each optionally substituted by one or more groups R X31 replace;

[0553] R X31 Each independently selected from C 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, -OH, -O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -NH2, -NH(C 1-5 Alkyl), -N(C 1-5 Alkyl)(C 1-5 alkyl), halogen, C 1-5 Haloalkyl, -O-(C 1-5 haloalkyl), -CN, -CHO, -CO-(C 1-5 alkyl), -COOH, -CO-O-(C 1-5 alkyl), -O-CO-(C 1-5alkyl), -CO-NH2, -CO-NH(C 1-5 Alkyl), -CO-N(C 1-5 Alkyl)(C 1-5 alkyl), -NH-CO-(C 1-5 Alkyl), -N(C 1-5 alkyl)-CO-(C 1-5 alkyl), -SO2-NH2, -SO2-NH(C 1-5 Alkyl), -SO2-N(C 1-5 Alkyl)(C 1-5 Alkyl), -NH-SO2-(C 1-5 Alkyl), -N(C 1-5 alkyl)-SO2-(C 1-5 alkyl), cycloalkyl, and heterocycloalkyl;

[0554] R X4 Selected from hydrogen, C 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, -(C 0-3 Alkylene)-OH, -(C 0-3 Alkylene)-O(C 1-5 Alkyl), -(C 0-3 Alkylene)-SH, -(C 0-3 Alkylene)-S(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH2, -(C 0-3 Alkylene)-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-halogen, -(C 0-3 alkylene)-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-O-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-CN,-(C 0-3 Alkylene)-CHO, -(C 0-3 alkylene)-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-COOH, -(C 0-3 Alkylene)-CO-O-(C 1-5 Alkyl), -(C 0-3 Alkylene)-O-CO-(C 1-5 Alkyl), -(C 0-3Alkylene)-CO-NH2, -(C 0-3 Alkylene)-CO-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-CO-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 alkyl)-CO-(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO2-NH2, -(C 0-3 Alkylene)-SO2-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO2-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH-SO2-(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 alkyl)-SO2-(C 1-5 Alkyl), -(C 0-3 Alkylene)-aryl, -(C 0-3 Alkylene)-heteroaryl, -(C 0-3 alkylene)-cycloalkyl and -(C 0-3 alkylene)-heterocycloalkyl, wherein the -(C 0-3 Alkylene)-aryl in the aryl part, the -(C 0-3 The heteroaryl portion of the -(C 0-3 The cycloalkyl portion of the -(C 0-3 The heterocycloalkyl moieties of the alkylene)-heterocycloalkyl groups are each optionally substituted by one or more groups R X41 replace;

[0555] R X41 Each independently selected from C 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, -OH, -O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -NH2, -NH(C 1-5 Alkyl), -N(C 1-5 Alkyl)(C 1-5 alkyl), halogen, C 1-5 Haloalkyl, -O-(C1-5 haloalkyl), -CN, -CHO, -CO-(C 1-5 alkyl), -COOH, -CO-O-(C 1-5 alkyl), -O-CO-(C 1-5 alkyl), -CO-NH2, -CO-NH(C 1-5 Alkyl), -CO-N(C 1-5 Alkyl)(C 1-5 alkyl), -NH-CO-(C 1-5 Alkyl), -N(C 1-5 alkyl)-CO-(C 1-5 alkyl), -SO2-NH2, -SO2-NH(C 1-5 Alkyl), -SO2-N(C 1-5 Alkyl)(C 1-5 Alkyl), -NH-SO2-(C 1-5 Alkyl), -N(C 1-5 alkyl)-SO2-(C 1-5 alkyl), cycloalkyl, and heterocycloalkyl;

[0556] or a pharmaceutically acceptable salt thereof;

[0557] Provided that the following compounds are excluded from formula (I):

[0558]

[0559] 2. The compound of item 1, wherein R 1 Selected from one of the following groups:

[0560]

[0561]

[0562] wherein each of the groups depicted above is optionally replaced by one or more groups R 11 replace;

[0563] or where R 1 Any one selected from the following groups:

[0564]

[0565] wherein each of the groups depicted above is optionally further substituted by one or more groups R 11 replace.

[0566] 3. The compound of item 1, wherein R 1 Selected from one of the following groups:

[0567]

[0568] wherein each of the groups depicted above is optionally replaced by one or more groups R 11 replace.

[0569] 4. The compound of item 1, wherein R 1 Selected from one of the following groups:

[0570]

[0571] wherein each of the groups depicted above is optionally replaced by one or more groups R 11 replace;

[0572] And preferably R 1 is a group:

[0573]

[0574] wherein the groups depicted above are optionally replaced by one or more groups R 11 replace.

[0575] 5. The compound according to any one of items 1 to 4, wherein R 11 Each independently selected from C 1-5 Alkyl, -(C 0-3 Alkylene)-OH, -(C 0-3 Alkylene)-O(C 1-5 Alkyl), -(C 0-3 Alkylene)-SH, -(C 0-3 Alkylene)-S(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH2, -(C 0-3 Alkylene)-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-halogen, -(C 0-3 alkylene)-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-O-(C 1-5 haloalkyl) and -(C 0-3 alkylene)-CN.

[0576] 6. The compound of any one of items 1 to 5, wherein X2 is C(-LR X2 ).

[0577] 7. The compound of any one of items 1 to 5, wherein X1 is C(RX1 ), X2 is C(-LR X2 ), X3 is C(R X3 ), and X4 is C(R X4 ).

[0578] 8. The compound according to any one of items 1 to 7, wherein R X1 Selected from hydrogen, C 1-5 Alkyl, -(C 0-3 Alkylene)-OH, -(C 0-3 Alkylene)-O(C 1-5 Alkyl), -(C 0-3 Alkylene)-SH, -(C 0-3 Alkylene)-S(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH2, -(C 0-3 Alkylene)-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-halogen, -(C 0-3 alkylene)-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-O-(C 1-5 haloalkyl) and -(C 0-3 alkylene)-CN.

[0579] 9. The compound of any one of items 1 to 8, wherein L is selected from a covalent bond, C 1-5 Alkylene, -O-, -O-(C 1-5 Alkylene)-, -NH-, -NH-(C 1-5 Alkylene)-, -N(C 1-5 alkyl)- and -N(C 1-5 alkyl)-(C 1-5 Alkylene)-, wherein the C 1-5 Alkylene or the -O-(C 1-5 Alkylene)-, the -NH-(C 1-5 Alkylene)- and said-N(C 1-5 alkyl)-(C 1-5 C contained in any one of alkylene)- 1-5 The alkylene moiety is optionally substituted with one or more groups independently selected from the group consisting of halogen, -CF3, -CN, -OH, -O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -NH2, -NH(C1-5 alkyl) and -N(C 1-5 Alkyl)(C 1-5 alkyl).

[0580] 10. The compound of any one of items 1 to 8, wherein L is selected from a covalent bond, C 1-5 Alkylene, -O- and -O-(C 1-5 alkylene)-.

[0581] 11. The compound according to any one of items 1 to 10, wherein R X2 is selected from cycloalkyl, aryl, heterocycloalkyl and heteroaryl, wherein the cycloalkyl, the aryl, the heterocycloalkyl and the heteroaryl are each optionally substituted by one or more groups R X22 replace.

[0582] 12. The compound according to any one of items 1 to 8, wherein the group -LR X2 Selected from -R X2 、-(C 1-5 Alkylene)-R X2 、-OR X2 and -O-(C 1-5 Alkylene)-R X2 , where R X2 is selected from cycloalkyl, aryl, heterocycloalkyl and heteroaryl, wherein the cycloalkyl, the aryl, the heterocycloalkyl and the heteroaryl are each optionally substituted by one or more groups R X22 replace.

[0583] 13. The compound according to any one of items 1 to 12, wherein R X2 is selected from azetidinyl, oxetanyl, pyrrolidinyl, oxopyrrolidinyl, tetrahydrofuranyl, piperidinyl, oxopiperidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, 2-oxa-7-aza-spiro[3.5]nonyl, 6-oxa-2-aza-spiro[3.4]octyl, 3-oxa-9-aza-spiro[5.5]undecyl, 7-oxa-2-aza-spiro[4.5]decyl, 8-oxa-2-aza-spiro[4.5]decyl, phenyl, oxazolyl, pyridinyl, pyrazinyl and pyrimidinyl, wherein each of the above cyclic groups is optionally substituted by one or more radicals R X22 replace.

[0584] 14. The compound according to any one of items 1 to 13, wherein R X3 Selected from hydrogen, C 1-5 Alkyl, -(C 0-3 Alkylene)-OH, -(C 0-3 Alkylene)-O(C 1-5 Alkyl), -(C 0-3Alkylene)-SH, -(C 0-3 Alkylene)-S(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH2, -(C 0-3 Alkylene)-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-halogen, -(C 0-3 alkylene)-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-O-(C 1-5 haloalkyl) and -(C 0-3 alkylene)-CN.

[0585] 15. The compound according to any one of items 1 to 14, wherein R X4 Selected from hydrogen, C 1-5 Alkyl, -(C 0-3 Alkylene)-OH, -(C 0-3 Alkylene)-O(C 1-5 Alkyl), -(C 0-3 Alkylene)-SH, -(C 0-3 Alkylene)-S(C 1-5 Alkyl), -(C 0-3 Alkylene)-NH2, -(C 0-3 Alkylene)-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-halogen, -(C 0-3 alkylene)-(C 1-5 haloalkyl), -(C 0-3 Alkylene)-O-(C 1-5 haloalkyl), -(C 0-3 alkylene)-CN, cycloalkyl and heterocycloalkyl.

[0586] 16. The compound according to any one of items 1 to 14, wherein R X4 is selected from hydrogen, methyl, -OCH3, halogen and cyclopropyl.

[0587] 17. The compound according to any one of items 1 to 14, wherein R X4 Selected from methyl, -OCH3, halogen and cyclopropyl.

[0588] 18. The compound according to item 1, wherein the compound is selected from:

[0589] 6-(3-pyridin-4-yl-propoxy)-2-pyrrolo[1,2-c]pyrimidin-3-yl-3H-quinazolin-4-one;

[0590] 2-Isoquinolin-3-yl-6-(3-pyridin-4-yl-propoxy)-3H-quinazolin-4-one;

[0591] 6-(3-pyridin-4-yl-propoxy)-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one;

[0592] 6-(3-pyridin-4-yl-propoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0593] 2-pyridin-2-yl-6-(3-pyridin-4-yl-propoxy)-3H-quinazolin-4-one;

[0594] 2-(4-Methoxy-pyridin-2-yl)-6-(3-pyridin-4-yl-propoxy)-3H-quinazolin-4-one;

[0595] 2-(5-Fluoro-pyridin-2-yl)-6-(3-pyridin-4-yl-propoxy)-3H-quinazolin-4-one;

[0596] 6-(3-Pyridin-4-yl-propoxy)-2-(5-trifluoromethyl-pyridin-3-yl)-3H-quinazolin-4-one;

[0597] 6-[3-(4-pyridinyl)propoxy]-2-[5-(trifluoromethyl)-2-pyridinyl]-3H-quinazolin-4-one;

[0598] 2-(4-methyl-2-pyridinyl)-6-[3-(4-pyridinyl)propoxy]-3H-quinazolin-4-one;

[0599] 2-(6-methyl-2-pyridinyl)-6-[3-(4-pyridinyl)propoxy]-3H-quinazolin-4-one;

[0600] 2-(5-methylpyrazin-2-yl)-6-[3-(4-pyridinyl)propoxy]-3H-quinazolin-4-one;

[0601] 2-[5-chloro-4-(trifluoromethyl)-2-pyridinyl]-6-[3-(4-pyridinyl)propoxy]3H-quinazolin-4-one;

[0602] 2-(4-chloro-2-pyridinyl)-6-[3-(4-pyridinyl)propoxy]-3H-quinazolin-4-one;

[0603] 2-(4-ethyl-2-pyridinyl)-6-[3-(4-pyridinyl)propoxy]-3H-quinazolin-4-one;

[0604] 6-[3-(4-pyridinyl)propoxy]-2-[6-(trifluoromethyl)-2-pyridinyl]-3H-quinazolin-4-one;

[0605] 2-(4-bromo-2-pyridinyl)-6-[3-(4-pyridinyl)propoxy]-3H-quinazolin-4-one;

[0606] 2-(4-cyclopropyl-2-pyridyl)-6-[3-(4-pyridyl)propoxy]-3H-quinazolin-4-one;

[0607] 2-(2-Methyl-oxazol-4-yl)-6-(3-pyridin-4-yl-propoxy)-3H-quinazolin-4-one;

[0608] 6-(2-pyridin-3-yl-ethoxy)-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one;

[0609] 6-(4-Bromo-benzyloxy)-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one;

[0610] tert-Butyl 3-(4-hydroxy-2-pyrrolo[1,2-c]pyrimidin-3-yl-quinazolin-6-yl)oxyazetidine-1-carboxylate;

[0611] 6-(azetidin-3-yloxy)-2-pyrrolo[1,2-c]pyrimidin-3-yl-3H-quinazolin-4-one;

[0612] 6-(1-pyrimidin-4-yl-azetidin-3-yloxy)-2-pyrrolo[1,2-c]pyrimidin-3-yl-3H-quinazolin-4-one;

[0613] 3-(4-Hydroxy-2-thieno[2,3-c]pyridin-5-yl-quinazolin-6-yloxy)-azetidine-1-carboxylic acid tert-butyl ester;

[0614] 6-(azetidin-3-yloxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0615] 6-(1-propionyl-azetidin-3-yloxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0616] 6-(piperidin-4-yloxy)-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one;

[0617] 6-(1-propionyl-piperidin-4-yloxy)-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one;

[0618] 6-(2-morpholin-4-yl-ethoxy)-2-pyrrolo[1,2-c]pyrimidin-3-yl-3H-quinazolin-4-one;

[0619] 6-(2-methoxy-ethoxy)-2-pyrrolo[1,2-c]pyrimidin-3-yl-3H-quinazolin-4-one;

[0620] 6-(2-morpholin-4-yl-ethoxy)-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one;

[0621] 6-(2-methoxy-ethoxy)-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one;

[0622] 6-(3-pyridin-3-yl-propoxy)-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one;

[0623] 4-(4-Oxo-2-pyridin-2-yl-3,4-dihydro-quinazolin-6-yloxy)-piperidine-1-carboxylic acid tert-butyl ester;

[0624] 6-(piperidin-4-yloxy)-2-pyridin-2-yl-3H-quinazolin-4-one;

[0625] 6-(1-Acetyl-piperidin-4-yloxy)-2-pyridin-2-yl-3H-quinazolin-4-one;

[0626] 4-[4-Oxo-2-(4-trifluoromethyl-pyridin-2-yl)-3,4-dihydro-quinazolin-6-yloxymethyl]-piperidine-1-carboxylic acid tert-butyl ester;

[0627] 6-(Piperidin-4-ylmethoxy)-2-(4-trifluoromethyl-pyridin-2-yl)-3H-quinazolin-4-one;

[0628] 6-(1-Acetyl-piperidin-4-ylmethoxy)-2-(4-trifluoromethyl-pyridin-2-yl)-3H-quinazolin-4-one;

[0629] tert-Butyl 4-[(4-oxo-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-6-yl)oxymethyl]piperidine-1-carboxylate;

[0630] 6-(4-Piperidinylmethoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0631] 6-(1-acetyl-piperidin-4-ylmethoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0632] 6-(1-propionyl-piperidin-4-ylmethoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0633] 3-(4-Oxo-2-thieno[2,3-c]pyridin-5-yl-3,4-dihydro-quinazolin-6-yloxy)-pyrrolidine-1-carboxylic acid tert-butyl ester;

[0634] 6-(Pyrrolidin-3-yloxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0635] 6-(1-acetyl-pyrrolidin-3-yloxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0636] 4-[4-Oxo-2-(4-trifluoromethyl-pyridin-2-yl)-3,4-dihydro-quinazolin-6-yl]-piperazine-1-carboxylic acid tert-butyl ester;

[0637] 6-Piperazin-1-yl-2-(4-trifluoromethyl-pyridin-2-yl)-3H-quinazolin-4-one;

[0638] 6-(4-Propanyl-piperazin-1-yl)-2-(4-trifluoromethyl-pyridin-2-yl)-3H-quinazolin-4-one;

[0639] 4-(4-Oxo-2-thieno[2,3-c]pyridin-5-yl-3,4-dihydro-quinazolin-6-yl)-piperidine-1-carboxylic acid tert-butyl ester;

[0640] 6-Piperidin-4-yl-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0641] 6-(1-acetyl-piperidin-4-yl)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0642] 6-[2-(Tetrahydro-pyran-4-yl)-ethoxy]-2-(4-trifluoromethyl-pyridin-2-yl)-3H-quinazolin-4-one;

[0643] 6-[3-(3-Fluoro-pyridin-4-yl)-propoxy]-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0644] 6-[3-(4-Methanesulfonyl-phenyl)-propyloxy]-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0645] 6-(3-Pyrazin-2-yl-propyloxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0646] 6-[3-(3-Methoxy-pyridin-4-yl)-propoxy]-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0647] 6-[3-(2-methyl-pyridin-4-yl)-propoxy]-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0648] 6-(3-oxazol-4-yl-propoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0649] 8-methyl-6-(3-pyridin-4-yl-propoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0650] 6-(3-pyridin-4-yl-propoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-pyrido[3,2-d]pyrimidin-4-one;

[0651] 6-(3-Pyridin-4-yl-propoxy)-2-(4-trifluoromethyl-pyridin-2-yl)-3H-pyrido[3,2-d]pyrimidin-4-one;

[0652] 6-(3-Pyridin-4-yl-propoxy)-2-(4-trifluoromethyl-pyridin-2-yl)-3H-pyrido[2,3-d]pyrimidin-4-one;

[0653] 6-(3-Pyridin-4-yl-propoxy)-2-(4-trifluoromethyl-pyridin-2-yl)-3H-pyrido[3,4-d]pyrimidin-4-one;

[0654] 6-(3-pyridin-4-yl-propoxy)-2-thieno[2,3-c]pyridin-5-yl-7-trifluoromethyl-3H-quinazolin-4-one;

[0655] 5-chloro-6-(3-pyridin-4-yl-propoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0656] 8-Chloro-6-(3-pyridin-4-yl-propoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0657] 8-cyclopropyl-6-(3-pyridin-4-yl-propoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0658] 8-ethyl-6-(3-pyridin-4-yl-propoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0659] 8-Fluoro-6-(3-pyridin-4-yl-propoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0660] 8-methyl-6-(tetrahydro-pyran-4-ylmethoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0661] 8-methyl-6-(2-oxetan-3-yl-ethoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0662] 8-methyl-6-[2-(tetrahydro-furan-3-yl)-ethoxy]-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0663] 8-Methyl-6-[2-(tetrahydro-pyran-4-yl)-ethoxy]-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0664] 8-methyl-6-(tetrahydro-furan-3-ylmethoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0665] R-8-methyl-6-(tetrahydro-furan-3-ylmethoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0666] S-8-methyl-6-(tetrahydro-furan-3-ylmethoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0667] 8-methyl-6-(1-methyl-6-oxo-piperidin-3-yloxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0668] R-8-methyl-6-((1-methyl-6-oxopiperidin-3-yl)oxy)-2-(thieno[2,3-c]pyridin-5-yl)quinazolin-4(3H)-one;

[0669] S-8-methyl-6-((1-methyl-6-oxopiperidin-3-yl)oxy)-2-(thieno[2,3-c]pyridin-5-yl)quinazolin-4(3H)-one;

[0670] 8-methyl-6-(1-propionyl-pyrrolidin-3-yloxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0671] R-8-methyl-6-(1-propionyl-pyrrolidin-3-yloxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0672] S-8-methyl-6-(1-propionyl-pyrrolidin-3-yloxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0673] 8-methyl-6-(1-oxetan-3-ylpyrrolidin-3-yloxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0674] R-8-methyl-6-(1-oxetan-3-ylpyrrolidin-3-yloxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0675] S-8-methyl-6-(1-oxetan-3-ylpyrrolidin-3-yloxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0676] 8-Methyl-6-[2-(2-oxa-7-aza-spiro[3.5]non-7-yl)-ethoxy]-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0677] 8-methyl-6-(piperidin-4-ylmethoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0678] 8-methyl-6-(1-oxetan-3-yl-piperidin-4-ylmethoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0679] 8-methyl-6-(1-propionyl-piperidin-4-ylmethoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0680] 6-(1-Methanesulfonyl-piperidin-4-ylmethoxy)-8-methyl-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0681] 8-methyl-6-(2-oxa-7-aza-spiro[3.5]non-7-yl)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0682] 8-methyl-6-(6-oxa-2-aza-spiro[3.4]octan-2-yl)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0683] 8-methyl-6-(3-oxa-9-aza-spiro[5.5]undec-9-yl)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0684] 8-methyl-6-(7-oxa-2-aza-spiro[4.5]dec-2-yl)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0685] 8-Methyl-6-(8-oxa-2-aza-spiro[4.5]dec-2-yl)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0686] 6-(2-Hydroxy-2-methyl-propylamino)-8-methyl-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0687] 8-Methyl-6-(2-piperidin-3-yl-ethoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0688] 6-[2-(1-acetyl-piperidin-3-yl)-ethoxy]-8-methyl-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0689] 6-[2-(4-Acetyl-piperazin-1-yl)-ethoxy]-8-methyl-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0690] 3-(8-Methyl-4-oxo-2-thieno[2,3-c]pyridin-5-yl-3,4-dihydro-quinazolin-6-yl)-propanal;

[0691] 8-methyl-6-(3-morpholin-4-yl-propyl)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0692] 8-methyl-6-(2-morpholin-4-yl-ethyl)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0693] 8-Methyl-6-(3-pyridin-4-yl-propoxy)-2-(4-trifluoromethyl-pyridin-2-yl)-3H-quinazolin-4-one;

[0694] 8-Methyl-6-(tetrahydro-furan-3-ylmethoxy)-2-(4-trifluoromethyl-pyridin-2-yl)-3H-quinazolin-4-one;

[0695] 8-Methyl-6-(1-propionyl-azetidin-3-yloxy)-2-(4-trifluoromethyl-pyridin-2-yl)-3H-quinazolin-4-one;

[0696] 8-Methyl-6-(1-oxetan-3-yl-piperidin-4-yloxy)-2-(4-trifluoromethyl-pyridin-2-yl)-3H-quinazolin-4-one;

[0697] 8-Methyl-6-(3-oxa-9-aza-spiro[5.5]undec-9-yl)-2-(4-trifluoromethyl-pyridin-2-yl)-3H-quinazolin-4-one;

[0698] 8-methyl-6-(3-pyridin-4-yl-propoxy)-2-pyrrolo[1,2-c]pyrimidin-3-yl-3H-quinazolin-4-one;

[0699] 8-methyl-2-pyrrolo[1,2-c]pyrimidin-3-yl-6-(tetrahydro-furan-3-ylmethoxy)-3H-quinazolin-4-one;

[0700] 8-methyl-6-(3-oxa-9-aza-spiro[5.5]undec-9-yl)-2-pyrrolo[1,2-c]pyrimidin-3-yl-3H-quinazolin-4-one;

[0701] 8-methyl-6-(1-oxetan-3-yl-piperidin-4-yloxy)-2-pyrrolo[1,2-c]pyrimidin-3-yl-3H-quinazolin-4-one;

[0702] 8-Methyl-6-[1-(tetrahydro-pyran-4-yl)-ethoxy]-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0703] R-8-methyl-6-[1-(tetrahydro-pyran-4-yl)-ethoxy]-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0704] S-8-Methyl-6-[1-(tetrahydro-pyran-4-yl)-ethoxy]-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0705] 8-Methyl-6-[1-(tetrahydro-pyran-4-yl)-ethoxy]-2-(4-trifluoromethyl-pyridin-2-yl)-3H-quinazolin-4-one;

[0706] R-8-Methyl-6-[1-(tetrahydro-pyran-4-yl)-ethoxy]-2-(4-trifluoromethyl-pyridin-2-yl)-3H-quinazolin-4-one;

[0707] S-8-Methyl-6-[1-(tetrahydro-pyran-4-yl)-ethoxy]-2-(4-trifluoromethyl-pyridin-2-yl)-3H-quinazolin-4-one;

[0708] 6-[(3-fluorotetrahydrofuran-3-yl)methoxy]-8-methyl-2-[4-(trifluoromethyl)-2-pyridinyl]-3H-quinazolin-4-one;

[0709] 8-methyl-6-(3-oxa-9-azaspiro[5.5]undec-9-yl)-2-thieno[2,3-c]pyridin-5-yl-3-(2-trimethylsilylethoxymethyl)pyrido[3,2-d]pyrimidin-4-one;

[0710] 8-methyl-6-(morpholinomethyl)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0711] 8-methyl-6-(morpholinomethyl)-2-[4-(trifluoromethyl)-2-pyridinyl]-3H-quinazolin-4-one;

[0712] 8-methyl-6-(1-propionylazetidin-3-yl)oxy-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0713] 8-methyl-6-(2-morpholinoethyl)-2-[4-(trifluoromethyl)-2-pyridinyl]-3H-quinazolin-4-one;

[0714] 8-methyl-6-[(1-methyl-6-oxo-3-piperidinyl)oxy]-2-pyrrolo[1,2-c]pyrimidin-3-yl-3H-quinazolin-4-one;

[0715] 8-methyl-6-(morpholinomethyl)-2-(thieno[3,2-c]pyridin-6-yl)quinazolin-4(3H)-one;

[0716] 8-methyl-6-(3-oxa-9-azaspiro[5.5]undec-9-yl)-2-(thieno[3,2-c]pyridin-6-yl)quinazolin-4(3H)-one;

[0717] 8-methyl-6-(2-[1,4]oxazepan-4-yl-ethyl)-2-thieno[2,3-b]pyridin-5-yl-3H-quinazolin-4-one;

[0718] 8-methyl-6-(2-[1,4]oxazepan-4-yl-ethyl)-2-thieno[3,2-b]pyridin-6-yl-3H-quinazolin-4-one;

[0719] 8-methyl-6-(2-morpholin-4-yl-ethyl)-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one;

[0720] 8-Methyl-6-(2-morpholin-4-yl-ethyl)-2-pyrrolo[1,2-c]pyrimidin-3-yl-3H-quinazolin-4-one;

[0721] 8-methyl-6-(morpholinomethyl)-2-pyrrolo[1,2-c]pyrimidin-3-yl-3H-quinazolin-4-one;

[0722] 8-methyl-6-(2-morpholino-2-oxoethyl)-2-(thieno[3,2-c]pyridin-6-yl)quinazolin-4(3H)-one;

[0723] 8-methyl-6-(2-morpholino-2-oxo-ethyl)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0724] 8-methyl-6-(2-piperidin-1-yl-ethyl)-2-thieno[2,3-b]pyridin-5-yl-3H-quinazolin-4-one;

[0725] 8-methyl-6-(1-methyl-6-oxo-piperidin-3-yloxy)-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one;

[0726] 8-Methyl-6-(1-methyl-2-oxo-piperidin-4-ylmethoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one

[0727] 8-methyl-6-(1-piperidinylmethyl)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0728] 8-methyl-6-(2-morpholino-2-oxo-ethyl)-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one;

[0729] 8-methyl-6-[(4-methylpiperazin-1-yl)methyl]-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0730] 8-methyl-6-(pyrrolidin-1-ylmethyl)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0731] 8-methyl-6-(2-morpholino-2-oxo-ethyl)-2-pyrrolo[1,2-c]pyrimidin-3-yl-3H-quinazolin-4-one;

[0732] 8-methyl-6-(morpholine-4-carbonyl)-2-pyrrolo[1,2-c]pyrimidin-3-yl-3H-quinazolin-4-one;

[0733] 8-Methyl-6-(1-methyl-6-oxo-piperidin-3-yloxy)-2-(4-trifluoromethyl-pyridin-2-yl)-3H-quinazolin-4-one;

[0734] 8-methyl-2-thieno[2,3-c]pyridin-5-yl-6-(thiomorpholinomethyl)-3H-quinazolin-4-one;

[0735] 8-methyl-6-[2-(1,4-oxazepan-4-yl)-2-oxo-ethyl]-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0736] 8-methyl-6-(pyrrolidin-1-ylmethyl)-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one;

[0737] 8-methyl-6-(1-methyl-5-oxo-pyrrolidin-3-yl)oxy-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one;

[0738] 8-methyl-6-[(3R)-1-methyl-5-oxo-pyrrolidin-3-yl]oxy-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one;

[0739] 8-methyl-6-[(3S)-1-methyl-5-oxo-pyrrolidin-3-yl]oxy-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one;

[0740] benzyl 3-[(8-methyl-4-oxo-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-6-yl)oxy]pyrrolidine-1-carboxylate;

[0741] benzyl (3S)-3-[(8-methyl-4-oxo-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-6-yl)oxy]pyrrolidine-1-carboxylate;

[0742] benzyl (3R)-3-[(8-methyl-4-oxo-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-6-yl)oxy]pyrrolidine-1-carboxylate;

[0743] 8-methyl-6-[2-(4-methyl-3-oxo-piperazin-1-yl)ethyl]-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0744] 8-methyl-6-[2-(4-methyl-3-oxo-piperazin-1-yl)ethyl]-2-[4-(trifluoromethyl)-2-pyridinyl]-3H-quinazolin-4-one;

[0745] 8-methyl-6-[2-(2-oxa-6-azaspiro[3.3]hept-6-yl)ethyl]-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one;

[0746] 8-methyl-6-[2-(2-oxa-6-azaspiro[3.3]heptane-6-yl)ethyl]-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one;

[0747] 8-methyl-6-[(4-methyl-3-oxo-piperazin-1-yl)methyl]-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one;

[0748] 6-(2-((2-methoxyethyl)(methyl)amino)ethyl)-8-methyl-2-(thieno[3,2-c]pyridin-6-yl)quinazolin-4(3H)-one;

[0749] 6-(2-(1,1-dioxythiomorpholino)ethyl)-8-methyl-2-(thieno[3,2-c]pyridin-6-yl)quinazolin-4(3H)-one;

[0750] 6-[(1,1-dioxo-1,4-thiazin-4-yl)methyl]-8-methyl-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one;

[0751] 6-(((2-methoxyethyl)(methyl)amino)methyl)-8-methyl-2-(thieno[3,2-c]pyridin-6-yl)quinazolin-4(3H)-one;

[0752] 6-[(4-methoxy-1-piperidinyl)methyl]-8-methyl-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one;

[0753] 6-[(2,2-dimethylmorpholin-4-yl)methyl]-8-methyl-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one;

[0754] 8-chloro-6-(2-morpholinoethyl)-2-(4-(trifluoromethyl)pyridin-2-yl)quinazolin-4(3H)-one;

[0755] 8-methyl-6-(2-oxa-7-azaspiro[3.5]nonan-7-ylmethyl)-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one;

[0756] N,N-dimethyl-1-((8-methyl-4-oxo-2-(thieno[3,2-c]pyridin-6-yl)-3,4-dihydroquinazolin-6-yl)methyl)piperidine-4-carboxamide;

[0757] 6-((4-(methoxymethyl)piperidin-1-yl)methyl)-8-methyl-2-(thieno[3,2-c]pyridin-6-yl)quinazolin-4(3H)-one;

[0758] 8-methoxy-6-(2-morpholinoethyl)-2-(4-(trifluoromethyl)pyridin-2-yl)quinazolin-4(3H)-one;

[0759] 8-Bromo-6-(2-morpholinoethyl)-2-(4-(trifluoromethyl)pyridin-2-yl)quinazolin-4(3H)-one;

[0760] 6-(2-(2,2-dimethylmorpholino)ethyl)-8-methyl-2-(4-(trifluoromethyl)pyridin-2-yl)quinazolin-4(3H)-one;

[0761] 8-methyl-6-((4-methyl-3-oxopiperazin-1-yl)methyl)-2-(4-(trifluoromethyl)pyridin-2-yl)quinazolin-4(3H)-one;

[0762] 6-(2-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)ethyl)-8-methyl-2-(4-(trifluoromethyl)pyridin-2-yl)quinazolin-4(3H)-one;

[0763] 6-(2-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)ethyl)-8-methyl-2-(4-(trifluoromethyl)pyridin-2-yl)quinazolin-4(3H)-one;

[0764] 6-(2-(4-hydroxypiperidin-1-yl)ethyl)-8-methyl-2-(4-(trifluoromethyl)pyridin-2-yl)quinazolin-4(3H)-one;

[0765] 6-(2-(4,4-difluoropiperidin-1-yl)ethyl)-8-methyl-2-(4-(trifluoromethyl)pyridin-2-yl)quinazolin-4(3H)-one;

[0766] 6-(2-(4-methoxypiperidin-1-yl)ethyl)-8-methyl-2-(4-(trifluoromethyl)pyridin-2-yl)quinazolin-4(3H)-one;

[0767] 8-methyl-6-(2-morpholinoethyl)-2-(4-(trifluoromethyl)pyridin-2-yl)pyrido[3,2-d]pyrimidin-4(3H)-one;

[0768] and a pharmaceutically acceptable salt of any one of the above compounds.

[0769] 19. A pharmaceutical composition comprising a compound according to any one of items 1 to 18 and a pharmaceutically acceptable excipient.

[0770] 20. The compound according to any one of items 1 to 18 for use as a medicament.

[0771] 21. A compound according to any one of items 1 to 18 or a pharmaceutical composition according to item 19 for use in treating or preventing a disorder associated with altered glutamatergic signalling and / or function or a disorder that can be affected by alterations in glutamate levels or signalling.

[0772] 22. Use of a compound according to any one of items 1 to 18 for the preparation of a medicament for treating or preventing a disorder associated with altered glutamatergic signalling and / or function or a disorder that can be affected by alterations in glutamate levels or signalling.

[0773] 23. A method of treating or preventing a condition associated with altered glutamatergic signalling and / or function, or a condition that can be affected by alterations in glutamate levels or signalling, said method comprising administering to a subject in need thereof a compound according to item 1.

[0774] 24. The compound for use according to item 21 or the pharmaceutical composition for use according to item 21 or the use according to item 22 or the method according to item 23, wherein the condition to be treated or prevented is selected from any one of the following: epilepsy; dementia and related diseases, including Alzheimer's type dementia, Alzheimer's disease, Pick's disease, vascular dementia, Lewy body disease, dementia caused by metabolic, toxic and deficiency diseases, AIDS dementia syndrome, Creutzfeldt-Jakob disease and atypical subacute spongiform encephalopathy; Parkinson's syndrome and movement disorders, including Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, hepatolenticular degeneration, chorea, Huntington's disease, hemishake, athetosis, dystonia, spasmodic torticollis, occupational movement disorder, Gilles de la Tourette syndrome, tardive dyskinesia or drug Drug-induced dyskinesia, levodopa-induced dyskinesia, tremor and myoclonus; motor neuron disease or amyotrophic lateral sclerosis; neurodegenerative and / or genetic disorders of the nervous system, including spinocerebellar degeneration, Friedreich's ataxia and other hereditary cerebellar ataxias, primarily spinal muscular atrophy, hereditary neuropathies and macular hamartomatosis; peripheral nervous system disorders, including trigeminal neuralgia, facial nerve disorders, other cranial nerve disorders, nerve root and plexus disorders, mononeuritis, carpal tunnel syndrome, sciatica, hereditary and idiopathic peripheral neuropathies, inflammatory and toxic neuropathies; multiple sclerosis and other autoimmune diseases, including systemic lupus erythematosus and psoriasis; infantile cerebral palsy; hemiparesis, hemiparesis, and other paralysis syndromes; cerebrovascular disorders, including subarachnoid hemorrhage, intracerebral hemorrhage, anterior cerebral artery occlusion and stenosis, cerebral artery occlusion, including thrombosis and embolism, cerebral ischemia, stroke, transient ischemic attack, atherosclerosis, cerebrovascular dementia, aneurysm, brain defects caused by heart bypass surgery and transplantation; migraine, including classic migraine and variants, including cluster headache; headache; myoneural disorders, including myasthenia gravis, acute muscle spasm, myopathies, including muscular dystrophy, myotonia, and familial periodic paralysis; eye and visual pathway disorders, including retinal disorders and visual disturbances; intracranial trauma / injury and its sequelae; trauma / injury to the nerves and spinal cord and its sequelae; intoxication and toxic effects of non-drug substances; accidental poisoning by drugs, pharmaceutical substances, and biological products acting on the central, peripheral, and autonomic nervous systems; neurological and psychiatric adverse effects of drugs, pharmaceutical substances, and biological substances; disorders of sphincter control and sexual function; social skills disorders, including autism or autism spectrum disorder, or fragile X syndrome; psychiatric disorders, Including mental retardation, learning disabilities, motor skills disorders, communication disorders, comprehensive mental development disorders, attention deficit disorder and disruptive behavior disorder, feeding and eating disorders, tic disorders, excretion disorders; delirium and other cognitive disorders;Substance-related disorders, including alcohol-related disorders, nicotine-related disorders, and disorders related to cocaine, opioids, cannabis, hallucinogens, and other drugs; schizophrenia and other psychotic disorders; mood disorders, including depressive disorders and bipolar disorder; anxiety disorders, including panic disorder, phobias, obsessive-compulsive disorder, stress disorder, and generalized anxiety disorder; eating disorders, including anorexia and bulimia; sleep disorders, including parasomnias, insomnia, hypersomnia, narcolepsy, and breathing-related sleep disorders, and parasomnias; drug-induced movement disorders, including neuroleptic-induced parkinsonism and tardive dyskinesia; endocrine and metabolic disorders, including diabetes, endocrine gland disorders, and hypoglycemia; acute and chronic pain; nausea and vomiting; irritable bowel syndrome; and cancer;

[0775] 25. The compound for use according to item 21 or the pharmaceutical composition for use according to item 21 or the use according to item 22 or the method according to item 23, wherein the condition to be treated or prevented is selected from any one of the following: dementia and related diseases, including Alzheimer's dementia, Alzheimer's disease, Pick's disease, vascular dementia, Lewy body disease, dementia caused by metabolic, toxic and deficiency diseases, AIDS dementia syndrome, Creutzfeldt-Jakob disease and atypical subacute spongiform encephalopathy; Parkinson's syndrome and movement disorders, including Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, hepatolenticular degeneration, chorea, Huntington's disease, hemishake, athetosis, dystonia, spasmodic torticollis, occupational movement disorder, Gilles de la Tourette syndrome, Tardive dyskinesia or drug-induced dyskinesia, levodopa-induced dyskinesia, tremor, and myoclonus; social skills disorders, including autism or autism spectrum disorder, or fragile X syndrome; acute and chronic pain; anxiety disorders, including panic disorder, phobias, obsessive-compulsive disorder, stress disorder, and generalized anxiety disorder; schizophrenia and other psychiatric disorders; mood disorders, including depressive disorders and bipolar disorder; endocrine and metabolic diseases, including diabetes, endocrine gland disorders, and hypoglycemia; and cancer.

[0776] 26. The compound according to any one of items 1 to 18 or the pharmaceutical composition according to item 19, for use in treating or preventing Parkinson's disease.

[0777] 27. Use of a compound according to any one of items 1 to 28 for the preparation of a medicament for treating or preventing Parkinson's disease.

[0778] 28. A method for treating or preventing Parkinson's disease, comprising administering the compound of item 1 to a subject in need thereof.

[0779] 29. The compound for use according to any one of items 20, 21 or 24-26, or the pharmaceutical composition for use according to any one of items 21 or 24-26, or the use according to item 22, 24, 25 or 27, or the method according to item 23, wherein the compound, the pharmaceutical composition or the medicament is administered orally.

[0780] 30. The compound for use according to any one of items 20, 21, 24-26 or 29, or the pharmaceutical composition for use according to any one of items 21, 24-26 or 29, or the use according to any one of items 22, 24, 25, 27 or 29, wherein the compound, the pharmaceutical composition or the medicament is administered to a human subject.

[0781] 31. The method of item 23, wherein the individual is a human.

[0782] 32. A method for identifying a test substance that binds to metabotropic glutamate receptor 4 (mGluR4), the method comprising the steps of:

[0783] (a) contacting mGluR4 with a compound according to any one of items 1 to 18, wherein the compound is radiolabeled or fluorescently labeled under conditions that allow binding of the compound to mGluR4, thereby producing a bound, labeled compound;

[0784] (b) detecting a signal corresponding to the amount of bound, labeled compound in the absence of the test substance;

[0785] (c) contacting the bound, labeled compound with a test substance;

[0786] (d) detecting a signal corresponding to the amount of bound, labeled compound in the presence of the test substance; and

[0787] (e) comparing the signal detected in step (d) with the signal detected in step (b) to determine whether the test substance binds to mGluR4.

[0788] 33. Use of a compound as defined in any one of items 1 to 18 as a positive allosteric modulator of mGluR4 in vitro.

[0789] The invention is further described by means of the following exemplary drawings, which show:

[0790] Figure 1The anti-cataleptic effects of exemplary compounds of Formula (I) were determined in vivo in a haloperidol-induced catalepsy model in mice (see Section III of the Examples). The figure shows the mean latency time each group of animals spent on the rod and measured between 135 and 270 minutes after haloperidol injection. The anti-cataleptic effects of the compounds were compared to the vehicle-treated group using an ANOVA test followed by a Dunnett's test. Compounds 81, 100, 114, 119, 143, and 144, administered orally at 1 mg / kg 60 minutes after haloperidol injection, exhibited significant anti-cataleptic effects (with adjusted p-values ​​of <0.0001, 0.0065, 0.0066, 0.0307, ​​0.0176, and 0.0115, respectively).

[0791] The present invention will now be described with reference to the following examples, which are illustrative only and should not be construed as limiting the scope of the invention.

[0792] The compounds described in the Examples section below are defined by their chemical formulas and corresponding chemical names. In the event of a conflict between any chemical formula and the corresponding chemical name given herein, the present invention relates to both the compound defined by the chemical formula and the compound defined by the chemical name, and in particular to the compound defined by the chemical formula. Example

[0793] General experimental methods

[0794] All reagents were commercial grade and used without further purification. Commercially available anhydrous solvents were used where necessary. Most reactions were performed under an inert atmosphere (argon). Column chromatography was typically performed using a Biotage KP-Sil column and a Biotage Isolera Four instrument. Thin-layer chromatography was performed using pre-coated silica gel F-254 plates.

[0795] Recorded using a Bruker AMX-400 spectrophotometer 1 H NMR spectra. Proton chemical shifts are listed relative to residual CDCl (7.26 ppm), DMSO (2.50 ppm), or D O (4.78 ppm). Splitting patterns are designated as s (singlet), d (doublet), dd (doublet-doublet), t (triplet), tt (triplet-triplet), td (triplet-doublet), q (quartet), quint (quintet), sex (sextet), sept (septet), m (multiplet), and b (broad).

[0796] The HPLC system was a Waters platform with a 2767 sample handler, a 2525 pump, and a photodiode array detector (190-400 nm). The HPLC was coupled to a Waters Acquity QDa detector. All mass spectra were full scan experiments (mass range 110-850 amu). Mass spectra were acquired using electrospray ionization. The column used in the analytical mode was an XSelect CSHC 18 3.5 μM (4.6 × 50 mm), the column used in the preparative mode was XSelect CSH Preparative C 18 5 μM (19×100 mm). In both cases, the mobile phase consisted of an appropriate gradient of A and B. A was water containing 0.1% formic acid, and B was acetonitrile containing 0.1% formic acid. The flow rate was 1 mL / min in analytical mode and 25 mL / min in preparative mode. All HPLC-MS were performed at room temperature. The UPLC system was a Waters Aquity platform with a photodiode array detector (190-400 nm). The column used was an Acquity CSH C 18 1.7 μM (2.1 × 30 mm). The mobile phase consisted of a gradient of A and B. A was water with 0.025% TFA, and B was acetonitrile with 0.025% TFA. The flow rate was 0.8 mL / min. All analyses were performed at 55°C. The UPLC was coupled to a Waters SQD2 platform. All mass spectra were full scan experiments (mass range 100-800 amu). Mass spectra were acquired using electrospray ionization.

[0797] Melting points were measured using a Barnstead Electrothermal 9100 and are uncorrected.

[0798] I. Synthesis of Selected Compounds of the Invention

[0799] The following compounds were synthesized and characterized as described below.

[0800] Pyrrolo[1,2-c]pyrimidine-3-carboxylic acid, thieno[3,2-c]pyridine-6-carboxylic acid, and thieno[2,3-c]pyridine-5-carboxylic acid were prepared according to conditions described in the literature (J. Org. Chem., 1999, 64, 7788-7801; J. Med. Chem. 2006, 49, 4425-4436; and WO 2004 / 39815).

[0801] Example 1 –Synthesis of Compound 1 (6-(3-pyridin-4-yl-propoxy)-2-pyrrolo[1,2-c]pyrimidin-3-yl-3H-quinazolin-4-one)

[0802]

[0803] Step 1:

[0804] Under an inert atmosphere, a solution of 5-fluoro-2-nitrobenzoic acid (2.50 g, 13.5 mmol), ammonia (0.5 M in dioxane, 54.0 mL, 27.0 mmol), benzotriazol-1-yloxy-tris(dimethylamino)-phosphonium hexafluorophosphate (8.90 g, 20.3 mmol), and diisopropylethylamine (6.10 mL, 35.1 mmol) in anhydrous dichloromethane (68.0 mL) was stirred at room temperature for 16 h. The mixture was then poured into saturated aqueous ammonium chloride (250 mL) and extracted with dichloromethane (2 x 200 mL). The combined organic extracts were washed with brine (100 mL), dried over MgSO₄, and concentrated in vacuo. The crude dark solid was purified by flash column chromatography on silica gel using cyclohexane / ethyl acetate as eluent to give 5-fluoro-2-nitrobenzamide (2.40 g, 13.0 mmol, 96%) as a brown solid.

[0805]

[0806] M / Z(M+H) + =185.2.

[0807] Step 2:

[0808] To a suspension of sodium hydride (60% dispersion in oil, 0.84 g, 21.7 mmol) in anhydrous DMF (15.0 mL) at 0°C under an inert atmosphere was added a solution of 4-pyridinepropanol (1.49 g, 10.8 mmol) in DMF (15.0 mL) dropwise. After 5 min, a solution of 5-fluoro-2-nitrobenzamide (2.00 g, 10.8 mmol) in DMF (15.0 mL) was added dropwise at 0°C with vigorous stirring. The resulting reddish mixture was stirred at room temperature for 1 h, then diluted with water (100 mL) and extracted with ethyl acetate (3 x 300 mL). The combined organic extracts were washed with brine (100 mL), dried over MgSO4, and concentrated in vacuo. The crude dark oil was purified by flash column chromatography on silica gel using dichloromethane / methanol as eluent to give 2-nitro-5-(3-pyridin-4-yl-propoxy)-benzamide (2.05 g, 63%) as an orange oil.

[0809]

[0810] 1H-NMR (400MHz, DMSO): 2.09 (m, 2H, CH2); 2.78 (t, J 7.6Hz, 2H, CH2); 4.15 (t, J6.5Hz, 2H, CH2-O); 7.05 (d, J 2.8Hz, 1H, Ar); 7.14 (dd, J 9.0, 2.8Hz, 1H, Ar); 7.28 (d, J5.8Hz, 2H, Ar); 7.64 (bs, 1H, NH); 8.02 (bs, 1H, NH); 8.04 (d, J 9.0Hz, 1H, Ar); 8.47 (d, J5.8Hz, 2H, Ar).M / Z (M+H) + =302.1.

[0811] Step 3:

[0812] To a solution of 2-nitro-5-(3-pyridin-4-yl-propoxy)-benzamide (2.05 g, 6.80 mmol) in methanol (23.0 mL) and DMF (8.0 mL) was added 10% palladium on carbon (1.45 g). The suspension was placed under a hydrogen atmosphere at atmospheric pressure and stirred at room temperature for 2 h. The mixture was then filtered through a pad of celite. The methanol was removed in vacuo to afford an orange solution, which was partitioned between water (50 mL) and ethyl acetate (50 mL) and extracted with ethyl acetate (2 x 50 mL). The combined organic extracts were washed with brine (100 mL), dried over MgSO4, and concentrated in vacuo. The crude oil was purified by flash column chromatography on silica gel using dichloromethane / methanol as eluent to afford 2-amino-5-(3-pyridin-4-yl-propoxy)-benzamide (0.96 g, 3.54 mmol, 52%) as a yellow solid.

[0813]

[0814] 1 H-NMR (400MHz, DMSO): 1.99 (m, 2H, CH2); 2.75 (t, J 7.6Hz, 2H, CH2); 3.89 (t, J6.6Hz, 2H, CH2-O); 6.12 (bs, 2H, NH2); 6.63 (d, J 8.9Hz, 1H, Ar); 6.84 (dd, J 8.9, 2.8Hz, 1H, Ar); 7.05 (bs, 1H, NH); 7.12 (d, J 2.8Hz, 1H, Ar); 7.26 (d, J 5.9Hz, 2H, Ar); 7.67 (bs, 1H, NH); 8.46 (d, J 5.9Hz, 2H, Ar).M / Z (M+H) + =272.2.

[0815] Step 4:

[0816] A suspension of 2-amino-5-(3-pyridin-4-yl-propoxy)-benzamide (100 mg, 0.37 mmol), pyrrolo[1,2-c]pyrimidine-3-carboxylic acid (70 mg, 0.41 mmol), benzotriazol-1-yloxy-tris(dimethylamino)-phosphonium hexafluorophosphate (245 mg, 0.56 mmol), and diisopropylethylamine (0.20 mL, 1.11 mmol) in anhydrous DMF (1.0 mL) was stirred at 70°C for 4 h. The mixture was then poured into ice water (10 mL) to give a gray precipitate, which was collected by filtration and triturated with dichloromethane (2 x 2 mL). The gray solid was suspended in a mixture of sodium hydroxide (5% aqueous solution, 0.5 mL) and ethanol (0.5 mL) and heated at reflux for 1 h. The ethanol was removed in vacuo, and the resulting solution was poured into saturated aqueous ammonium chloride (5.0 mL). A brown precipitate formed, which was collected by filtration and rinsed several times with water (3.0 mL).The solid was then dried under high vacuum at 50°C in the presence of P2O5 overnight to give compound 1 (60 mg, 41%) as a brown powder.

[0817]

[0818] 1 H-NMR (400MHz, DMSO): 2.12 (m, 2H, CH2); 2.82 (t, J 7.6Hz, 2H, CH2); 4.12 (t, J6.4Hz, 2H, CH2-O); 6.85 (d, J 3.4Hz, 1H, Ar); 7.06 (t, J 2.9Hz, 1H, Ar); 7.30 (d, J 5.6Hz, 2H, Ar); 7.48 (dd, J 8.8, 2.9Hz, 1H, Ar); 7.52 (d, J 2.9Hz, 1H, Ar); 7.69 (d, J 8.8 Hz, 1H, Ar); 7.89 (s, 1H, Ar); 8.48 (m, 3H, Ar); 9.33 (s, 1H, Ar); no NH signal was observed. M / Z (M+H) + =398.1.MP=202-206℃.

[0819] Compound 2 (2-isoquinolin-3-yl-6-(3-pyridin-4-yl-propoxy)-3H-quinazolin-4-one hydrochloride)

[0820]

[0821] Compound 2 was prepared according to the procedure of Step 4 of Example 1, using 2-amino-5-(3-pyridin-4-yl-propoxy)-benzamide and isoquinoline-3-carboxylic acid as starting materials. Excess HCl (2N in Et2O) was added to a solution of the free base in dichloromethane, and the HCl salt was obtained by filtration. Compound 2 was obtained as a white solid in 92% yield.

[0822] 1 H-NMR (400MHz, DMSO): 2.37 (m, 2H, CH2); 3.26 (t, J 7.6Hz, 2H, CH2); 4.28 (t, J 6.4Hz, 2H, CH2-O); 7.55 (dd, J 8.9, 2.8Hz, 1H, Ar); 7.69 (d, J 2.8Hz, 1H, Ar); 7.96 (d, J 8.9Hz, 1H, Ar); 7.97 (d, J 7.3Hz, 1H, Ar); 8.05 (t, J 7.3Hz, 1H, Ar); 8.09 (d, J 6.5Hz, 2H, Ar); 8.25 (d, J 8.2Hz, 1H, Ar); 8.36 (d, J 8.2Hz,1H,Ar); 8.78 (d,J 6.5Hz,2H,Ar); 9.04(s,1H,Ar); 9.58(s,1H,Ar); No NH signal was observed; No HCl salt signal was observed. M / Z(M+H) + =409.2.MP>250℃.

[0823] Compound 3 (6-(3-pyridin-4-yl-propoxy)-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one hydrochloride)

[0824]

[0825] Compound 3 was prepared according to the procedure of Step 4 of Example 1, using 2-amino-5-(3-pyridin-4-yl-propoxy)-benzamide and thieno[3,2-c]pyridine-6-carboxylic acid as starting materials. Excess HCl (2N in Et2O) was added to a solution of the free base in dichloromethane and methanol, and the HCl salt was obtained by filtration. Compound 3 was obtained as a yellow solid in 93% yield.

[0826] 1H-NMR (400 MHz, DMSO): 2.17 (m, 2H, CH2); 3.06 (t, J 7.6 Hz, 2H, CH2); 4.13 (t, J 6.4 Hz, 2H, CH2-O); 7.38 (dd, J 9.0, 3.0 Hz, 1H, Ar); 7.49 (d, J 3.0 Hz, 1H, Ar); 7.70 (m, 2H, Ar); 7.96 (d, J 6.6 Hz, 2H, Ar); 8.06 (d, J 5.5 Hz, 1H, Ar); 8.77 (d, J 6.6 Hz, 2H, Ar); 9.08 (s, 1H, Ar); 9.24 (s, 1H, Ar); No NH signal was observed; no HCl salt signal was observed. M / Z (M+H) + =415.2.MP>250℃.

[0827] Compound 4 (6-(3-pyridin-4-yl-propoxy)-2-thieno[2,3-c]pyridin-6-yl-3H-quinazolin-4-one hydrochloride)

[0828]

[0829] Compound 4 was prepared according to the procedure of Step 4 of Example 1, using 2-amino-5-(3-pyridin-4-yl-propoxy)-benzamide and thieno[2,3-c]pyridine-6-carboxylic acid as starting materials. Excess HCl (2N in Et2O) was added to a solution of the free base in methanol, and the HCl salt was obtained by filtration. Compound 4 was obtained as a yellow solid in 73% yield.

[0830] 1 H-NMR (400MHz, DMSO): 2.24 (m, 2H, CH2); 3.13 (t, J 7.6Hz, 2H, CH2); 4.20 (t, J 6.4Hz, 2H, CH2-O); 7.44 (dd, J 9.0, 2.9Hz, 1H, Ar); 7.57 (d, J 2.9Hz, 1H, Ar); 7.78 (d, J 9.0Hz, 1H, Ar); 7.81 (d, J 5.2Hz, 1H, Ar); 8.04 (d, J 6.7Hz, 2H, Ar); 8.31 (d, J 5.2Hz, 1H, Ar); 8.85 (d, J 6.7Hz,2H,Ar); 8.95(s,1H,Ar); 9.47(s,1H, Ar); no NH signal was observed; no HCl salt signal was observed. M / Z (M+H) + =415.1.MP>250℃.

[0831] Compound 5 (2-pyridin-2-yl-6-(3-pyridin-4-yl-propoxy)-3H-quinazolin-4-one hydrochloride)

[0832]

[0833] Compound 5 was prepared according to the procedure of Step 4 of Example 1, using 2-amino-5-(3-pyridin-4-yl-propoxy)-benzamide and picolinic acid as starting materials. One equivalent of HCl (2N in Et2O) was added to a solution of the free base in dichloromethane, and the HCl salt was obtained by filtration. Compound 5 was obtained as a yellow solid in 84% yield.

[0834] 1 H-NMR (400MHz, DMSO): 2.23 (m, 2H, CH2); 3.13 (t, J 7.6Hz, 2H, CH2); 4.19 (t, J 6.4Hz, 2H, CH2-O); 7.43 (dd, J 9.0, 2.9Hz, 1H, Ar); 7.56 (d, J 2.9Hz, 1H, Ar); 7.66 (m, 1H, Ar); 7.77 (d, J 9.0Hz, 1H, Ar); 8.03 (d, J 6.6Hz, 2H, Ar); 8.08 (t, J 7.7Hz, 1H, Ar); 8.43 (d, J 7.7Hz, 1H, Ar); 8.76 (d, J 4.5Hz,1H,Ar);8.85(d,J 6.6 Hz, 2H, Ar); no NH signal was observed; no HCl salt signal was observed. M / Z (M+H) + =359.2.MP>250℃.

[0835] Reference compound 6 (2-pyridin-3-yl-6-(3-pyridin-4-yl-propoxy)-3H-quinazolin-4-one hydrochloride)

[0836]

[0837] Compound 6 (reference) was prepared according to the procedure of Step 4 of Example 1 using 2-amino-5-(3-pyridin-4-yl-propoxy)-benzamide and nicotinic acid as starting materials. Excess HCl (2N in Et2O) was added to a solution of the free base in dichloromethane, and the HCl salt was obtained by filtration. Compound 6 was obtained as a white solid in a 60% yield.

[0838] 1H-NMR (400 MHz, DMSO): 2.24 (m, 2H, CH2); 3.12 (t, J 7.6 Hz, 2H, CH2); 4.20 (t, J 6.4 Hz, 2H, CH2-O); 7.44 (dd, J 9.0, 2.9 Hz, 1H, Ar); 7.56 (d, J 2.9 Hz, 1H, Ar); 7.77 (d, J 9.0 Hz, 1H, Ar); 7.91 (dd, J 8.1, 5.3 Hz, 1H, Ar); 8.04 (d, J 6.5 Hz, 2H, Ar); 8.46 (m, 3H, Ar); 8.92 (d, J 5.3 Hz, 1H, Ar); 9.41 (s, 1H, Ar); no NH signal was observed; no HCl salt signal was observed. M / Z (M+H) + =359.2.MP>250℃.

[0839] Compound 7 (2-(4-methoxy-pyridin-2-yl)-6-(3-pyridin-4-yl-propoxy)-3H-quinazolin-4-one hydrochloride)

[0840]

[0841] Compound 7 was prepared according to the procedure of Step 4 of Example 1 using 2-amino-5-(3-pyridin-4-yl-propoxy)-benzamide and 4-methoxypicolinic acid as starting materials. Excess HCl (2N in Et2O) was added to a solution of the free base in dichloromethane, and the HCl salt was obtained by filtration. Compound 7 was obtained as a white solid in 86% yield.

[0842] 1 H-NMR (400 MHz, DMSO): 2.23 (m, 2H, CH2); 3.12 (t, J 7.6 Hz, 2H, CH2); 4.01 (s, 3H, CH3-O); 4.20 (t, J 6.4 Hz, 2H, CH2-O); 7.29 (m, 1H, Ar); 7.44 (dd, J 8.8, 2.9 Hz, 1H, Ar); 7.56 (d, J 2.9 Hz, 1H, Ar); 7.78 (d, J 8.8 Hz, 1H, Ar); 8.03 (m, 3H, Ar); 8.60 (d, J 5.8 Hz, 1H, Ar); 8.84 (d, J 6.5 Hz, 2H, Ar); no NH signal was observed; no HCl salt signal was observed. M / Z (M+H) + =389.1.MP>250℃.

[0843] Compound 8 (2-(5-Fluoro-pyridin-2-yl)-6-(3-pyridin-4-yl-propoxy)-3H-quinazolin-4-one hydrochloride)

[0844]

[0845] Compound 8 was prepared according to the procedure of Step 4 of Example 1, using 2-amino-5-(3-pyridin-4-yl-propoxy)-benzamide and 5-fluoropicolinic acid as starting materials. The crude product was purified by silica gel flash column chromatography using dichloromethane / methanol as eluent. After adding excess HCl (2N in Et2O) to a solution of the free base in dichloromethane, the HCl salt was obtained by filtration. Compound 8 was obtained as a yellow solid in 42% yield.

[0846] 1 H-NMR (400 MHz, DMSO): 2.23 (m, 2H, CH2); 3.11 (t, J 7.6 Hz, 2H, CH2); 4.19 (t, J 6.4 Hz, 2H, CH2-O); 7.43 (dd, J 8.8, 3.0 Hz, 1H, Ar); 7.55 (d, J 3.0 Hz, 1H, Ar); 7.75 (d, J 8.8 Hz, 1H, Ar); 8.00 (m, 3H, Ar); 8.48 (dd, J 8.8, 4.5 Hz, 1H, Ar); 8.75 (d, J 2.8 Hz, 1H, Ar); 8.83 (d, J 6.7 Hz, 2H, Ar); No NH signal was observed; no HCl salt signal was observed. M / Z (M+H) + =377.1.MP>250℃.

[0847] Compound 9 (6-(3-pyridin-4-yl-propoxy)-2-(4-trifluoromethyl-pyridin-2-yl)-3H-quinazolin-4-one hydrochloride)

[0848]

[0849] Compound 9 was prepared according to the procedure of Step 4 of Example 1 using 2-amino-5-(3-pyridin-4-yl-propoxy)-benzamide and 4-trifluoromethylpicolinic acid as starting materials. Excess HCl (2N in Et2O) was added to a solution of the free base in MeOH, and the HCl salt was obtained by filtration. Compound 9 was obtained as a white solid in 69% yield.

[0850] 1H-NMR (400MHz, DMSO): 2.23 (m, 2H, CH2); 3.11 (t, J 7.6Hz, 2H, CH2); 4.20 (t, J 6.4Hz, 2H, CH2-O); 7.46 (dd, J 8.9, 3.0Hz, 1H, Ar); 7.57 (d, J 3.0Hz, 1H, Ar); 7.84 (d, J 8.9Hz, 1H, Ar); 7.99 (d, J 6.5Hz, 2H, Ar); 8.04 (d, J 5.1Hz, 1H, Ar); 8.61 (s, 1H, Ar); 8.82 (d, J 6.5Hz, 2H, Ar); 9.03 (d, J 5.1Hz,1H,Ar); 12.10(bs,1H, NH); no HCl salt signal was observed. M / Z (M+H) + =427.1.MP=239-245℃.

[0851] Compound 10 (6-[3-(4-pyridyl)propoxy]-2-[5-(trifluoromethyl)-2-pyridyl]-3H-quinazolin-4-one hydrochloride)

[0852]

[0853] Compound 10 was prepared according to the procedure of Step 4 of Example 1, using 2-amino-5-(3-pyridin-4-yl-propoxy)-benzamide and 5-trifluoromethylpicolinic acid as starting materials. An excess of HCl in MeOH was added to a solution of the free base in MeOH, followed by concentration to dryness and trituration in EtO to obtain the HCl salt. Compound 10 was obtained as a yellow solid in 45% yield.

[0854] 1 H-NMR (400MHz, DMSO): 2.22 (tt, J 7.3, 6.1Hz, 2H, CH2); 3.08 (t, J 7.3Hz, 2H, CH2); 4.20 (t, J 6.1Hz, 2H, CH2-O); 7.46 (dd, J 8.8, 3.0Hz; 1H, Ar); 7.57 (d, J 3.0Hz,1H,Ar);7.79(d,J 8.8Hz,1H,Ar);7.94(d,J 6.6Hz,2H,Ar);8.47(dd,J 8.5, 1.8Hz,1H Ar);8.59(d,J 8.5Hz,1H,Ar);8.79(d,J 6.6 Hz, 2H, Ar); 9.11-9.12 (m, 1H, Ar); 12.06 (bs, 1H, NH). No HCl salt signal was observed. M / Z (M+H) + =427.4.MP>250℃.

[0855] Compound 11 (2-(4-methyl-2-pyridyl)-6-[3-(4-pyridyl)propoxy]-3H-quinazolin-4-one dihydrochloride)

[0856]

[0857] Compound 11 was prepared according to the procedure of Step 4 of Example 1, using 2-amino-5-(3-pyridin-4-yl-propoxy)-benzamide and 4-methylpyridine-2-carboxylic acid as starting materials. To a solution of the free base in MeOH and dichloromethane was added an excess of HCl in MeOH, followed by concentration to dryness and trituration in Et2O to obtain the HCl salt. Compound 11 was obtained as a yellow solid in 51% yield.

[0858] 1 H-NMR (400MHz, DMSO): 2.23(tt,J 7.1,5.9Hz,2H,CH2); 2.47(s,3H, CH3); 3.11(t,J 7.1Hz,2H,CH2); 4.19(t,J 5.9Hz,2H,CH2-O); 7.43(dd,J 8.8,2.3 Hz;1H,Ar);7.48(d,J 4.5Hz,1H,Ar);7.55(d,J 2.3Hz,1H,Ar);7.76(d,J 8.8Hz,1H,Ar);8.01(d,J 6.2Hz,2H Ar);8.23(s,1H,Ar);8.60(d,J 4.5Hz,1H,Ar);9.83 (d,J 6.2Hz, 2H, Ar). No NH signal was observed; no HCl salt signal was observed. M / Z (M+H) + = 373.3.MP = 175-250℃.

[0859] Compound 12 (2-(6-methyl-2-pyridyl)-6-[3-(4-pyridyl)propoxy]-3H-quinazolin-4-one dihydrochloride)

[0860]

[0861] Compound 12 was prepared according to the procedure of Step 4 of Example 1 using 2-amino-5-(3-pyridin-4-yl-propoxy)-benzamide and 6-methylpyridine-2-carboxylic acid as starting materials. An excess of HCl in MeOH was added to a solution of the free base in MeOH, followed by concentration to dryness and trituration in EtO to obtain the HCl salt. Compound 12 was obtained as a yellow solid in 34% yield.

[0862] 1H-NMR (400MHz, DMSO): 2.27(tt,J 7.5,6.2Hz,2H,CH2); 2.62(s,3H, CH3); 3.11(t,J 7.5Hz,2H,CH2); 4.19(t,J 6.2Hz,2H,CH2-O); 7.42(dd,J 8.8,2.9 Hz,1H,Ar);7.50(d,J 7.7Hz,1H,Ar);7.56(d,J 2.9Hz,1H,Ar);7.76(d,J 8.8Hz,1H Ar);7.95(t,J 7.7Hz,1H Ar);8.02(d,J 6.6Hz,2H,Ar);8.22(d,J 7.7Hz,1H, Ar); 8.83 (d, J 6.6 Hz, 2H, Ar). No NH and HCl salt signals were observed. M / Z (M+H) + =373.3. MP>250℃.

[0863] Compound 13 (2-(5-methylpyrazin-2-yl)-6-[3-(4-pyridyl)propoxy]-3H-quinazolin-4-one dihydrochloride)

[0864]

[0865] Compound 13 was prepared according to the procedure of Step 4 of Example 1, using 2-amino-5-(3-pyridin-4-yl-propoxy)-benzamide and 5-methylpyrazine-2-carboxylic acid as starting materials. An excess of HCl in MeOH was added to a solution of the free base in MeOH, followed by concentration to dryness and trituration in Et2O to obtain the HCl salt. Compound 13 was obtained as a yellow solid in 18% yield.

[0866] 1 H-NMR (400MHz, DMSO): 2.15(tt,J 7.5,6.2Hz,2H,CH2-O); 2.56(s,3H, CH3); 3.02(t,J 7.5Hz,2H,CH2); 4.12(t,J 6.2Hz,2H,CH2-O); 7.37(dd,J 8.9,2.9 Hz,1H,Ar);7.49(d,J 2.9Hz,1H,Ar);7.71(d,J 8.9Hz,1H,Ar);7.88(d,J 5.6Hz,2H,Ar);8.63(s,1H,Ar);8.73(d,J 5.6Hz,2H,Ar); 9.34(s,1H,Ar); 12.00(bs,1H, NH). No HCl salt signal was observed. M / Z (M+H) + =374.3.MP>250℃.

[0867] Compound 14 (2-[5-chloro-4-(trifluoromethyl)-2-pyridinyl]-6-[3-(4-pyridinyl)propoxy]-3H-quinazolin-4-one hydrochloride)

[0868]

[0869] Compound 14 was prepared according to the procedure of Step 4 of Example 1 using 2-amino-5-(3-pyridin-4-yl-propoxy)-benzamide and 5-chloro-4-(trifluoromethyl)pyridine-2-carboxylic acid as starting materials. Excess HCl (1.25 M in MeOH) was added to a solution of the free base in MeOH, followed by concentration to dryness and trituration in EtO to obtain the HCl salt. Compound 14 was obtained as a yellow solid in 47% yield.

[0870] 1 H-NMR (400 MHz, MeOD): 2.35 (tt, J 7.8, 5.9 Hz, 2H, CH2); 3.24 (t, J 7.8 Hz, 2H, CH2); 4.24 (t, J 5.9 Hz, 2H, CH2-O); 7.46 (dd, J 8.9, 2.9 Hz, 1H Ar); 7.64 (d, J 2.9 Hz, 1H, Ar); 7.84 (d, J 8.9 Hz, 1H, Ar); 8.05 (d, J 6.4 Hz, 2H, Ar); 8.75 (d, J 6.4 Hz, 2H, Ar); 8.80 (s, 1H, Ar); 8.97 (s, 1H, Ar). No NH and HCl salt signals were observed. M / Z (M+H) + =461.2.MP=134-250℃.

[0871] Compound 15 (2-(4-chloro-2-pyridinyl)-6-[3-(4-pyridinyl)propoxy]-3H-quinazolin-4-one hydrochloride)

[0872]

[0873] Compound 15 was prepared according to the procedure of Step 4 of Example 1, using 2-amino-5-(3-pyridin-4-yl-propoxy)-benzamide and lithium 4-chloropyridine-2-carboxylate as starting materials, and using 3 equivalents of benzotriazol-1-yloxy-tris(dimethylamino)-phosphonium hexafluorophosphate. After adding an excess of HCl in Et2O to a solution of the free base in dichloromethane, the HCl salt was obtained by filtration. Compound 15 was obtained as a yellow solid in 68% yield.

[0874] 1H-NMR (400 MHz, DMSO): 2.22 (tt, J 7.2, 6.2 Hz, 2H, CH2); 3.09 (t, J 7.2 Hz, 2H, CH2); 4.19 (t, J 6.2 Hz, 2H, CH2-O); 7.45 (dd, J 8.8, 3.0 Hz; 1H, Ar); 7.56 (d, J 3.0 Hz, 1H, Ar); 7.77-7.80 (m, 2H, Ar); 7.96 (d, J 6.2 Hz, 2H, Ar); 8.41 (d, J 2.0 Hz, 1H Ar); 8.72 (d, J 5.3 Hz, 1H, Ar); 8.80 (d, J 6.2 Hz, 2H, Ar). No NH and HCl salt signals were observed. M / Z (M+H) + =393.3.MP=232-241℃.

[0875] Lithium 4-chloropyridine-2-carboxylate was prepared as follows:

[0876]

[0877] To a suspension of methyl 4-chloropyridine-2-carboxylate (50 mg, 0.29 mmol) in THF (0.5 mL) and water (0.5 mL) was added LiOH (14 mg, 0.58 mmol) and the reaction mixture was stirred at room temperature overnight. The reaction mixture was then concentrated to dryness to give the product (quantitative yield).

[0878] 1 H-NMR (400MHz, DMSO): 7.53 (dd, J 5.4, 2.3Hz; 1H, Ar); 7.92 (dd, J 2.3, 0.5Hz; 1H, Ar); 8.43 (dd, J 5.4, 0.5Hz; 1H, Ar).

[0879] Compound 16 (2-(4-ethyl-2-pyridyl)-6-[3-(4-pyridyl)propoxy]-3H-quinazolin-4-one dihydrochloride)

[0880]

[0881] Compound 16 was prepared following the procedure for compound 15, starting with 2-amino-5-(3-pyridin-4-yl-propoxy)-benzamide and lithium 4-ethylpyridine-2-carboxylate. The HCl salt was obtained by adding excess HCl in Et2O to a solution of the free base in dichloromethane and concentrating to dryness. Compound 16 was obtained as a brown solid in 38% yield.

[0882] 1H-NMR (400MHz, DMSO): 1.33(t,J 7.4Hz,3H,CH3); 2.29(tt,J 7.7,6.2Hz, 2H,CH2); 2.85(q,J 7.4Hz,2H,CH2); 3.18(t,J 7.7Hz,2H,CH2); 4.25(t,J 6.2Hz, 2H, CH2-O); 7.49-7.51 (m; 1H, Ar); 7.54-7.62 (m, 2H, Ar); 7.83-7.85 (m, 1H, Ar); 8.09 (d, J 6.3Hz, 2H, Ar); 8.35 (bs, 1H Ar);8.68-8.70(m,1H,Ar);8.90(d,J 5.4Hz, 2H, Ar). No NH and HCl salt signals were observed. M / Z (M+H) + =387.3.

[0883] Lithium 4-ethylpyridine-2-carboxylate was prepared as follows:

[0884]

[0885] To a suspension of methyl 4-ethylpyridine-2-carboxylate (88 mg, 0.53 mmol) in THF (0.8 mL) and water (0.8 mL) was added LiOH (26 mg, 1.07 mmol) and the reaction mixture was stirred at room temperature overnight. The reaction mixture was then concentrated to dryness to give the product (quantitative yield).

[0886] 1 H-NMR (400MHz, DMSO): 1.20 (t, J 7.5Hz, 3H, CH3); 2.67 (m, 2H, CH2); 7.28 (bs, 1H, Ar); 7.84 (bs, 1H, Ar); 8.31 (bs, 1H, Ar).

[0887] Compound 17 (6-[3-(4-pyridyl)propoxy]-2-[6-(trifluoromethyl)-2-pyridyl]-3H-quinazolin-4-one hydrochloride)

[0888]

[0889] Compound 17 was prepared according to the procedure of Step 4 of Example 1 using 2-amino-5-(3-pyridin-4-yl-propoxy)-benzamide and 6-(trifluoromethyl)pyridine-2-carboxylic acid as starting materials. An excess of HCl in MeOH was added to a solution of the free base in MeOH, followed by concentration to dryness and trituration in EtO to obtain the HCl salt. Compound 17 was obtained as a yellow solid in 81% yield.

[0890] 1 H-NMR (400MHz, DMSO): 2.22(tt,J 7.5,6.2Hz,2H,CH2); 3.08(t,J 7.5Hz, 2H,CH2); 4.20(t,J 6.2Hz,2H,CH2-O);); 7.45(dd,J 8.8,3.0Hz;1H,Ar);7.58(d,J 3.0Hz,1H,Ar);7.78(d,J 8.8Hz,1H,Ar);7.95(d,J 6.7Hz,2H,Ar);8.14(d,J 7.8Hz,1H,Ar);8.35(t,J 7.8Hz,1H,Ar); 8.64(d,J 7.8Hz,1H,Ar); 8.79(d,J 6.7 Hz, 2H, Ar); 11.94 (bs, 1H, NH). No HCl salt signal was observed. M / Z (M+H) + =427.3.MP =238-250℃.

[0891] Compound 18 (2-(4-bromo-2-pyridinyl)-6-[3-(4-pyridinyl)propoxy]-3H-quinazolin-4-one)

[0892]

[0893] Compound 18 was prepared according to the procedure of step 4 of Example 1 using 2-amino-5-(3-pyridin-4-yl-propoxy)-benzamide and 4-bromopyridine-2-carboxylic acid as starting materials to obtain compound 18 as a beige solid in 88% yield.

[0894] 1 H-NMR (400MHz, DMSO): 2.10 (tt, J 7.5, 6.3Hz, 2H, CH2); 2.81 (t, J 7.5Hz, 2H, CH2); 4.04 (t, J 6.3Hz, 2H, CH2-O); 7.15 (dd, J 8.8, 3.0Hz; 1H, Ar); 7.29 (dd, J 5.9Hz,2H,Ar);7.43(d,J 3.0Hz,1H,Ar);7.53(d,J 8.8Hz,1H,Ar);7.64(dd,J 5.3, 2.0Hz,1H Ar);8.46(d,J 5.9Hz,2H,Ar);8.51(d,J 5.3Hz,1H,Ar);8.59(d,J 2.0Hz,1H,Ar). No NH signal was observed. M / Z(M[ 81 Br]+H) + =439.1.MP>250℃.

[0895] Compound 19 (2-(4-cyclopropyl-2-pyridyl)-6-[3-(4-pyridyl)propoxy]-3H-quinazolin-4-one dihydrochloride)

[0896]

[0897] Compound 19 was prepared following the procedure for compound 15, starting with 2-amino-5-(3-pyridin-4-yl-propoxy)-benzamide and lithium 4-cyclopropylpyridine-2-carboxylate. The HCl salt was obtained by filtration after adding excess HCl in Et2O to a solution of the free base in dichloromethane. Compound 19 was obtained as a green solid in 70% yield.

[0898] 1 H-NMR (400 MHz, DMSO): 0.88-1.00 (m, 2H, CH2); 1.17-1.21 (m, 2H, CH2); 2.12-2.26 (m, 3H, CH2+CH); 3.10 (t, J 7.2 Hz, 2H, CH2); 4.18 (t, J 6.1 Hz, 2H, CH2-O); 7.28-7.59 (m, 3H, Ar); 7.73-7.83 (m, 1H, Ar); 7.97-8.05 (m, 2H, Ar); 8.09-8.18 (m, 1H, Ar); 8.50-8.60 (m, 1H, Ar); 8.78-8.88 (m, 2H, Ar). No NH and HCl salt signals were observed. M / Z (M+H) + =399.3.MP=110-156℃.

[0899] Lithium 4-cyclopropylpyridine-2-carboxylate was prepared as follows:

[0900]

[0901] To a suspension of methyl 4-cyclopropylpyridine-2-carboxylate (131 mg, 0.69 mmol) in THF (1.2 mL) and water (1.2 mL) was added LiOH (34 mg, 1.43 mmol), and the reaction mixture was stirred at room temperature for 2 h. The reaction mixture was then concentrated to dryness to afford the product (142 mg, quantitative yield).

[0902] 1 H-NMR (400MHz, DMSO): 0.81 (s, 2H, CH2); 1.08 (s, 2H, CH2); 1.99 (s, 1H, CH); 7.14 (bs, 1H, Ar); 7.56 (bs, 1H, Ar); 8.22 (bs, 1H, Ar).

[0903] Methyl 4-cyclopropylpyridine-2-carboxylate was prepared as follows:

[0904]

[0905] Under an inert atmosphere, methyl 4-bromopyridine-2-carboxylate (150 mg, 0.69 mmol) was dissolved in dry dioxane (5 mL). Copper iodide (26 mg, 0.14 mmol) and PdCl2(dppf).CH2Cl2 (56 mg, 0.07 mmol) were added, followed by cyclopropylzinc bromide (0.5 M in THF, 4.0 mL, 2.08 mmol). The reaction mixture was then stirred at 80°C for 2 h. The mixture was then partitioned between water and ethyl acetate, extracted with ethyl acetate, washed with water and brine, dried over sodium sulfate, and concentrated in vacuo to afford methyl 4-cyclopropylpyridine-2-carboxylate (quantitative yield) as a red oil.

[0906] 1 H-NMR (400MHz, DMSO): 0.85 (tt, J 4.5, 6.7Hz, 2H, CH2); 1.11 (m, 2H, CH2); 2.07 (m, 1H, CH); 3.86 (s, 3H, CH3); 7.32 (dd, J 1.7, 5.1Hz, 1H, Ar); 7.75 (d, J 1.7Hz,1H Ar); 8.50(d,5.1Hz,1H,Ar).

[0907] Reference compound 20 (2-(3-chlorophenyl)-6-[3-(4-pyridyl)propoxy]-3H-quinazolin-4-one hydrochloride)

[0908]

[0909] Compound 20 (reference) was prepared according to the procedure of step 4 of Example 1 using 2-amino-5-(3-pyridin-4-yl-propoxy)-benzamide and 3-chlorobenzoic acid as starting materials. The product was purified by silica gel column chromatography using dichloromethane / methanol as eluent. After adding excess HCl (1.25 M in Et2O) to a solution of the free base in dichloromethane, the HCl salt was obtained by filtration. Compound 20 was obtained as a white solid in 5% yield.

[0910] 1H-NMR (400MHz, DMSO): 2.22 (m, 2H, CH2); 3.11 (t, J 7.6Hz, 2H, CH2); 4.18 (t, J6.2Hz, 2H, CH2-O); 7.41 (dd, J 2.9, 8.8Hz, 1H, Ar); 7.53 (d, J 2.9Hz, 1H, Ar); 7.58 (t, 7.9Hz, 1H, Ar); 7.65 (qd, J 1.1, 8.0H, 1H, Ar); 7.72 (d, J 8.8Hz, 1H, Ar); 7.99 (d, J 6.4Hz, 2H, Ar); 8.13 (td, J 1.3,7.8Hz,1H,Ar);8.23(t,J 1.8Hz,1H, Ar); 8.82 (d, J 6.6 Hz, 2H, Ar); 12.58 (bs, 1H, NH); no HCl salt signal was observed. M / Z (M+H) + =392.MP>250℃.

[0911] Reference compound 21 (6-[3-(4-pyridyl)propoxy]-2-[3-(trifluoromethyl)phenyl]-3H-quinazolin-4-one hydrochloride)

[0912]

[0913] Compound 21 (reference) was prepared according to the procedure of step 4 of Example 1 using 2-amino-5-(3-pyridin-4-yl-propoxy)-benzamide and 3-(trifluoromethyl)benzoic acid as raw materials. The product was purified by silica gel column chromatography using dichloromethane / methanol as eluent. After adding excess HCl (1.25 M in Et2O) to a solution of the free base in dichloromethane, the HCl salt was obtained by filtration. Compound 21 was obtained as a white solid in 15% yield.

[0914] 1H-NMR (400MHz, DMSO): 2.23 (q, J 6.9Hz, 2H, CH2); 3.11 (t, J 7.6Hz, 2H, CH2); 4.18 (t, J 6.2Hz, 2H, CH2-O); 7.42 (dd, J 3.0, 8.9Hz, 1H, Ar); 7.54 (d, J 3.0 Hz,1H,Ar);7.75(d,J 8.9Hz,1H,Ar);7.79(t,J 7.9Hz,1H,Ar);7.94(d,J 7.8Hz,1H,Ar);8.02(d,J6.6Hz,2H,Ar);8.47(d,J 8.1Hz,1H,Ar); 8.52(s,1H,Ar); 8.83 (d,J 6.7 Hz, 2H, Ar); 12.73 (bs, 1H, NH); no HCl salt signal was observed. M / Z (M+H) + = 426.MP>250℃.

[0915] Compound 22 (2-(2-methyl-oxazol-4-yl)-6-(3-pyridin-4-yl-propoxy)-3H-quinazolin-4-one hydrochloride)

[0916]

[0917] Compound 22 was prepared according to the procedure of Step 4 of Example 1, using 2-amino-5-(3-pyridin-4-yl-propoxy)-benzamide and 2-methyloxazole-4-carboxylic acid as starting materials. Excess HCl (2N in Et2O) was added to a solution of the free base in MeOH, and the HCl salt was obtained by concentration. Compound 22 was obtained as a yellow solid in 83% yield.

[0918] 1 H-NMR (400 MHz, DMSO): 2.22 (m, 2H, CH2); 2.54 (s, 3H, CH3); 3.10 (t, J 7.6 Hz, 2H, CH2); 4.17 (t, J 6.4 Hz, 2H, CH2-O); 7.40 (dd, J 8.9, 2.9 Hz, 1H, Ar); 7.51 (d, J 2.9 Hz, 1H, Ar); 7.68 (d, J 8.9 Hz, 1H, Ar); 8.03 (d, J 6.7 Hz, 2H, Ar); 8.84 (m, 3H, Ar); no NH signal was observed; no HCl salt signal was observed. M / Z (M+H) + =363.1.MP>250℃.

[0919] Example 2–Synthesis of Compound 23 (6-(2-pyridin-3-yl-ethoxy)-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one hydrochloride)

[0920]

[0921] Step 1:

[0922] According to the procedure of step 2 of Example 1, 2-nitro-5-fluorobenzamide and 2-pyridin-3-yl-ethanol were used as raw materials to prepare 2-nitro-5-(2-pyridin-3-yl-ethoxy)-benzamide to obtain the compound as a white powder in 31% yield.

[0923]

[0924] 1 H-NMR (400MHz, CDCl3): 3.11 (t, J 6.6Hz, 2H, CH2); 4.40 (t, J 6.6Hz, 2H, CH2-O); 7.07 (d, J 2.7Hz, 1H, Ar); 7.15 (dd, J 9.0, 2.7Hz, 1H, Ar); 7.35 (dd, J 7.8, 4.8Hz,1H,Ar); 7.64(bs,1H,NH); 7.78(d,J 7.8Hz,1H,Ar); 8.01(bs,1H,NH); 8.03(d,J 9.0Hz,1H,Ar); 8.45(dd,J 4.8,1.7Hz,1H,Ar); 8.56(d,J 1.7Hz,1H,Ar).M / Z(M+H) + =288.1.

[0925] Step 2:

[0926] 2-Amino-5-(2-pyridin-3-yl-ethoxy)-benzamide was prepared according to the procedure of Example 1, Step 3 and isolated as a beige solid in 86% yield.

[0927]

[0928] 1H-NMR (400MHz, CDCl3): 3.01 (t, J 6.6Hz, 2H, CH2-C); 4.12 (t, J 6.6Hz, 2H, CH2-O); 6.15 (bs, 2H, NH2); 6.63 (d, J 8.8Hz, 1H, Ar); 6.83 (dd, J 8.8, 2.9Hz, 1H, Ar); 7.04 (bs, 1H, NH); 7.11 (d, J 2.9Hz, 1H, Ar); 7.35 (dd, J 7.7, 4.8Hz, 1H, Ar); 7.71 (bs, 1H, NH); 7.74 (d, J 7.7Hz, 1H, Ar); 8.44 (dd, J 4.8,1.7Hz,1H,Ar); 8.54(d,J 1.7Hz,1H,Ar).M / Z(M+H) + =258.1.

[0929] Step 3:

[0930] Compound 23 was prepared according to the procedure in Step 4 of Example 1 using 2-amino-5-(2-pyridin-3-yl-ethoxy)-benzamide and thieno[3,2-c]pyridine-6-carboxylic acid as starting materials. Excess HCl (2N in Et2O) was added to a solution of the free base in MeOH, and the HCl salt was obtained by concentration. Compound 23 was obtained as a yellow solid in 80% yield.

[0931]

[0932] 1 H-NMR (400MHz, DMSO): 3.49 (t, J 6.0Hz, 2H, CH2); 4.54 (t, J 6.0Hz, 2H, CH2-O); 7.57 (dd, J 9.0, 2.9Hz, 1H, Ar); 7.75 (d, J 2.9Hz, 1H, Ar); 7.87 (d, J 5.4Hz, 1H,Ar);7.94(d,J 9.0Hz,1H,Ar);8.13(dd,J 8.1,5.7Hz,1H,Ar);8.19(d,J 5.4Hz,1H,Ar);8.76(d,J8.1Hz,1H,Ar);8.81(d,J 5.7Hz,1H,Ar); 8.97(s,1H,Ar); 9.20 (s, 1H, Ar); 9.43 (s, 1H, Ar); no NH signal was observed; no HCl salt signal was observed. M / Z (M+H) + =401.0.MP>250℃.

[0933] Example 3–Synthesis of Compound 24 (6-(4-bromo-benzyloxy)-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one)

[0934]

[0935] Step 1:

[0936] 2-Nitro-5-(4-bromo-benzyloxy)benzamide was prepared using 2-nitro-5-fluorobenzamide and 4-bromobenzyl alcohol as raw materials according to the procedure of step 2 of Example 1. The compound was obtained as a yellow solid in 63% yield.

[0937]

[0938] M / Z(M[ 79 Br]+H) + =351.0.

[0939] Step 2:

[0940] 2-Amino-5-(4-bromo-benzyloxy)benzamide was prepared according to the procedure of Example 1, Step 3 and isolated as a light yellow solid in 55% yield.

[0941]

[0942] M / Z(M[ 79 Br]+H) + =321.0.

[0943] Step 3:

[0944] Compound 24 was prepared according to the procedure of step 4 of Example 1 using 2-amino-5-(4-bromo-benzyloxy)benzamide and thieno[3,2-c]pyridine-6-carboxylic acid as starting materials to obtain compound 24 as a beige solid in a 69% yield.

[0945]

[0946] 1H-NMR (400 MHz, DMSO): 5.16 (s, 2H, CH2-O); 7.24 (dd, J 8.8, 2.9 Hz, 1H, Ar); 7.47 (d, J 8.5 Hz, 2H, Ar); 7.53 (d, J 2.9 Hz, 1H, Ar); 7.57 (d, J 8.8 Hz, 1H, Ar); 7.61 (d, J 8.5 Hz, 2H, Ar); 7.67 (d, J 5.4 Hz, 1H, Ar); 7.91 (d, J 5.4 Hz, 1H, Ar); 9.05 (s, 1H, Ar); 9.18 (s, 1H, Ar); No NH signal was observed. M / Z (M[ 79 Br]+H) + =364.0.MP>250℃.

[0947] Example 4 – Synthesis of Compound 25 (tert-butyl 3-(4-hydroxy-2-pyrrolo[1,2-c]pyrimidin-3-yl-quinazolin-6-yl)oxyazetidine-1-carboxylate), Compound 26 (6-(azetidin-3-yloxy)-2-pyrrolo[1,2-c]pyrimidin-3-yl-3H-quinazolin-4-one hydrochloride), and Compound 27 (6-(1-pyrimidin-4-yl-azetidin-3-yloxy)-2-pyrrolo[1,2-c]pyrimidin-3-yl-3H-quinazolin-4-one)

[0948]

[0949] Step 1:

[0950] 3-(4-nitro-3-carbamoyl-phenoxy)-azetidine-1-carboxylic acid tert-butyl ester was prepared using 2-nitro-5-fluorobenzamide and 1-boc-3-hydroxyazetidine as starting materials according to the procedure of step 2 of Example 1. The compound was obtained as a yellow oil in 94% yield.

[0951]

[0952] M / Z(M+Na) + =360.1.

[0953] Step 2:

[0954] 3-(4-Amino-3-carbamoyl-phenoxy)-azetidine-1-carboxylic acid tert-butyl ester was prepared according to the procedure of Step 3 of Example 1 and isolated as a light yellow oil in 94% yield. The crude product was used in the next step.

[0955]

[0956] 1 H-NMR (400MHz, DMSO): 1.38 (s, 9H, tert-butyl); 3.76 (m, 2H, 2CH); 4.24 (m, 2H, 2CH); 4.87 (m, 1H, CH); 6.21 (bs, 2H, NH2); 6.65 (d, J 8.8Hz, 1H, Ar); 6.78 (dd, J 8.8,2.8Hz,1H,Ar);6.97(d,J 2.8Hz,1H,Ar);7.08(bs,1H,NH);7.74 (bs,1H,NH).M / Z(M+Na) + =330.1.

[0957] Step 3:

[0958] 3-(4-Hydroxy-2-pyrrolo[1,2-c]pyrimidin-3-yl-quinazolin-6-yloxy)-azetidine-1-carboxylic acid tert-butyl ester 25 was prepared by following the procedure of step 4 of Example 1 using 3-(4-amino-3-carbamoyl-phenoxy)-azetidine-1-carboxylic acid tert-butyl ester and pyrrolo[1,2-c]pyrimidine-3-carboxylic acid as starting materials. The compound was obtained as a green solid in 50% yield.

[0959]

[0960] 1 H-NMR (400MHz, DMSO): 1.45 (s, 9H, tert-butyl); 3.91 (m, 2H, 2CH); 4.40 (m, 2H, 2CH); 5.21 (m, 1H, CH); 6.90 (d, J 3.8Hz, 1H, Ar); 7.11 (dd, J 3.8, 2.7Hz, 1H,Ar);7.38(d,J2.9Hz,1H,Ar);7.47(dd,J 8.8,2.9Hz,1H,Ar);7.76(d,J 8.8Hz,1H,Ar);7.94(d,J 2.7Hz,1H,Ar);8.54(s,1H,Ar);9.37(s,1H,Ar);11.11(bs,1H,NH).M / Z(M+H) + =434.1.MP>250℃.

[0961] Step 4:

[0962] To a solution of tert-butyl 3-(4-hydroxy-2-pyrrolo[1,2-c]pyrimidin-3-yl-quinazolin-6-yloxy)-azetidine-1-carboxylate 25 (135 mg, 0.31 mmol) in dichloromethane (2.0 mL) was added HCl (2N in Et2O, 1.55 mL) dropwise at 0°C. The reaction mixture was stirred at room temperature for 2 h, after which the dark precipitate was collected by filtration, triturated in dichloromethane, and dried under vacuum. 6-(azetidin-3-yloxy)-2-pyrrolo[1,2-c]pyrimidin-3-yl-quinazolin-4-ol hydrochloride 26 (148 mg, quantitative yield) was obtained with a purity of 70% (UV by LC / MS), and the crude product was used in the next step without purification.

[0963]

[0964] M / Z(M+H) + =334.1.

[0965] Step 5:

[0966] Under an inert atmosphere, a suspension of 6-(azetidin-3-yloxy)-2-pyrrolo[1,2-c]pyrimidin-3-yl-quinazolin-4-ol hydrochloride 26 (148 mg, 0.40 mmol), 4-bromopyrimidine hydrochloride (156 mg, 0.80 mmol) and diisopropylethylamine (0.30 mL, 1.60 mmol) in ethanol (2.2 mL) was stirred at room temperature for 20 h. The solvent was evaporated in vacuo and the crude dark oil was purified by flash column chromatography on silica gel using dichloromethane / methanol as eluent to give compound 27 (30 mg, 18%) as a yellow solid.

[0967]

[0968] 1 H-NMR (400MHz, DMSO): 4.10 (m, 2H, 2CH); 4.58 (m, 2H, 2CH); 5.39 (m, 1H, CH); 6.50 (d, J 5.9Hz, 1H, Ar); 6.86 (d, J 6.7Hz, 1H, Ar); 7.06 (m, 1H, Ar); 7.48(m,2H,Ar);7.75(d,J8.2Hz,1H,Ar);7.89(s,1H,Ar);8.20(d,J 5.9Hz,1H, Ar);8.51(m,2H,Ar);9.31(s,1H,Ar);11.16(bs,1H,NH).M / Z(M+H) + =412.1. MP>250℃.

[0969] Example 5 – Synthesis of Compound 28 (tert-butyl 3-(4-hydroxy-2-thieno[2,3-c]pyridin-5-yl-quinazolin-6-yloxy)-azetidine-1-carboxylate), Compound 29 (6-(azetidin-3-yloxy)-2-thieno[2,3-c]pyridin-5-yl-quinazolin-4-ol 2,2,2-trifluoroacetate), and Compound 30 (6-(1-propionyl-azetidin-3-yloxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one)

[0970]

[0971] Step 1:

[0972] 3-(4-Hydroxy-2-thieno[2,3-c]pyridin-5-yl-quinazolin-6-yloxy)-azetidine-1-carboxylic acid tert-butyl ester 28 was prepared by following the procedure of step 4 of Example 1 using 3-(4-amino-3-carbamoyl-phenoxy)-azetidine-1-carboxylic acid tert-butyl ester (440 mg, 0.94 mmol) and thieno[2,3-c]pyridine-5-carboxylic acid (252 mg, 1.41 mmol). The compound was obtained as a white solid (430 mg, quantitative yield).

[0973]

[0974] M / Z(M+H) + =451.0.

[0975] Step 2:

[0976] To a solution of tert-butyl 3-(4-hydroxy-2-thieno[2,3-c]pyridin-5-yl-quinazolin-6-yloxy)-azetidine-1-carboxylate 28 (430 mg, 0.95 mmol) in dichloromethane (5.0 mL) was added TFA (750 μL, 9.60 mmol) dropwise at 0°C. The reaction mixture was stirred at room temperature for 2 h and then concentrated to dryness in vacuo. Trituration in diethyl ether afforded 6-(azetidin-1-ium-3-yloxy)-2-thieno[2,3-c]pyridin-5-yl-quinazolin-4-ol 2,2,2-trifluoroacetate 29 (quantitative yield) as a yellow solid.

[0977]

[0978] M / Z(M+H) + =350.9.

[0979] Step 3:

[0980] To a mixture of 6-(azetidin-3-yloxy)-2-thieno[2,3-c]pyridin-5-yl-quinazolin-4-ol 2,2,2-trifluoroacetate 29 (200 mg, 0.43 mmol) and triethylamine (180 μL, 1.29 mmol) in DMF (4.5 mL) was added propionyl chloride (40 μL, 0.43 mmol) at 0 ° C. The reaction mixture was stirred at room temperature for 16 h and then poured into ice water (20 mL). The resulting beige precipitate was collected by filtration and purified by silica gel column chromatography using dichloromethane / methanol as eluent to give compound 30 (69 mg, 39%) as a white solid.

[0981]

[0982] 1 H-NMR (400MHz, DMSO): 0.97 (t, J 7.5Hz, 3H, ethyl); 2.12 (q, J 7.5Hz, 2H, ethyl); 3.86 (m, 1H, CH); 4.14 (m, 1H, CH); 4.34 (m, 1H, CH); 4.62 (m, 1H, CH); 5.23(m,1H,CH);7.40(d,J 2.9Hz,1H,Ar);7.48(dd,J 8.8,2.9Hz,1H,Ar);7.80 (m,2H,Ar);8.27(d,J 5.4Hz,1H,Ar);8.93(s,1H,Ar);9.43(s,1H,Ar);11.81(s,1H,NH).M / Z(M+H) + =406.9.MP>250℃.

[0983] Example 6 – Synthesis of Compound 31 (6-(piperidin-4-yloxy)-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one) and Compound 32 (6-(1-propionyl-piperidin-4-yloxy)-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one)

[0984]

[0985] Step 1:

[0986] 5-(1-Acetyl-piperidin-4-yloxy)-2-nitro-benzamide was prepared using 2-nitro-5-fluorobenzamide and 1-acetyl-4-hydroxypiperidine as raw materials according to the procedure of step 2 of Example 1. The compound was obtained as a yellow oil in 33% yield.

[0987]

[0988] M / Z(M+H) + =308.1.

[0989] Step 2:

[0990] 5-(1-Acetyl-piperidin-4-yloxy)-2-amino-benzamide was prepared according to step 3 of example 2 and isolated as a yellow solid in 85% yield. It was used in the next step without purification.

[0991]

[0992] M / Z(M+Na) + =300.1.

[0993] Step 3:

[0994] 6-(Piperidin-4-yloxy)-2-thieno[3,2-c]pyridin-6-yl-quinazolin-4-ol was prepared using 5-(1-acetyl-piperidin-4-yloxy)-2-amino-benzamide and thieno[3,2-c]pyridine-6-carboxylic acid as starting materials according to the procedure of Step 4 of Example 1. Compound 31 was obtained as a yellow solid in 88% yield.

[0995]

[0996] M / Z(M+Na) + =379.1.

[0997] Step 4:

[0998] Compound 32 was prepared from compound 31 according to the procedure of step 3 of Example 5 to obtain the compound as a white solid in 35% yield.

[0999]

[1000] 1H-NMR (400MHz, DMSO): 1.06 (t, J 7.4Hz, 3H, ethyl); 1.68 (m, 2H, 2CH); 2.07 (m, 2H, 2CH); 2.41 (q, J 7.4Hz, 2H, ethyl); 3.45 (m, 2H, 2CH); 3.77 (m, 1H, CH); 3.95 (m, 1H, CH); 4.90 (m, 1H, CH); 7.58 (dd, J 8.9, 2.9Hz, 1H, Ar); 7.71 (d, J 2.9Hz,1H,Ar);7.82(d,J5.4Hz,1H,Ar);7.83(d,J 8.9Hz,1H,Ar);8.17(d,J 5.4Hz,1H,Ar);9.20(s,1H,Ar);9.36(s,1H,Ar);11.83(s,1H,NH).M / Z(M+H) + = 435.0.MP>250℃.

[1001] Example 7 –Synthesis of Compound 33 (6-(2-morpholin-4-yl-ethoxy)-2-pyrrolo[1,2-c]pyrimidin-3-yl-3H-quinazolin-4-one hydrochloride)

[1002]

[1003] Step 1:

[1004] To a suspension of anthranilamide (2.2 g, 16.4 mmol) in aqueous sodium bicarbonate (5%, 0.1 M, 165 mL) was added iodine (4.6 g, 18.0 mmol). The reaction mixture was stirred at room temperature for 16 h, then poured into saturated aqueous sodium sulfite (300 mL) and extracted with ethyl acetate (3 x 300 mL). The combined organic extracts were washed with brine (100 mL), dried over MgSO₄, and concentrated in vacuo. Purification by flash column chromatography on silica gel using ethyl acetate / cyclohexane as eluent afforded 2-amino-5-iodo-phenylamide (2.7 g, 63%) as a beige solid.

[1005]

[1006] 1H-NMR (400MHz, DMSO): 6.54 (d, J 8.7Hz, 1H, Ar); 6.70 (bs, 2H, NH2); 7.13 (bs, 1H, NH); 7.38 (dd, J 8.7, 2.0Hz, 1H, Ar); 7.80 (d, J 2.0Hz, 1H, Ar); 7.81 (bs,1H,NH).M / Z(M+H) + =263.0.

[1007] Step 2:

[1008] 6-Iodo-2-pyrrolo[1,2-c]pyrimidin-3-yl-quinazolin-4-ol was prepared using 2-amino-5-iodo-phenylamide and pyrrolo[1,2-c]pyrimidine-3-carboxylic acid as raw materials according to the procedure of step 4 of Example 1. The compound was obtained as a green solid in 70% yield.

[1009]

[1010] 1 H-NMR (400MHz, DMSO): 6.67 (d, J 3.8Hz, 1H, Ar); 6.99 (dd, J 3.8, 2.7Hz, 1H, Ar); 7.42 (d, J 8.6Hz, 1H, Ar); 7.78 (dd, J 8.6, 2.2Hz, 1H, Ar); 7.85 (d, J 2.7Hz, 1H,Ar);8.33(d,J 2.2Hz,1H,Ar);8.53(s,1H,Ar);9.20(s,1H,Ar).M / Z(M+H) + = 289.0.

[1011] Step 3:

[1012] Under an inert atmosphere, a suspension of 6-iodo-2-pyrrolo[1,2-c]pyrimidin-3-yl-quinazolin-4-ol (50 mg, 0.13 mmol), cuprous iodide (5 mg, 0.03 mmol), 1,10-phenanthroline (9 mg, 0.05 mmol), and cesium carbonate (84 mg, 0.26 mmol) in 4-(2-hydroxyethyl)morpholine (1.0 mL) was heated at 120°C for 24 h in a sealed tube. After cooling to room temperature, the mixture was poured into ice water (10 mL), and the resulting dark precipitate was collected by filtration. This precipitate was dissolved in DMSO (5 mL) and purified by preparative HPLC. After adding excess HCl (2N in Et2O) to a solution of the free base in MeOH, the HCl salt was obtained by filtration, yielding compound 33 (9 mg, 16%) as a brown solid.

[1013]

[1014] 1 H-NMR (400 MHz, DMSO): 3.22 (m, 2H, CH2); 3.52 (m, 2H, CH2); 3.61 (m, 2H, CH2); 3.85 (m, 2H, CH2); 3.96 (m, 2H, CH2); 4.59 (m, 2H, CH2); 6.88 (bs, 1H, Ar); 7.08 (m, 1H, Ar); 7.53 (bs, 1H, Ar); 7.63 (m, 1H, Ar); 7.76 (bs, 1H, Ar); 7.92 (bs, 1H, Ar); 8.53 (s, 1H, Ar); 9.36 (s, 1H, Ar); 11.30 (bs, NH); no HCl salt signal was observed. M / Z (M+H) + =392.0.MP=165-173℃.

[1015] Compound 34 (6-(2-methoxy-ethoxy)-2-pyrrolo[1,2-c]pyrimidin-3-yl-3H-quinazolin-4-one)

[1016]

[1017] Compound 34 was prepared using 6-iodo-2-pyrrolo[1,2-c]pyrimidin-3-yl-quinazolin-4-ol and 2-methoxyethanol as starting materials according to the procedure of Step 3 of Example 7. It was purified by silica gel flash column chromatography using dichloromethane / methanol as the eluent to obtain compound 34 as a yellow solid in 10% yield.

[1018] 1 H-NMR (400MHz, DMSO): 3.33 (s, 3H, CH3); 3.72 (m, 2H, CH2); 4.24 (m, 2H, CH2); 6.86 (d, J 3.8Hz, 1H, Ar); 7.07 (dd, J 3.8, 2.7Hz, 1H, Ar); 7.46 (dd, J 8.8, 2.9Hz...

Claims

1. Compounds of formula (I) in: R 1 Any one selected from the following groups: wherein each of the groups depicted above is optionally replaced by one or more groups R 11 replace; or R 1 It is a group It is optionally substituted by one or more groups R 11A replace; R 11 and R 11A Each independently selected from C 1-5 Alkyl, -O(C 1-5 alkyl), halogen, C 1-5 Haloalkyl and C 3-7 Cycloalkyl; X1 is C(R X1 ) or N; X3 is C(R X3 ) or N; X4 is C(R X4 ) or N; R X1 Selected from hydrogen, C 1-5 Alkyl, -O(C 1-5 alkyl), halogen and C 1-5 Haloalkyl; L is C 1-8 Alkylene, wherein the C 1-8 One -CH2- unit contained in the alkylene group is optionally replaced by a group selected from -O- and -CO-; R X2 is selected from phenyl, heteroaryl and heterocycloalkyl, wherein the phenyl, the heteroaryl and the heterocycloalkyl are each optionally substituted by one or more groups R X22 wherein the heteroaryl is a 5- or 6-membered monocyclic ring containing one, two or three ring heteroatoms independently selected from O, S and N; wherein the heterocycloalkyl is a 3-11-membered saturated cyclic group which is a monocyclic ring or a bridged, spiro and / or fused ring system consisting of two or three rings, wherein the saturated cyclic group contains one, two, three or four ring heteroatoms independently selected from O, S and N, wherein if one or more S ring atoms are present and / or if one or more N ring atoms are present, the S ring atoms and / or the N ring atoms are optionally oxidized, and wherein one or more carbon ring atoms are optionally oxidized; R X22 Each independently selected from C 1-5 Alkyl, -(C 0-3 Alkylene)-OH, -(C 0-3 Alkylene)-O(C 1-5 alkyl), halogen, C 1-5 Haloalkyl, -(C 0-3 Alkylene)-CO-(C 1-5 alkyl), -CO-O-(C 1-5 Alkyl), -(C 0-3 Alkylene)-CO-NH(C 1-5 Alkyl), -(C 0-3 Alkylene)-CO-N(C 1-5 Alkyl)(C 1-5 Alkyl), -(C 0-3 Alkylene)-SO2-(C 1-5 Alkyl), -(C 0-3 alkylene)-heteroaryl and -(C 0-3 wherein the heteroaryl is a 5- or 6-membered monocyclic ring containing one, two or three ring heteroatoms independently selected from O, S and N; wherein the heterocycloalkyl is a 3-11 membered saturated ring group which is a monocyclic ring or a bridged, spiro and / or fused ring system consisting of two or three rings, wherein the saturated ring group contains one, two, three or four ring heteroatoms independently selected from O, S and N, wherein if one or more S ring atoms are present and / or if one or more N ring atoms are present, the S ring atoms and / or the N ring atoms are optionally oxidized, and wherein one or more carbon ring atoms are optionally oxidized; R X3 Selected from hydrogen, C 1-5 Alkyl, -O(C 1-5 alkyl), halogen and C 1-5 Haloalkyl; R X4 Selected from hydrogen, C 1-5 Alkyl, -O(C 1-5 alkyl), halogen, C 1-5 Haloalkyl and C 3-7 Cycloalkyl; or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, wherein R 1 It is a group It is optionally substituted by one or more groups R 11A replace.

3. The compound of claim 1, wherein the compound is 8-methyl-6-(2-morpholinoethyl)-2-[4-(trifluoromethyl)-2-pyridinyl]-3H-quinazolin-4-one or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 or 2, wherein X1 is C(R X1 ), X3 is C(R X3 ), and X4 is C(R X4 ).

5. The compound of claim 1 or 2, wherein R X2 is a heterocycloalkyl group, which is optionally substituted by one or more groups R X22 Substituted, wherein the heterocycloalkyl is a 3-11 membered saturated ring group, which is a monocyclic ring or a bridged ring, spiro ring and / or fused ring system composed of two or three rings, wherein the saturated ring group contains one, two, three or four ring heteroatoms independently selected from O, S and N.

6. The compound of claim 1 or 2, wherein the group -LR X2 Selected from -(C 1-5 Alkylene)-R X2 、-OR X2 and -O-(C 1-5 Alkylene)-R X2 , where R X2 is a heterocycloalkyl group, which is optionally substituted by one or more groups R X22 Substituted, wherein the heterocycloalkyl is a 3-11 membered saturated ring group, which is a monocyclic ring or a bridged ring, spiro ring and / or fused ring system composed of two or three rings, wherein the saturated ring group contains one, two, three or four ring heteroatoms independently selected from O, S and N.

7. The compound of claim 1 or 2, wherein R X2 is selected from azetidinyl, oxetanyl, pyrrolidinyl, oxopyrrolidinyl, tetrahydrofuranyl, piperidinyl, oxopiperidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, 2-oxa-7-aza-spiro[3.5]nonyl, 6-oxa-2-aza-spiro[3.4]octyl, 3-oxa-9-aza-spiro[5.5]undecyl, 7-oxa-2-aza-spiro[4.5]decyl, 8-oxa-2-aza-spiro[4.5]decyl, phenyl, oxazolyl, pyridinyl, pyrazinyl and pyrimidinyl, wherein each of the above cyclic groups is optionally substituted by one or more radicals R X22 replace.

8. The compound of claim 1 or 2, wherein R X4 Selected from hydrogen, methyl, -OCH3, halogen and cyclopropyl.

9. The compound of claim 1 or 2, wherein R X4 Selected from methyl, -OCH3, halogen and cyclopropyl.

10. A compound, wherein the compound is selected from: 6-(3-pyridin-4-yl-propoxy)-2-pyrrolo[1,2-c]pyrimidin-3-yl-3H-quinazolin-4-one; 2-isoquinolin-3-yl-6-(3-pyridin-4-yl-propoxy)-3H-quinazolin-4-one; 6-(3-Pyridin-4-yl-propoxy)-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one; 6-(3-pyridin-4-yl-propoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; 2-pyridin-2-yl-6-(3-pyridin-4-yl-propoxy)-3H-quinazolin-4-one; 2-(4-Methoxy-pyridin-2-yl)-6-(3-pyridin-4-yl-propoxy)-3H-quinazolin-4-one; 2-(5-Fluoro-pyridin-2-yl)-6-(3-pyridin-4-yl-propoxy)-3H-quinazolin-4-one; 6-(3-Pyridin-4-yl-propoxy)-2-(4-trifluoromethyl-pyridin-2-yl)-3H-quinazolin-4-one; 6-[3-(4-pyridinyl)propoxy]-2-[5-(trifluoromethyl)-2-pyridinyl]-3H-quinazolin-4-one; 2-(4-methyl-2-pyridinyl)-6-[3-(4-pyridinyl)propoxy]-3H-quinazolin-4-one; 2-(6-methyl-2-pyridinyl)-6-[3-(4-pyridinyl)propoxy]-3H-quinazolin-4-one; 2-(5-methylpyrazin-2-yl)-6-[3-(4-pyridinyl)propoxy]-3H-quinazolin-4-one; 2-[5-chloro-4-(trifluoromethyl)-2-pyridinyl]-6-[3-(4-pyridinyl)propoxy]3H-quinazolin-4-one; 2-(4-chloro-2-pyridinyl)-6-[3-(4-pyridinyl)propoxy]-3H-quinazolin-4-one; 2-(4-ethyl-2-pyridinyl)-6-[3-(4-pyridinyl)propoxy]-3H-quinazolin-4-one; 6-[3-(4-pyridinyl)propoxy]-2-[6-(trifluoromethyl)-2-pyridinyl]-3H-quinazolin-4-one; 2-(4-bromo-2-pyridinyl)-6-[3-(4-pyridinyl)propoxy]-3H-quinazolin-4-one; 2-(4-cyclopropyl-2-pyridinyl)-6-[3-(4-pyridinyl)propoxy]-3H-quinazolin-4-one; 2-(2-Methyl-oxazol-4-yl)-6-(3-pyridin-4-yl-propoxy)-3H-quinazolin-4-one; 6-(2-Pyridin-3-yl-ethoxy)-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one; 6-(4-Bromo-benzyloxy)-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one; 6-(1-pyrimidin-4-yl-azetidin-3-yloxy)-2-pyrrolo[1,2-c]pyrimidin-3-yl-3H-quinazolin-4-one; 6-(1-Propanyl-azetidin-3-yloxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; 6-(1-propionyl-piperidin-4-yloxy)-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one; 6-(2-Morpholin-4-yl-ethoxy)-2-pyrrolo[1,2-c]pyrimidin-3-yl-3H-quinazolin-4-one; 6-(2-methoxy-ethoxy)-2-pyrrolo[1,2-c]pyrimidin-3-yl-3H-quinazolin-4-one; 6-(2-Morpholin-4-yl-ethoxy)-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one; 6-(2-methoxy-ethoxy)-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one; 6-(3-pyridin-3-yl-propoxy)-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one; 4-(4-Oxo-2-pyridin-2-yl-3,4-dihydro-quinazolin-6-yloxy)-piperidine-1-carboxylic acid tert-butyl ester; 6-(1-Acetyl-piperidin-4-yloxy)-2-pyridin-2-yl-3H-quinazolin-4-one; 6-(1-Acetyl-piperidin-4-ylmethoxy)-2-(4-trifluoromethyl-pyridin-2-yl)-3H-quinazolin-4-one; 6-(1-Acetyl-piperidin-4-ylmethoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; 6-(1-propionyl-piperidin-4-ylmethoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; 6-(1-acetyl-pyrrolidin-3-yloxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; 6-(4-Propanyl-piperazin-1-yl)-2-(4-trifluoromethyl-pyridin-2-yl)-3H-quinazolin-4-one; 6-(1-Acetyl-piperidin-4-yl)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; 6-[2-(Tetrahydro-pyran-4-yl)-ethoxy]-2-(4-trifluoromethyl-pyridin-2-yl)-3H-quinazolin-4-one; 6-[3-(3-Fluoro-pyridin-4-yl)-propoxy]-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; 6-[3-(4-methanesulfonyl-phenyl)-propoxy]-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; 6-(3-Pyrazin-2-yl-propoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; 6-[3-(3-methoxy-pyridin-4-yl)-propoxy]-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; 6-[3-(2-methyl-pyridin-4-yl)-propoxy]-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; 6-(3-oxazol-4-yl-propoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; 8-methyl-6-(3-pyridin-4-yl-propoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; 6-(3-pyridin-4-yl-propoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-pyrido[3,2-d]pyrimidin-4-one; 6-(3-Pyridin-4-yl-propoxy)-2-(4-trifluoromethyl-pyridin-2-yl)-3H-pyrido[3,2-d]pyrimidin-4-one; 6-(3-Pyridin-4-yl-propoxy)-2-(4-trifluoromethyl-pyridin-2-yl)-3H-pyrido[2,3-d]pyrimidin-4-one; 6-(3-Pyridin-4-yl-propoxy)-2-(4-trifluoromethyl-pyridin-2-yl)-3H-pyrido[3,4-d]pyrimidin-4-one; 6-(3-pyridin-4-yl-propoxy)-2-thieno[2,3-c]pyridin-5-yl-7-trifluoromethyl-3H-quinazolin-4-one; 5-Chloro-6-(3-pyridin-4-yl-propoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; 8-Chloro-6-(3-pyridin-4-yl-propoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; 8-Cyclopropyl-6-(3-pyridin-4-yl-propoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; 8-ethyl-6-(3-pyridin-4-yl-propoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; 8-Fluoro-6-(3-pyridin-4-yl-propoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; 8-methyl-6-(tetrahydro-pyran-4-ylmethoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; 8-methyl-6-(2-oxetan-3-yl-ethoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; 8-methyl-6-[2-(tetrahydro-furan-3-yl)-ethoxy]-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; 8-methyl-6-[2-(tetrahydro-pyran-4-yl)-ethoxy]-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; 8-methyl-6-(tetrahydro-furan-3-ylmethoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; R-8-methyl-6-(tetrahydro-furan-3-ylmethoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; S-8-methyl-6-(tetrahydro-furan-3-ylmethoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; 8-methyl-6-(1-methyl-6-oxo-piperidin-3-yloxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; R-8-methyl-6-((1-methyl-6-oxopiperidin-3-yl)oxy)-2-(thieno[2,3-c]pyridin-5-yl)quinazolin-4(3H)-one; S-8-methyl-6-((1-methyl-6-oxopiperidin-3-yl)oxy)-2-(thieno[2,3-c]pyridin-5-yl)quinazolin-4(3H)-one; 8-methyl-6-(1-propionyl-pyrrolidin-3-yloxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; R-8-methyl-6-(1-propionyl-pyrrolidin-3-yloxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; S-8-methyl-6-(1-propionyl-pyrrolidin-3-yloxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; 8-methyl-6-(1-oxetan-3-ylpyrrolidin-3-yloxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; R-8-methyl-6-(1-oxetan-3-ylpyrrolidin-3-yloxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; S-8-methyl-6-(1-oxetan-3-ylpyrrolidin-3-yloxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; 8-Methyl-6-[2-(2-oxa-7-aza-spiro[3.5]non-7-yl)-ethoxy]-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; 8-methyl-6-(1-oxetan-3-yl-piperidin-4-ylmethoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; 8-methyl-6-(1-propionyl-piperidin-4-ylmethoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; 6-(1-Methanesulfonyl-piperidin-4-ylmethoxy)-8-methyl-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; 8-methyl-6-(2-oxa-7-aza-spiro[3.5]non-7-yl)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; 8-methyl-6-(6-oxa-2-aza-spiro[3.4]octan-2-yl)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; 8-methyl-6-(3-oxa-9-aza-spiro[5.5]undec-9-yl)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; 8-methyl-6-(7-oxa-2-aza-spiro[4.5]dec-2-yl)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; 8-Methyl-6-(8-oxa-2-aza-spiro[4.5]dec-2-yl)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; 6-(2-Hydroxy-2-methyl-propylamino)-8-methyl-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; 6-[2-(1-Acetyl-piperidin-3-yl)-ethoxy]-8-methyl-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; 6-[2-(4-Acetyl-piperazin-1-yl)-ethoxy]-8-methyl-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; 8-Methyl-6-(3-morpholin-4-yl-propyl)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; 8-Methyl-6-(2-morpholin-4-yl-ethyl)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; 8-Methyl-6-(3-pyridin-4-yl-propoxy)-2-(4-trifluoromethyl-pyridin-2-yl)-3H-quinazolin-4-one; 8-Methyl-6-(tetrahydro-furan-3-ylmethoxy)-2-(4-trifluoromethyl-pyridin-2-yl)-3H-quinazolin-4-one; 8-Methyl-6-(1-propionyl-azetidin-3-yloxy)-2-(4-trifluoromethyl-pyridin-2-yl)-3H-quinazolin-4-one; 8-methyl-6-(1-oxetan-3-yl-piperidin-4-yloxy)-2-(4-trifluoromethyl-pyridin-2-yl)-3H-quinazolin-4-one; 8-Methyl-6-(3-oxa-9-aza-spiro[5.5]undec-9-yl)-2-(4-trifluoromethyl-pyridin-2-yl)-3H-quinazolin-4-one; 8-methyl-6-(3-pyridin-4-yl-propoxy)-2-pyrrolo[1,2-c]pyrimidin-3-yl-3H-quinazolin-4-one; 8-methyl-2-pyrrolo[1,2-c]pyrimidin-3-yl-6-(tetrahydro-furan-3-ylmethoxy)-3H-quinazolin-4-one; 8-methyl-6-(3-oxa-9-aza-spiro[5.5]undec-9-yl)-2-pyrrolo[1,2-c]pyrimidin-3-yl-3H-quinazolin-4-one; 8-methyl-6-(1-oxetan-3-yl-piperidin-4-yloxy)-2-pyrrolo[1,2-c]pyrimidin-3-yl-3H-quinazolin-4-one; 8-methyl-6-[1-(tetrahydro-pyran-4-yl)-ethoxy]-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; R-8-methyl-6-[1-(tetrahydro-pyran-4-yl)-ethoxy]-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; S-8-Methyl-6-[1-(tetrahydro-pyran-4-yl)-ethoxy]-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; 8-Methyl-6-[1-(tetrahydro-pyran-4-yl)-ethoxy]-2-(4-trifluoromethyl-pyridin-2-yl)-3H-quinazolin-4-one; R-8-Methyl-6-[1-(tetrahydro-pyran-4-yl)-ethoxy]-2-(4-trifluoromethyl-pyridin-2-yl)-3H-quinazolin-4-one; S-8-Methyl-6-[1-(tetrahydro-pyran-4-yl)-ethoxy]-2-(4-trifluoromethyl-pyridin-2-yl)-3H-quinazolin-4-one; 6-[(3-fluorotetrahydrofuran-3-yl)methoxy]-8-methyl-2-[4-(trifluoromethyl)-2-pyridinyl]-3H-quinazolin-4-one; 8-methyl-6-(3-oxa-9-azaspiro[5.5]undec-9-yl)-2-thieno[2,3-c]pyridin-5-yl-3-(2-trimethylsilylethoxymethyl)pyrido[3,2-d]pyrimidin-4-one; 8-methyl-6-(morpholinomethyl)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; 8-methyl-6-(morpholinomethyl)-2-[4-(trifluoromethyl)-2-pyridinyl]-3H-quinazolin-4-one; 8-methyl-6-(1-propionylazetidin-3-yl)oxy-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; 8-methyl-6-(2-morpholinoethyl)-2-[4-(trifluoromethyl)-2-pyridinyl]-3H-quinazolin-4-one; 8-methyl-6-[(1-methyl-6-oxo-3-piperidinyl)oxy]-2-pyrrolo[1,2-c]pyrimidin-3-yl-3H-quinazolin-4-one; 8-methyl-6-(morpholinomethyl)-2-(thieno[3,2-c]pyridin-6-yl)quinazolin-4(3H)-one; 8-methyl-6-(3-oxa-9-azaspiro[5.5]undec-9-yl)-2-(thieno[3,2-c]pyridin-6-yl)quinazolin-4(3H)-one; 8-methyl-6-(2-[1,4]oxazepan-4-yl-ethyl)-2-thieno[2,3-b]pyridin-5-yl-3H-quinazolin-4-one; 8-methyl-6-(2-[1,4]oxazepan-4-yl-ethyl)-2-thieno[3,2-b]pyridin-6-yl-3H-quinazolin-4-one; 8-Methyl-6-(2-morpholin-4-yl-ethyl)-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one; 8-Methyl-6-(2-morpholin-4-yl-ethyl)-2-pyrrolo[1,2-c]pyrimidin-3-yl-3H-quinazolin-4-one; 8-Methyl-6-(morpholinomethyl)-2-pyrrolo[1,2-c]pyrimidin-3-yl-3H-quinazolin-4-one; 8-methyl-6-(2-morpholino-2-oxoethyl)-2-(thieno[3,2-c]pyridin-6-yl)quinazolin-4(3H)-one; 8-methyl-6-(2-morpholino-2-oxo-ethyl)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; 8-Methyl-6-(2-piperidin-1-yl-ethyl)-2-thieno[2,3-b]pyridin-5-yl-3H-quinazolin-4-one; 8-Methyl-6-(1-methyl-6-oxo-piperidin-3-yloxy)-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one; 8-Methyl-6-(1-methyl-2-oxo-piperidin-4-ylmethoxy)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one 8-Methyl-6-(1-piperidinylmethyl)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; 8-Methyl-6-(2-morpholino-2-oxo-ethyl)-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one; 8-methyl-6-[(4-methylpiperazin-1-yl)methyl]-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; 8-methyl-6-(pyrrolidin-1-ylmethyl)-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; 8-methyl-6-(2-morpholino-2-oxo-ethyl)-2-pyrrolo[1,2-c]pyrimidin-3-yl-3H-quinazolin-4-one; 8-methyl-6-(morpholine-4-carbonyl)-2-pyrrolo[1,2-c]pyrimidin-3-yl-3H-quinazolin-4-one; 8-Methyl-6-(1-methyl-6-oxo-piperidin-3-yloxy)-2-(4-trifluoromethyl-pyridin-2-yl)-3H-quinazolin-4-one; 8-methyl-2-thieno[2,3-c]pyridin-5-yl-6-(thiomorpholinomethyl)-3H-quinazolin-4-one; 8-methyl-6-[2-(1,4-oxazepan-4-yl)-2-oxo-ethyl]-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; 8-methyl-6-(pyrrolidin-1-ylmethyl)-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one; 8-methyl-6-(1-methyl-5-oxo-pyrrolidin-3-yl)oxy-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one; 8-methyl-6-[(3R)-1-methyl-5-oxo-pyrrolidin-3-yl]oxy-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one; 8-methyl-6-[(3S)-1-methyl-5-oxo-pyrrolidin-3-yl]oxy-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one; Benzyl 3-[(8-methyl-4-oxo-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-6-yl)oxy]pyrrolidine-1-carboxylate; (3S)-benzyl 3-[(8-methyl-4-oxo-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-6-yl)oxy]pyrrolidine-1-carboxylate; 8-methyl-6-[2-(4-methyl-3-oxo-piperazin-1-yl)ethyl]-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; 8-methyl-6-[2-(4-methyl-3-oxo-piperazin-1-yl)ethyl]-2-[4-(trifluoromethyl)-2-pyridinyl]-3H-quinazolin-4-one; 8-methyl-6-[2-(2-oxa-6-azaspiro[3.3]heptane-6-yl)ethyl]-2-thieno[2,3-c]pyridin-5-yl-3H-quinazolin-4-one; 8-methyl-6-[2-(2-oxa-6-azaspiro[3.3]heptane-6-yl)ethyl]-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one; 8-methyl-6-[(4-methyl-3-oxo-piperazin-1-yl)methyl]-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one; 6-(2-((2-methoxyethyl)(methyl)amino)ethyl)-8-methyl-2-(thieno[3,2-c]pyridin-6-yl)quinazolin-4(3H)-one; 6-(2-(1,1-dioxythiomorpholino)ethyl)-8-methyl-2-(thieno[3,2-c]pyridin-6-yl)quinazolin-4(3H)-one; 6-[(1,1-dioxo-1,4-thiazin-4-yl)methyl]-8-methyl-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one; 6-(((2-methoxyethyl)(methyl)amino)methyl)-8-methyl-2-(thieno[3,2-c]pyridin-6-yl)quinazolin-4(3H)-one; 6-[(4-methoxy-1-piperidinyl)methyl]-8-methyl-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one; 6-[(2,2-dimethylmorpholin-4-yl)methyl]-8-methyl-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one; 8-Chloro-6-(2-morpholinoethyl)-2-(4-(trifluoromethyl)pyridin-2-yl)quinazolin-4(3H)-one; 8-methyl-6-(2-oxa-7-azaspiro[3.5]nonan-7-ylmethyl)-2-thieno[3,2-c]pyridin-6-yl-3H-quinazolin-4-one; N,N-dimethyl-1-((8-methyl-4-oxo-2-(thieno[3,2-c]pyridin-6-yl)-3,4-dihydroquinazolin-6-yl)methyl)piperidine-4-carboxamide; 6-((4-(methoxymethyl)piperidin-1-yl)methyl)-8-methyl-2-(thieno[3,2-c]pyridin-6-yl)quinazolin-4(3H)-one; 8-methoxy-6-(2-morpholinoethyl)-2-(4-(trifluoromethyl)pyridin-2-yl)quinazolin-4(3H)-one; 8-Bromo-6-(2-morpholinoethyl)-2-(4-(trifluoromethyl)pyridin-2-yl)quinazolin-4(3H)-one; 6-(2-(2,2-dimethylmorpholino)ethyl)-8-methyl-2-(4-(trifluoromethyl)pyridin-2-yl)quinazolin-4(3H)-one; 8-methyl-6-((4-methyl-3-oxopiperazin-1-yl)methyl)-2-(4-(trifluoromethyl)pyridin-2-yl)quinazolin-4(3H)-one; 6-(2-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)ethyl)-8-methyl-2-(4-(trifluoromethyl)pyridin-2-yl)quinazolin-4(3H)-one; 6-(2-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)ethyl)-8-methyl-2-(4-(trifluoromethyl)pyridin-2-yl)quinazolin-4(3H)-one; 6-(2-(4-hydroxypiperidin-1-yl)ethyl)-8-methyl-2-(4-(trifluoromethyl)pyridin-2-yl)quinazolin-4(3H)-one; 6-(2-(4,4-difluoropiperidin-1-yl)ethyl)-8-methyl-2-(4-(trifluoromethyl)pyridin-2-yl)quinazolin-4(3H)-one; 6-(2-(4-methoxypiperidin-1-yl)ethyl)-8-methyl-2-(4-(trifluoromethyl)pyridin-2-yl)quinazolin-4(3H)-one; and a pharmaceutically acceptable salt of any one of the above compounds.

11. A pharmaceutical composition comprising a compound according to any one of claims 1 to 10 and a pharmaceutically acceptable excipient.

12. Use of a compound according to any one of claims 1 to 10 for the preparation of a medicament for the treatment or prevention of a disorder associated with altered glutamatergic signalling and / or function or a disorder that can be affected by alterations in glutamate levels or signalling.

13. The use according to claim 12, wherein the condition to be treated or prevented is selected from any one of the following: dementia and related diseases; Parkinson's syndrome and movement disorders; social skills disorders; acute and chronic pain; anxiety disorders; schizophrenia and other mental disorders; mood disorders; endocrine and metabolic diseases; and cancer.

14. The use according to claim 13, wherein the dementia and related diseases are selected from Alzheimer's dementia, Alzheimer's disease, Pick's disease, vascular dementia, Lewy body disease, dementia caused by metabolic, toxic and deficiency diseases, AIDS dementia syndrome, Creutzfeldt-Jakob disease and atypical subacute spongiform encephalopathy.

15. The method of claim 13, wherein the parkinsonian syndrome and movement disorders are selected from Parkinson's disease, multiple systemic atrophy, progressive supranuclear palsy, corticobasal degeneration, hepatolenticular degeneration, chorea, hemitremor, athetosis, dystonia, spasmodic torticollis, occupational dyskinesia, Gilles de la Tourette syndrome, tardive dyskinesia or drug-induced movement disorders, tremor and myoclonus.

16. The use according to claim 13, wherein the parkinsonism and dyskinesia are levodopa-induced dyskinesias.

17. The use according to claim 13, wherein the Parkinson's syndrome and movement disorder is Huntington's disease.

18. The use according to claim 13, wherein the social skills disorder is selected from autism or autism spectrum disorder, or fragile X syndrome.

19. The use according to claim 13, wherein the anxiety disorder is selected from panic disorder, phobia, obsessive-compulsive disorder, stress disorder and generalized anxiety disorder.

20. The use according to claim 13, wherein the mood disorder is selected from depressive disorder and bipolar disorder.

21. The use according to claim 13, wherein the endocrine and metabolic diseases are selected from diabetes, endocrine gland disorders and hypoglycemia.

22. Use of a compound according to any one of claims 1 to 10 in the preparation of a medicament for treating or preventing Parkinson's disease.

23. An in vitro non-therapeutic and non-diagnostic method for identifying a test substance that binds to metabotropic glutamate receptor 4 (mGluR4), the method comprising the steps of: (a) contacting mGluR4 with a compound according to any one of claims 1 to 10, wherein the compound is radiolabeled or fluorescently labeled under conditions that allow the compound to bind to mGluR4, thereby producing a bound, labeled compound; (b) detecting a signal corresponding to the amount of bound, labeled compound in the absence of the test substance; (c) contacting the bound, labeled compound with a test substance; (d) detecting a signal corresponding to the amount of bound, labeled compound in the presence of the test substance; and (e) comparing the signal detected in step (d) with the signal detected in step (b) to determine whether the test substance binds to mGluR4.

24. Non-therapeutic and non-diagnostic use of a compound as defined in any one of claims 1 to 10 as a positive allosteric modulator of mGluR4 in vitro.